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Background - Under-reporting of adverse drug reactions (ADRs) is a challenging medication 
safety problem globally. Even though ADRs are associated with significant morbidity and 
mortality, poor reporting among healthcare professionals (HCPs) persists, particularly in 
resource-limited settings. This study aimed to explore HCP experiences and factors influencing 
ADR reporting in the Ghanaian hospital setting.  
Methods - A concurrent mixed methods design was undertaken using face-to-face semi-
structured qualitative interviews, focus groups and a survey.  Nursing, pharmacy and medical 
staff were sampled using a stratified random sample from five hospitals in Tamale, Ghana 
coupled with purposive sampling for interviews. Survey data were analysed descriptively using 
SPSS and in-depth interviews and focus group discussions analysed using a six-stage thematic 
analysis using NVivo.  
Findings - 386 HCPs (86% response rate) participated in the survey.  Pharmacovigilance (PV) 
knowledge was low (19%) with the majority being unaware of the national PV centre (68%) 
and basic information on reporting forms (65%). Pharmacy staff were however more 
knowledgeable compared to nursing and medical staff. Only 13% of HCPs reported to have 
observed an ADR at least once in a year and another 14% had completed a form. The majority 
(92%) of HCPs agreed that patient safety could improve if they reported ADRs and disagreed 
that litigation (82%) and lethargy (81%) were a hindrance. Pharmacists were perceived to have 
a key ADR reporting role. Use of verbal reporting was perceived to reduce ADR reporting 
formally along with complex interrelated system and human factors, such as lack of forms, 
inadequate infrastructure, stakeholder issues, uncertainty about reporting responsibilities, poor 
interpersonal relations, perceive patient attitudes, bureaucracies, fear of wrongdoing and 
blame.  
Conclusions – This study suggests that ADR reporting is low and often informal in the 
Ghanaian hospital setting but enhancing the role of pharmacists may be important in improving 
ADR reporting, as well as increasing HCP awareness through training – particularly for non-
pharmacy staff - and logistical changes such as electronic ADR reporting.   
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OUTLINE OF THESIS 
This thesis presents the findings of a concurrent mixed-method empirical research study that 
sought to explore the perceptions and experiences of frontline healthcare professionals (HCPs) 
concerning adverse drug reaction (ADR) reporting in hospital settings in Ghana. The rationale 
for the study originates from the global importance of ADRs and associated reporting linked to 
adverse health outcomes, and for HCPs to recognise and appropriately communicate suspected 
ADRs in routine practice. Ghana was selected as the focus of the study based on the lack of 
current literature and evidence in this setting and the much lower than recommended ADR 
reporting levels in this country. The study used a combination of interviews and surveys and 
identified various human and system factors influencing reporting. 
In relation to the thesis structure, it is organised into 6 main chapters. The first chapter is 
written in sections A and B. Section A, offers an introduction and overview of the focus of this 
research, namely ADRs and related key aspects such as their clinical consequence and more 
specific issues related to their reporting. Firstly, the broader concept of pharmacovigilance (PV) 
will be described and ADRs will be argued to be a key part of PV. Following this, definitions 
and classifications of ADRs and other related concepts will be provided, to further orientate 
the reader to understand how ADRs are distinguishable from medication errors and adverse 
drug events. The chapter will then go on to indicate the scale of ADRs, associated patient risk 
factors, factors influencing reporting and interventions to improve reporting. Section B then 
provides specific aspects of ADR reporting in Ghana and the reporting process. The second 
main chapter provides an empirical narrative literature review of the current research relating 
to the reporting of ADRs in Africa. The chapter concludes with a justification for this study, 
stating the primary and secondary research questions relating to this topic. The third chapter 
goes on to provide the methodological details and justification for a mixed-methods approach 
and how it best answers the research questions. The procedures are described in detail, offering 
transparency about the key choices of sampling, data collection and analysis strategies for both 
qualitative and quantitative phases of the research. The chapter concludes with a description of 
the quality of the research and ethical considerations, as well as methodological issues, unique 
to mixed methods. The findings are presented in chapters four (qualitative findings) and five 
(quantitative survey), with the final chapter six being an integrated discussion of findings, 






1.0 Introduction  
 
This introductory chapter presents a review of the concept of pharmacovigilance (PV) and 
associated terminologies. The chapter also presents a review of the literature on epidemiology 
of adverse drug reactions (ADRs) and factors that potentially influence the reporting of ADRs. 
The methods for reporting, interventions to improve reporting and specific issues on ADR 
reporting in Ghana are presented here to give an overview and highlight the importance of the 
topic. 
 
1.1 Pharmacovigilance and Related Concepts 
 
The concept of PV and reporting adverse reactions was popularised by Dr William McBride, 
after the thalidomide disaster in the early 1960s led to the deaths of tens of thousands and 
caused severe congenital disabilities (Neil et al., 2015). Even though safety and prevention of 
potential harm from medications has been a key historical principle in medicine, the devastation 
caused by this disaster led health authorities to demand a more critical approach to the 
assessment of potential harm of medications. Therefore, in 1968, the World Health 
Organization (WHO) initiated the Programme for International Drug Monitoring (PIDM) in 
Uppsala, Sweden, intending to support countries worldwide to set up and run their vigilance 
systems.  
 
The PIDM membership has increased over the years, currently reaching a membership of 166 
countries (136 full members and 30 associate members) in 2019. Out of the 54 African member 
countries, Morocco and South Africa were the first two countries to join the PIDM in 1992, 
after 24 years of its existence. Since then, its African membership has also increased to 41 – 
comprising 34 full member countries and seven associate members (https://www.who-
umc.org/). Coupled with weak infrastructure, the indifference of national governments and 
over-reliance on development partners, PV systems on the African continent are still basic 
compared to the rest of the developed world (Ampadu et al., 2018; Appiah, 2012; Dodoo and 
Ampadu, 2014; Pirmohamed et al., 2007). This deficiency reflects the number of Individual 
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Case Safety Reports (ICSR) sent to the PIDM centre from Africa. For example, Ampadu and 
colleagues have reported that only 0.88% of the ICSR analysed in 2015 were from Africa 
(Ampadu et al., 2016). Africa faces a higher risk of adverse effects because of poor 
pharmaceutical governance, high disease burden, and the proliferation of substandard and 
falsified medicinal products (WHO, 2017). Forty-two per cent of falsified products in the world 
are found in Africa, with antibiotics and antimalarials being commonly cited drugs. It was 
reported that in some African countries, up to 70% of their pharmaceuticals were substandard 
(Ghanem, 2019). Based on this primacy, one would expect a higher number of case safety 
reports from Africa due to falsified products, which is not the case. Even though effective action 
may not be possible in an unregulated environment, serious ADR cases may eventually be 
referred to regulated healthcare facilities where action may be required. Most people, 
particularly healthcare professionals (HCPs), are however still unfamiliar with the concept of 
PV and the associated benefits of ADR reporting, and this has been argued to influence their 
poor reporting behaviour (Terblanche et al., 2018). Pharmacovigilance represents a specific 
discipline of science, defined as: 
 
“the science and activities relating to the detection, assessment, understanding and 
prevention of adverse effects or any other drug-related problem” (WHO, 2015).  
 
PV seeks to improve patient care and safety through the monitoring and evaluation of 
medicines in use by individuals and public health programmes (Harmark and van Grootheest, 
2008).  Safety is essential because clinical trials of medicinal products usually lack the required 
number of participants and the length of time to adequately detect long-term adverse effects of 
medicines.  
Also, large patient populations, such as pregnant women and children who are not usually 
included in clinical trials for ethical reasons, are covered through post-marketing surveillance 
and wider use of a marketed product. PV, therefore, contributes to the ongoing assessment of 
the risks, benefits and effectiveness of medicines needed to promote understanding about the 
safe use of medicine (Jeetu and Anusha, 2010). ADR reporting is, therefore, a key component 
of PV, which helps to improve medicinal products by incorporating additional warnings or 
withdrawing them from the market where they cause serious harm (Onakpoya et al., 2015; 
Tabali et al., 2012; Vaidya et al., 2010).   
 
 3 
1.2 Adverse Drug Reaction  
 
The term ‘adverse drug reaction’ (ADR) has often been used broadly in medical literature to 
refer to several related but, importantly, different concepts such as side effects, adverse reaction 
and events, medication errors and adverse drug effects. However, defining ADR is problematic 
since this definition has changed over time. The traditional definition of an ADR was developed 
in 1973 by the WHO, and defined as: 
 
“Any response to a drug that is noxious and unintended and that occurs at doses 
normally used in humans for prophylaxis, diagnosis, or therapy of disease, or for the 
modification of physiological function” (WHO, 1973).  
 
Various authors (Bates et al., 1995; Ferner and Aronson, 1999; Laurence et al., 1998) have 
argued, however, that this and other definitions are old, vague, ambiguous, over-simplified and 
lacking specificity (Edwards and Aronson, 2000; Aronson and Ferner, 2005). Numerous 
definitions have therefore been proposed, with the most recent defining ADR as:  
 
“An appreciably harmful or unpleasant reaction resulting from an intervention related 
to the use of a medicinal product; adverse effects usually predict hazard from future 
administration and warrant prevention, or specific treatment, or alteration of the 
dosage regimen, or withdrawal of the product” Aronson and Ferner, 2005, p.855). 
 
Notwithstanding these attempts to develop a clear, consistent and unambiguous definition for 
reliable ADR communication, the use of ‘appreciably harmful’ in Aronson and Ferner’s 
definition also excludes trivial adverse effects which are similar to ‘noxious’ in the WHO 
definition.  For this study, the WHO definition will be adopted since it is still widely used and 
accepted (Alhawassi et al., 2014). To further complicate the definitions and terminology, three 
closely related key terms, which appear to be used interchangeably in the literature and with a 
considerable degree of overlap, are medication errors, adverse drug reactions and adverse drug 





Figure 1: Inter-relationship among medication-related concepts (adapted from Nebeker 
et al., 2004) 
 
 
An ADR – which is also sometimes referred to as an ADE, using the word ‘event’ instead of 
‘reaction’ – is a sub-type of the broader adverse event which is not limited to drug-related 
events, and it also overlaps with some types of medication error. As Table 1 illustrates, the 
various terms and definitions are closely related, and this arguably can be confused with ADRs. 
To avoid the confusion of terminologies, Aronson and Ferner (2005) therefore recommended 
avoiding terms such as ‘side effects’ in drug safety terminology. Also, caution must be taken 
not to interchange adverse drug reaction (ADR) and adverse drug event (ADE). All ADRs are 
as a result of ADEs, but not all ADEs result in ADRs, whether as a result of medication error 
or not (Figure 1) (Aronson and Ferner, 2005).  In the literature, the term ‘adverse effect’ is 
widely used to compare synonyms such as toxic effect, side effect or unwanted effects. Even 
though these synonyms are generally not considered positive, there have been instances where 
some side effects were beneficial. 
 
A classic example is sildenafil, which was manufactured originally for the treatment of 
hypertension and angina and turned out to have a beneficial side effect and was licensed for 
the treatment of erectile dysfunction (Guay et al., 2001). In addition, minoxidil, a blood 
pressure medication that had the side effect of excessive hair growth in some parts of the body, 
was exploited and later used to treat hair loss. Older antihistamines, such as diphenhydramine, 
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which had the problematic side effect of sedation, have subsequently been exploited for their 
use as short-term treatments for insomnia.  An ADR may therefore not be reported if it is 
effective in supporting desirable life functions, such as helping a patient to sleep, boosting their 
sex drive or relieving them of other non-indicated symptoms. 
 
Table 1: Definition of key concepts  
 
Term  Definition Notes 
Medication 
Errors (ME)  
 
“Any preventable event that may cause or lead 
to inappropriate medication use or patient harm, 
while the medication is in the control of the 
health care professional, patient, or consumer.” 
(Patel et al., 2016) 
ME is the most common form of 
patient harm which may not 
necessarily result in ADR or ADE (see 
Fig.1). Traditionally not part of PV 
system but has an inter-relationship.  
Adverse Drug 
Event (ADE) 
“An injury resulting from a medicinal 
intervention relating to a drug.” (Boyle et al., 
1995) 
 
ADE includes all ADRs and 
sometimes may be due to preventable 
medication errors. They may occur 




“Any untoward medical occurrence in a patient 
or clinical investigation subject administered a 
pharmaceutical product and which does not 
necessarily have a causal relationship with the 
treatment.” (ICH, 2009) 
 
“Any abnormal sign, symptom, laboratory test, 
a syndromic combination of such abnormalities, 
untoward or unplanned occurrence (e.g. an 
accident or unplanned pregnancy) or any 
unexpected deterioration of concurrent illness.” 
(Aronson and Ferner, 2005) 
International Conference on 
Harmonization (ICH) definition is 
typically used in clinical trial studies. 
All AEs are expected to be reported. 
AEs are sometimes generically 
referred to as ME, especially in 
Australia (Shah et al., 2013). They can 
be further classified as serious or not, 
expected or not, possible, mild, 
moderate, severe, life-threatening and 
death related. AE could involve a 
medicinal product or not. When they 
do, and the cause is attributed to a drug 
or medicinal product, they can be 




“An unintended reaction to a drug administered 
at normal dosage.” (Duan et al., 2013) 
ADEf may also be used 
interchangeably to refer to ‘side 
effect’ or ADR. If thought to be 
associated with a drug, it is called a 
suspected ADE, but if unknown it 




“The company or legal entity in whose name the 
marketing authorisation for a product has been 
granted and which is responsible for all aspects 
of the product and compliance with the 
conditions of marketing authorisation.” (Blake 
et al., 2011) 
MAH usually appoints a qualified 
person for PV to monitor drugs and 





1.3 Classification of ADRs 
 
There are no universal standards for the classification of ADRs despite the different levels of 
risk associated with them. Reports have been subjective and described based on severity levels 
of mild, moderate, severe and lethal (Lucas and Colley, 1992). In the 1970s, ADRs were 
classified into two broad types: type A and type B for Augmented (dose-related) and Bizarre 
(non-dose-related) respectively, based on known pharmacology of a drug (Rawlins and 
Thompson, 1977).  Type A is the most common type (80%) of ADR in hospital settings which 
is dose-related, has high morbidity, low mortality and can be predicted from known 
pharmacological action of the drug. Examples include drug toxicity dysrhythmia caused by 
digoxin and constipation from chronic opioid use. These are usually managed by reducing the 
dose, stopping the medicine or checking for associated medications interaction. Type B ADRs 
are referred to as: 
   
 “[…] aberrant effects that are not to be expected from the known pharmacological actions 
of a drug when given in normal therapeutic doses to a patient whose body handles the drug in 
the normal way” (Rawlins, 1981).  
 
These types of ADR come across as idiosyncratic, unusual, not dose-related and more serious 
than type A, resulting in high morbidity and mortality when they occur. Examples include 
intolerance from small doses of aspirin causing tinnitus, and also allergies caused by penicillin-
induced anaphylaxis due to immune response. Type B ADRs are managed by withholding the 
drug and avoiding future use. 
 
Over time, however, this typology has evolved and others have been developed with the 
pharmacology of the drug, including non-dose-time (type C), delayed reactions (type D) (Smith 
et al., 1996), withdrawal effects (type E) (Royer, 1997), and, most recently, type F which 
reflects unexpected failure of therapy. These distinctions and classifications are very important 
for modelling automatic electronic classification systems for the detection of ADRs in the 




1.4 The Typology Debate  
 
Attempts have also been made to categorise ADRs based on aetiology using a pharmacological 
and clinical perspective. Additionally, categories of types G and H have also emerged to 
capture genetic/genomic and hypersensitive (allergic) reaction respectively for either 
immunological or non-immunological factors responsible for ADR (Riedl and Casillas, 2003).  
 
Aronson and Ferner (2005) have also challenged the dominant typology and noted that 
distinguishing between dose and non-dose-related ADRs is incorrect since all ADRs are dose-
related. They proposed an alternative based on three parameters, i.e. dose-related reaction (sub-
therapeutic concentrations, collateral effects and hyper susceptibility), time-related effects 
(rapid, the first dose, early, late and delayed) and susceptibility factors (age, sex, disease, 
physiological and genetic), as a better approach to classify ADRs (Aronson and Ferner, 2003; 
Ferner and Aronson, 1999). These were argued to better reflect ADRs, although the new 
categories only reorganise the traditional typologies. For example, types A, B and F are dose-
related, types C, D and E are time-related, and types G and H are susceptibility factors. 
 
1.5 Epidemiology of Adverse Drug Reactions 
 
Having considered the various ADR definitions and related concepts, it is important to 
understand the scale and extent of ADRs. Epidemiological measurement of the scale of ADRs 
has been inaccurate because of high levels of under-reporting by both patients and HCPs, 
suggesting that the actual prevalence and incidence may be higher (Hazell and Shakir, 2006b; 
Rehan et al., 2012; Tandon et al., 2015). Even with the lower incidence and prevalence rates, 
exposure of many patients, especially in public health interventions, may lead to economically 
or socially important events being considered. Evidence suggests that prospective studies 
(Lucca et al., 2016) tend to have higher incidence and prevalence rates than retrospective 
studies (Palappallil et al., 2016) (Table 2). Prevalence and incidence have therefore been tried 
in many research studies in a variety of health system settings globally which will be briefly 
reviewed in this section. Key outcomes and economic costs have also been assessed for ADRs 
and these are considered in turn in this section, further reflecting not only on related drugs and 






1.6 Prevalence and Incidence 
 
Prevalence of ADR aims to assess the total population of patients affected by an ADR incident 
expressed as a percentage of the population, while incidence deals with the rate of occurrence 
or the number of new cases over a specified period. Many studies have evidenced the 
prevalence of reported ADRs and ADEs, but with very different findings, which make accurate 
reporting on the scale of ADRs difficult; prevalence has been reported as low as 0.2% to as 
high as 54.5% using patients being admitted to hospital as a denominator (Angamo et al., 2016). 
These reports have shown ADRs to be higher in specialist populations (paediatric and 
geriatrics) and wards (Alexopoulou et al., 2008; Hallas et al., 1992) compared to general 
hospital admissions (Carrasco-Garrido et al., 2010; van der Hooft et al., 2006). For example, 
Peter et al. 2016, found an ADR incidence of 10.45% on medical wards, which was higher than 
the general ADR rate of 0.86% found in a study conducted in five hospitals (Jha et al., 2007; 
Peter et al., 2016). Even though published studies show a considerable level of prevalence of 
ADRs and ADEs in patients, the majority (65%) of side effects are underestimated and 
unpublished (Golder et al., 2016).  
 
Also, determining an exact figure for ADRs experienced could be a difficult task due to low 
reporting and quality of reports. Hazell and Shakir (2006) found under-reporting between 36% 
and 99% with a median of 95% after assessing 37 studies of HCPs. The bulk of the literature 
quantifying ADR prevalence and incidence has been based on hospital admissions and 
inpatients. There have been disparities in calculating both prevalence and incidence of ADRs 
due to the use of different methods, screening protocols, settings, patient populations, drug 
classes and definitions of ADEs, ADRs, Adverse Events (AEvs), Adverse Drug Effects 
(ADEfs) and Medication Errors (MEs) (Leendertse et al., 2010). For example, Dedefo et al. 
(2016) and Laatikainen et al. (2016) calculated ADR prevalence based on ADE incidence data. 
This type of analysis makes it difficult to find specific incidences of ADRs. Others have 
measured incidence based on incidence density calculated over person time (Lagnaoui et al., 
2000), per 1,000 months follow-up (Gerritsen et al., 2011), based on patient admissions 
(Baniasadi et al., 2008; Nakamura et al., 2014) and either at department or unit level (Kiguba 
et al., 2017b; Lucca et al., 2016) (Table 2). 
 
ADR data generated from prospective studies have been more accurate than retrospective 
studies. This can be attributed to the robust prospective process of data collection which uses 
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different sources and rigorous follow-up compared to retrospective studies that rely on previous 
data which may be incomplete. For example, while a 20-year retrospective study of 43,380 
patients found 0.8% ADR-associated admissions (Burgess et al., 2005), a two-year prospective 
study of 18,820 patients reported 6.5%, which was higher (Pirmohamed et al., 2004). 
Generally, studies have shown that the prevalence rates are lower in the USA (5.6%), England 
(3.2%), Germany (4.8%) and Europe (4.6%) compared to global prevalence (6%) (Angamo et 
al., 2016; Bouvy et al., 2015).  Table 2 summarises the prevalence and incidence of some 
selected recent studies between 2015 and 2019. It should be noted, however, that some studies 
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1.7 Hospitalisation and Length of Stay 
 
Hospitalisation and length of stay refers to the amount of time spent in a hospital bed due to an 
adverse reaction. It is influenced by several factors including concomitant medication, 
inadequate or improper therapy, disease complication, toxicities, age, sex and genetic 
disposition. A prolonged hospital stay as a result of an ADR can have consequences on patients, 
such as increasing cost of service and pressure on the HCP workforce and on other aspects of 
the healthcare system. 
An observational study in the UK reported that 6.5% of hospital admissions and 1.9% of bed 
stays were due to ADRs. Furthermore, an average bed stay of about eight days, accounting for 
4% of bed capacity, was also reported (Golder, 2013; Pirmohamed et al., 2004). A study 
conducted in Brazil by Moura and colleagues evaluated an intensive care unit (ICU) to assess 
their ADEfs on the length of stay and found that each ADR presented by the patient was related 
to an increase of 2.38 days in the ICU (Moura et al., 2009). A similar study conducted in an 
Internal Medicine Department of a French hospital found a mean length of stay of about 5.8 
days (range 1–26 days) (Lagnaoui et al., 2000). Apart from specific studies on ADRs, some 
studies have focused on the wider topic of ADEs, which also encompasses ADRs, and has been 
reported to be responsible for a mean hospital stay of eight days (range 5–15 days) (Hardmeier 
et al., 2004).  
 
1.8 Healthcare Costs of ADRs  
 
The economic impact of medication-related problems (MRPs) has been assessed in various 
settings (Field et al., 2005; Vilhelmsson, 2015) and is estimated to be a significant burden on 
healthcare systems. The proliferation of substandard and falsified medical products on the 
African continent is worrying, with studies showing up to 18.7% prevalence of essential 
medicines such as antimalarials and antibiotics. Also, the WHO (2017) estimates that 42% of 
globally detected cases of falsified medicinal products come from Africa and result in several 
adverse consequences:  
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“Adverse effects (including lack of efficacy) caused by substandard and falsified 
medical products may lead to additional spending on repeat treatment with quality-
assured medicines, as well as to extra health care costs associated with adverse 
reactions or infections that would not have occurred had the original product been safe 
and effective” (WHO, 2017). 
 
The calculation of healthcare costs varies due to different methods used by authors to calculate 
cost based on population, setting, profession, drug class, system class, disease and associated 
factors. The major direct costs, however, have mainly been calculated based on incomes, 
disposable goods and drugs with an estimated cost of £640,089 (1CHF=£0.78) over a six-
month period (Field et al., 2005). In England, the NHS is estimated to spend £637 million per 
year on hospital admissions-related ADRs (Patel et al., 2007), while it costs the US healthcare 
system USD30 (£24) billion annually (Sultana et al., 2013). In the UK, cost due to ADRs could 
go up to £2 billion per year if indirect costs, such as loss of productivity, disability, reduced 
quality of life, confidence in the healthcare system and social costs from outpatients are 
factored in (Patel et al., 2007). In the UK, specific direct annual cost as a result of ADRs is 
estimated at £98.5 million (Elliot et al., 2018).  Similarly, the German national estimation of 
ADR cost based on 57,000 hospitalisations was €434 (£374) million per year, with 3.25% as 
serious outpatient ADRs (Rottenkolber et al., 2011). Others have estimated it to cost up to €79 
(£68) billion in the European Union (Vilhelmsson, 2015). Calculating the cost of ADRs in a 
smaller group of inpatients in France showed that a total of 371 ADRs cost more than €11 (£9) 
million at €4,150 (£3,551) per ADR (Gautier et al., 2003). Although cost estimates vary 
because of the different parameters used in the calculation, the significance of the cost element 
to ADRs cannot be discounted.  
However, only a limited number of studies have estimated the cost of ADRs on the African 
continent. The few available studies focused on specific patient populations and settings. For 
example, in Nigeria, the incidence and cost of ADRs on a paediatric population of 2,400 
admissions in a hospital setting was estimated as USD15,466.60 (£12,450) (Oshikoya et al., 
2011). ADR costs are truly variable depending on inpatient settings with more cost associated 
with ICUs (USD19,685) than non-ICUs (USD13,994) (Cullen et al., 1997). Costs of ADRs are 
therefore directly related to hospital admissions but may be variable based on setting, data 
collection methods and patient population. 
 




 The WHO defines health as: “A state of complete physical, mental, and social well-being not 
merely the absence of disease”. It therefore emphasises that frequency and severity of a disease 
are not the only ways to evaluate healthcare, but that an estimation of well-being by measuring 
improvement in health-related quality of life is equally important (WHO, 2004). ADR 
significantly affects the health, happiness and general well-being of individuals, which disrupts 
their normal functions or daily activities (Felce, 1997). Studies have mainly been targeted on 
ADRs that are more pronounced and life-threatening physically, rather than their impact on a 
person’s general well-being.  
Quality of life is of immense importance, and there have been concerns about poor information 
and lack of specific instruments put in place to measure it, especially in children and older 
adults who are mostly affected by ADRs (Del Pozzo-Magaña et al., 2015). For example, a study 
of the quality of life of tuberculosis patients experiencing ADRs in Canada was estimated as 
being more of a mental well-being issue than a physical one. Nevertheless, less pronounced 
MRPs, such as cough, depression, incontinence, dizziness, substance-induced mood disorders 
and minor symptoms that may not need hospitalisation, still have a long-term effect on the 
quality of life of a patient (Cohen et al., 2001). These subtle ADRs affect patient adherence to 
treatment regimen with lifelong consequences. For example, women using contraceptives may 
abandon treatment if they experience weight gain or disrupted menstrual cycles (Edwards et 
al., 2000). The distress caused by the medication could therefore affect the quality of life and 
daily function. 
Similarly, minor ADRs in patients on antibiotic treatment may create resistance because of 
non-adherence, which may impact their general well-being. This was further reflected in a 
qualitative study assessing an overview of HCPs’ and patients’ ADR reporting, which showed 
that the severity of an ADR and its effect had an impact on the daily lives of patients. A patient 
experiencing an ADR discomfort said: “I could not keep this up anymore, I could not wear my 





1.10 Mortality  
 
Apart from increasing hospital cost, decreasing quality of life and length of stay in hospital, 
ADRs can result in death. For example, a study conducted in the USA by Jemal and colleagues 
shows (from a 30-year analysis of causes of deaths in America) that ADRs are the fourth 
leading cause of death behind heart disease, cancers and strokes (Jemal et al., 2005). A decline 
in adverse event mortality has, however, been seen between 1990 and 2016, with the recent 
analysis of data showing an estimated 123,603 deaths in the USA (Sunshine et al., 2019). In 
2000, the Institute of Medicine of the United States reported that between 44,000 and 98,000 
deaths occur annually from MEs which include ADRs (Alomar, 2014). The Global Burden of 
Disease study analysed annual deaths in 188 countries being the high-income countries and 
middle to low-income countries (Haagsma et al., 2015). The study revealed that deaths from 
adverse effects of medical treatment rose from 94,000 in 1990 to 142,000 in 2013 and was the 
fourth leading cause of years of life lost (YLL) in high-income countries, while it accounted 
for the 14th cause in the middle to low-income countries (Haagsma et al., 2015). Serious and 
fatal outcomes of ADRs often result in death or disability. A worldwide characterisation of 
3,013,074 ADRs saw that, overall, 16% of them were serious (Aagaard et al., 2012) with 
potentially fatal outcomes underscoring the importance of collecting ADRs and medication-
related problems. 
Specific estimations of ADR mortalities accounted for 712 deaths annually in the UK (Elliot 
et al., 2018). Prescription drug overdose is said to account for a 62% rise in ADRs between 
1999 and 2004 and is said to have replaced cocaine and heroin as drugs commonly involved in 
fatal overdoses (Alomar, 2014; Paulozzi et al., 2011). This has been supported in an earlier 
analysis of 39 published studies carried out within the American pharmaceutical system over 
four decades, which found that, in 1994, 106,000 people died as a result of ADRs (Lazarou et 
al., 1998). The European Commission estimates that ADRs from prescription drugs cause 
200,000 deaths per year (Light et al., 2013). In light of this, several studies have reported death 
rates of between 1.4% (8) (Fattinger et al., 2000) and 5% (1,511 deaths) (Hakkarainen et al., 
2014; Mouton et al., 2015; Bouvy et al., 2015). Data on mortality rates in Africa are scant 
(Mekonnen et al., 2018). Only a few cross-sectional studies have attempted to estimate 
mortality related to ADRs. In South Africa, ADRs contributed to 2.9% of medical admissions, 
and 16% (56/357) of those admissions resulted in deaths (Mouton et al., 2015). Similarly, a 
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study in Ethiopia of 1,001 patients saw 1.5% (15/1001) of deaths resulting from ADRs 
(Angamo et al., 2018). 
 
1.11 The Risk Factors of ADR 
 
Several factors make ADRs a greater risk to one population over another (De Paepe et al., 2013; 
Martínez-Mir et al., 1999; Routledge et al., 2003). These may be related to age, sex, genetic 
factors, polypharmacy or clinical setting. This sub-section elaborates on these factors to further 
understand the nature of ADRs. 
 
1.11.1 Age of Patient 
 
An important predictor of ADR has been identified as age (Aronson and Ferner, 2005). It has, 
however, been challenging to categorise age as an independent risk factor or confounding 
factor. Age becomes a risk factor when it can be used to explain the causal pathway of a 
reaction, but becomes a confounder when associated with other factors. Furthermore, 
confounders may be related to risk factors but independently of the outcome of interest. For 
example, a study of 9,000 patients with ADRs saw that staying on a medical ward, alcohol 
intake, longer hospitalisation of more than 14 days, and having more than four concomitant 
medical conditions were independently associated risk factors, but not age, gender, smoking 
and previous history of fall (Carbonin et al., 1991). Classifying age as a risk factor for ADRs, 
therefore, depends on the patient population and a combination of other factors. Factors such 
as dementia, renal failure, polypharmacy and concomitant medication have, however, been 
found to be associated with the high occurrence of ADRs in older adults in some studies (Nair 
et al., 2016; Zopf et al., 2008). This occurrence could probably be an underestimation, as Hallas 
(1991) found that geriatric patients experienced difficulty in remembering their ADR 
experiences due to poor cognitive ability (Hallas et al., 1991).   
Recruiting geriatric and paediatric populations for drug trials is rare, thus, there has been 
growing interest in the assessment of ADRs in these populations to detect previously 
unidentified ADRs (Bowman et al., 1996). Children have developing immunological and body 
systems, while older adults have a weakening system which makes them more susceptible to 
ADRs compared to other populations (Alomar, 2014). Evidence from studies on ADRs in 
geriatric populations in Africa and elsewhere suggests that patients aged 60 and older had a 
much higher risk, with 82% having drug-related problems as a result of comorbidity and 
polypharmacy (Hailu et al., 2020; Lavan and Gallagher, 2016). Despite the lower risk in 
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paediatrics compared to older adults, ADRs account for a significant number of hospital 
admissions, of which 39% could be severe and life-threatening (Impicciatore et al., 2001). 
Reports on prevalence and incidence have been varied, with studies from Malaysia showing 
that 63.9% of ADRs reported from their national system were from children between 12 to 17 
years old (Rosli et al., 2016), while studies in Germany show an incidence of 60.7% of older 
adults experiencing at least one ADR (Egger et al., 2003). Multi-centre studies conducted in 
five countries – Australia, Germany, Hong Kong, Malaysia and the UK – found 18.6% 
incidence in children with several underlying differences (Rashed et al., 2012).  
 
1.11.2 Gender of Patient  
 
Research has shown that sex is an important susceptibility factor associated with susceptibility 
to ADRs, and that females are at a higher risk than their male counterparts, but the reasons 
behind this are unclear. For example, two-thirds of drug-induced torsade de pointes, which is 
a rare but life-threatening cardiovascular ADR, are more frequent in women than men (Drici 
and Clement, 2001). A Spanish study of children in a hospital also indicated females were at 
greater risk of ADRs, with a relative risk of 1.66 (95% CI 1.03–2.52) compared to males 
(Martínez-Mir et al., 1999). Accordingly, some suggested reasons for this high female 
incidence includes the pharmacodynamics of the drug, differences in the perception of ADR 
and hormonal differences (Kando et al., 1995; Schwartz, 2003). Furthermore, other underlining 
factors such as polypharmacy, disease and other gender-specific drugs like contraceptives may 
influence the higher incidence rate of women than men, but require further investigation 
(Fattinger et al., 2000).  
For example, in the study by Tran (1998), 75% of 2,367 ADRs occurred in females, and 50% 
of ADRs reported by women involved polypharmacy, compared with 33% of those reported 
by men. This was comparable to 53.1% of ADRs in adult females found in France, even though 
it was not statistically significant (Montastruc et al., 2002). A study by Zopf (2008), however, 
could not find any sex-specific differences in the pharmacokinetic and pharmacodynamic 
behaviour of drugs to explain why females experienced more ADRs. Another possible 
explanation might be centred on gender-based norms about risk perception, whereby females 
are more likely to report ADRs whereas males conceal them as a sign of strength or masculinity. 
Recent (2019) reports on analysis of the Vigibase between 1967 and 2018 showed more female 
ADR reports than male were submitted worldwide, with data pointing to females in their 
reproductive years while male reports were mostly serious and fatal ADRs. The largest 
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differences were observed by women in the 18–44 years age group but could not be explained 
after adjusting for genitourinary system and sex hormone drugs (Watson et al., 2019).  
 
1.11.3 Genetic Characteristics of the Patient 
 
Different individuals respond to medications differently due to hereditary factors that 
predispose them to ADRs. Many ADRs, which could not be predicted and were thought to be 
idiosyncratic or bizarre (type B) have now been explained genetically or using immunologic 
pathways (Kaufman, 2016). An important example of a contributor to genetically induced 
ADRs is the Glucose-6-Phosphate Dehydrogenase (G6PD) deficiency enzyme, which is 
common among African, Mediterranean and some Filipino populations (Kent, 2012). An 
estimated 400 million individuals are G6PD deficient worldwide with the highest prevalence 
in Sub-Saharan Africa (Nkhoma et al., 2009). Individuals with G6DP deficiency have increased 
risk of acute haemolysis and subsequent death when certain classes of drugs or foods are 
ingested. For example, haemolytic anaemia linked to G6PD deficiency was found in the use of 
intravenous artesunate for treating malaria (Mehta et al., 2007). This deficiency is mostly 
asymptomatic but can cause considerable harm to individuals. 
Another enzyme variability in drug pharmacokinetics and response is Cytochrome P450, which 
can alter drug metabolism, causing ADRs (Zanger and Schwab, 2013). It is estimated that at 
least 8% of the UK population, 30% of the Hong Kong population and 1% of Arabs are slower 
metabolisers and at risk of MRPs (Kent, 2012). Central nervous system drugs and 
cardiovascular system drugs are more likely to be affected by this genetic deficiency, thereby 







Polypharmacy is a recognised practice which promotes the use of two or more drugs to treat a 
disease condition or multiple diseases (Arnoldo et al., 2016; Davies et al., 2007). It does, 
however, increase the risk of ADRs occurring, especially in elderly patients (Rodrigues and 
Oliveira, 2016).  
Most drugs are remarkably safe, but safety has become a concern because of the large number 
of medications consumed (Jick, 1974). In reality, assessing the interaction of two or more 
medications in an individual is rarely investigated through clinical trials. It is, therefore, 
difficult to know what might happen when two or more medications are administered 
concurrently to a patient.  ADRs generated from drug interactions are usually captured through 
post-event surveillance when the drug is in normal use. 
A study of polypharmacy in the Italian health system showed that 67.2% of patients were on 
multiple drugs and 13.5% were patients on therapy with at least 10 drugs (Arnoldo et al., 2016). 
The use of multiple medications puts patients at risk of ADRs and this may be significantly 
exacerbated if the number of medicines is further increased (Gholami and Shalviri, 1999; 
Moore et al., 1998; Nguyen et al., 2006; Onder et al., 2002; Routledge et al., 2003).  
Even though polypharmacy may have the potential to affect patient rehabilitation negatively, 
it is necessary to prevent recurrence of some conditions (Kose et al., 2016). For example, 
elderly stroke patients may need to control their blood pressure, lipids and plasma glucose, 
which requires the use of multiple therapies. Notwithstanding this finding, the number of ADRs 
due to polypharmacy may be influenced by several other secondary factors, such as alcohol 
use, breastfeeding, pregnancy, age, renal function and clinical setting. 
 
1.11.5 Department/Clinical Setting 
 
It is expected that the occurrence of ADRs may vary depending on the type of clinical setting, 
hospital department or unit. HCPs work in various hospital departments and clinical settings 
based on job progression, the rank of professional (Junior or Senior), professional category 
(nurse, doctor or pharmacist) or chosen speciality. Working in a department with frequent ADR 
cases may influence HCP reporting behaviour positively or negatively. Even though there may 
be opportunities to submit more ADR reports, the workload in busy departments or clinical 
settings may hinder ADR reporting (Obonyo, 2014). 
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ADRs studied in different clinical settings/departments have shown that higher rates are 
recorded in specialised units, such as medical units, ICUs, psychiatric units, geriatric and 
paediatric units (Dedefo et al., 2016; Laatikainen et al., 2016; Lucca et al., 2017; Rojas-
Velandia et al., 2016) than general care (Chan et al., 2016). This may not always be the case, 
since general care usually has higher patient numbers. A systematic review of 95 studies found 
the prevalence of ADRs to be higher (3.03%) in general hospital admissions compared to 
admissions from acute care (1.14%) (Leendertse et al., 2010). There may also be variations 
between specialised hospital departments. Research comparing the much broader picture of 
ADEs (which includes ADRs) from medical intensive care units (MICUs) and surgical 
intensive care units (SICUs) found more ADRs in MICUs (19.4%) than SICUs (10.5%) (Bates 
et al., 1995; Davies et al., 2007). This could have been due to the large number of medications 
given in MICUs and medical departments in general due to worsening medical condition, as 
suggested by Davies et al. (2007). Furthermore, a review showed most ADRs (12.8%) were 
occurring in the medical department of a university hospital in Greece, which may reflect other 
issues such as polypharmacy and aggravated medical conditions (Alexopoulou et al., 2008; 
Bouvy et al., 2015).   
 
1.12 Methods of Monitoring and Collecting ADR Reports  
 
Monitoring and collecting ADR reports can be undertaken in either an isolated or organised 
manner among HCPs. In isolated individual reporting, HCPs send reports through to a 
regulatory agency or Marketing Authorization Holder (MAH) spontaneously, while organised 
individual reporting is done by collecting reports collated by groups of practising HCPs in 
hospitals, or groups of hospitals in a collaborative manner. Furthermore, comprehensive 
monitoring (intensive hospital monitoring) uses organised specialist physician groups, 
especially at referral centres (e.g. teaching hospitals) to survey drug use and identify all adverse 
effects. Population monitoring is characterised by automatically recording drug use and patient 
AEvs, and finding the association between the two (WHO, 1972). Other sources of generating 
ADR reports are literature reviews, database searches, post-marketing studies by MAH and 
public health programmes. 
The most commonly used method globally for monitoring and reporting ADRs is the 
Spontaneous Reporting System (SRS) (Pal et al., 2013). This is often complemented by other 
methods such as the Active Reporting System (ARS). They both involve volunteering 
information about adverse reactions to responsible authorities for causality assessment. These 
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systems traditionally relied on paper-based reporting forms, but online electronic systems have 
been made possible by the proliferation of technology in the last two decades (Wu et al., 2002).  
Monitoring ADR is essential for the identification and communication of medication safety 
problems. Spontaneously reporting ADRs is the most cost-effective way to collect drug ADRs 
routinely from HCPs, MAH and the general public through the SRS. The WHO recommends 
Targeted Spontaneous Reporting (TSR), which builds on the principles of SRS (Pal et al., 
2013). ARS also encompasses Cohort Event Monitoring (CEM), use of observational methods 
and related activities to continuously create awareness for enhanced patient reporting. Other 
sources include data from clinical trials and health records. In the UK, all suspected ADRs to 
newly licensed drugs (usually labelled with an inverted black triangle (▼)) should be reported 
to the Medicines and Healthcare products Regulatory Agency (MHRA). For established 
medicines, all serious suspected ADRs from over-the-counter medications, herbal products, 
food supplements and off-label drugs should be reported, even if adverse effects are well 
recognised. If unsure whether to report, it is recommended to go ahead and report an ADR to 
authorities for further assessment (Mann and Andrews, 2007).  
 
1.12.1 Spontaneous Reporting System (SRS) 
  
This method is referred to as a passive surveillance system, where information about ADRs is 
volunteered by healthcare professionals, patients and the general public to the regulatory 
authority or the pharmaceutical company marketing the drug. As the name suggests, there is 
no follow-up on patients, and reporting is solely based on personal motivation. This method is 
considered less expensive and able to provide safety surveillance throughout the lifespan of 
any drug. Rare and serious drug-related problems, such as deaths related to concentrated 
potassium, lidocaine, cisplatin and carboplatin, have been identified through this method 
(Murff et al., 2003). It is, however, challenged by issues relating to quality, biases and 
widespread under-reporting (Hazell and Shakir, 2006a). A review of SRS in 12 countries 
(Hughes et al., 2002) identified a wide variation in the type of reporting system and adverse 
reactions that were being reported by HCPs and the general public. The review also found that 
whilst some schemes recommended reporting all ADRs, others were more concerned about 
serious ADRs and those of new medicines only.   
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1.12.2 Targeted Spontaneous Reporting (TSR) 
 
This is a sub-set of SRS, which is an add-on to routine patient monitoring in a defined setting 
where they are receiving treatment (WHO, 2006). For example, patients switching treatments 
are sensitised to report medication problems they encounter. This was developed by the WHO 
and piloted in 2010 on patients receiving antiretroviral drugs (Pal et al., 2013). This method is 
simpler and less expensive compared to ARS and can focus on priority ADRs, providing some 
measures of rates and incidence. The challenge of this method lies in HCPs’ minimal 
experience with the method and individuals’ lack of motivation to monitor and report (Lobo et 
al., 2013). 
 
1.12.3 Active Reporting System (ARS) 
 
In an ARS, patients are given medication and followed up using methodological procedures to 
search for MRPs at designated sites. This ensures high quality and quantity of reports in a cost-
effective manner compared to the SRS (Kang and Lee, 2009). Worldwide active reporting 
systems include: the combined use of multiple databases, claims records, use of pharmacy 
benefits or safety managers, medical records, charts, general practitioner data, interviews and 
questionnaires to identify MRPs (Huang et al., 2014). Oshikoya used a similar strategy by 
reviewing medical and pharmacy bills, medical charts and diagnostic request forms, and by 
interviewing the patients for ADRs incidents in Nigeria (Oshikoya et al., 2011). 
  
1.12.4 Chart Reviews 
 
This takes the form of a retrospective or prospective manual collection of existing data from 
patient records, medication charts, prescription data and lab results, to identify MRPs. This 
method is actually considered the ‘gold standard’ for identifying and reporting ADEs, and 
requires the use of trained assessors (HCPs or designated research assistants) (Murff et al., 
2003) but can be useful in collecting ADRs too. A first and second assessor may be used to 
reduce bias and increase the reliability of assessment reports, for example, a nurse may take 
part in the case identification phase while a doctor does the case classifications (Morimoto et 
al., 2004). 
Prospectively, chart reviews are done while patients are still in the hospital setting. This allows 
collection of detailed data from lab results, doctor notes, nurse notes etc. This approach usually 
generates more data than retrospective chart reviews (Mazer et al., 2007). 
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Retrospective chart reviews, on the other hand, involve following up outpatients to collect data. 
This is usually less data-intense than prospective chart reviews due to sporadic visits of patients 
who are sometimes lost to follow-up. Some studies (Forster et al., 2003) have used patient 
interviews to complement this method, combined with sign-out notes, discharge summaries 
and lab results to help construct case summaries (Murff et al., 2003). The major challenge with 
chart reviews, however, is the high cost of maintenance involved, high reliance on assessors, 
and incomplete data, especially for outpatients (Brvar et al., 2009; Leape et al., 1991). 
 
1.12.5 Electronic/Computerised Systems 
 
This platform creates yet another fast and reliable way for HCPs to actively report MRPs in 
real time, to regulatory agencies or MAH. There has been a transition by regulatory agencies 
and hospitals from paper-based reporting to electronic-based reporting. Electronic patient 
databases of medical, pharmacy, lab and administrative records have also been automated to 
identify triggers. Triggers occur when a connection is made between two coded terms or rules 
which can lead to an adverse event (Jha et al., 1998). MRPs do not need implicit physician 
judgement to determine causality. For example, with technology, keywords such as 
‘convulsion’, ‘allergy’, ‘fall’, ‘drug names’ or ‘toxic serum’ levels of digoxin can be linked to 
form a rule that leads to a trigger (Murff et al., 2003). This is then flagged in the database for 
personnel to verify the abnormalities that occur. 
A further example is a study by Classen where hospital information systems were monitored 
for generation of ADEs in which pharmacist reviewed and monitored patients’ records (Classen 
et al., 2005). Electronic/computerised systems are less time-consuming, information can be 
transferred in real time, fewer personnel are involved, and they are capable of detecting more 
MRPs. They do, however, have an expensive initial setup cost, issues with incomplete data and 
may trigger false positives (Schneider, 2002). For example, ADEs identified through a hospital 
database review were found to be underestimated due to incomplete data (Carrasco-Garrido et 




1.12.6 Cohort Event Monitoring (CEM) 
 
This is a type of prospective observational study where trained personnel collect data of one or 
more medicines in a normal setting of routine clinical practice. This was adopted by the WHO 
in the 1970s to monitor medication safety in public health programmes, especially in resource-
limited countries (Pal et al., 2013), and malaria therapy (Bassi et al., 2013; Dodoo et al., 2014; 
Suku et al., 2015). It is based on the same principles as the UK’s Prescription Event Monitoring 
(PEM) (Hazell and Shakir, 2006a) or New Zealand’s Intensive Medicines Monitoring 
Programmes (CIOMS, 2009). CEM has the advantage of being able to capture all medication-
related events of interest, including MEs, ADEs, counterfeits and ADRs. It also has the ability 
to accurately calculate rate of occurrence and deaths. However, it is more laborious and 
expensive, and requires dedicated staff. Also, patient drop-out may affect cohort size and rare 
ADRs cannot be detected (Pal et al., 2013). For example, a CEM of artemisia-based 
combination therapy (ACT) for malaria in four African countries exceeded budget by 11.1%–
63.2%, took longer than expected and had data management problems (Suku et al., 2015). 
 
1.13 Under-Reporting of ADRs Globally 
 
As mentioned earlier, the cheapest way of generating ADR reports is through spontaneous 
reporting. However, unless reporting is stimulated, it is challenged by under-reporting. Even 
though the WHO promotes the use of stimulated reporting, such as TSR and CEM, especially 
for public health programmes, the implementation of these has been challenging (Pal et al., 
2013). HCPs, especially doctors, are key to the implementation of these reporting strategies, 
but the response has been poor. The WHO recommends a minimum of 200 ADR reports, per 
million population, per year, but only 10% of doctors reporting to the WHO Uppsala 
Monitoring Centre (UMC) meet this threshold (https://www.who-umc.org/); this could be 
much lower in developing countries (WHO, 2000). A systematic review suggests that 86% or 
more of serious ADRs leading to hospital admission go unreported (Hazell and Shakir, 2006). 
A more recent study reported that 70% of physicians had not reported an ADR, with the most 
important reason attributed to being that the ADRs were already known (41%). Several 
complex combinations of factors account for under-reporting. Inman (1976) suggested the 
‘seven deadly sins’ for under-reporting (i.e. complacency, fear, guilt, ambition, ignorance, 
diffidence and indifference) (Inman, 1996). These have been confirmed in several studies, 
including a systematic review by Lopez-Gonzales and colleagues, who suggested that the 
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factors identified in 45 research papers studied were more associated with Inman’s typologies 
than with personal and professional factors, such as age, workload, educational background, 
training and workplace (Lopez-Gonzalez et al., 2009). Previously, only doctors were allowed 
to report ADRs, but recent restructuring has made it possible for patients and other healthcare 
professionals to send direct reports to competent authorities. Although under-reporting is still 
an issue, the inclusion of other calibre reporters has increased ADR reports at the UMC to more 
than 20 million since its inception (https://www.who-umc.org/). 
 
1.14 Factors Influencing ADR Reporting Among HCPs 
 
Within the subject of ADR reporting and the wider topic of how patient safety incidents are 
reported, several theoretical approaches and models have been developed to explain and predict 
particular reporting behaviours. These include broader theoretical frameworks on patients’ 
safety, which identified 12 factors (Archer et al., 2017), as well as the use of behaviour change 
theories such as a theoretical domains framework (Shalviri et al., 2018). Arguably, the most 
influential – although somewhat outdated now – is the identification of the ‘seven deadly sins’ 
by Inman (1976, 1996) which has been used to suggest how a multitude of factors can influence 
under-reporting of ADR among doctors. However, to help frame this literature review, a model 
that captures ADR reporting very specifically was used to draw on not only both the personal 
and professional (intrinsic) factors but also those external system factors of the individual 
which are extrinsically linked. A framework developed by Obonyo (2014) was used, which in 
turn drew significantly on the earlier model by Herdeiro et al. (2004) to identify a conceptual 
framework representing three domains affecting reporting: contextual, extrinsic and intrinsic 
factors. The factors tend to be inter-related and influence each other bi-directionally. For 
example, knowledge (intrinsic) can only be improved if the right training (extrinsic) and 
policies (contextual) are in place. These would be explained thematically based on available 
literature, and key aspects of each factor will then be elaborated on further as sub-themes 
explaining inter-relations and reasons for low ADR reporting based on an adapted framework 





Figure 2: Conceptual framework of factors influencing reporting of ADR by HCPs  
(adapted from Obonyo, 2014) 
 
This was based on an earlier theoretical model by Herdeiro (2004) to explain this concept 
further, based on her mixed theoretical model (Appendix W). Herdeiro (2004) uses the theory 
of the acquisition of habits in health sciences – knowledge-attitudes practices (KAP) (Hong et 
al., 1995), and the theory of satisfaction of needs (Slotnick, 1996) to explain how intrinsic 
factors are influenced by other extrinsic factors towards ADR reporting, and therefore 
recommends combined strategies to improve reporting (Herdeiro et al., 2004). Similar factors 
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also emerged from an integrative review of nurses by De Angelis (2016). The authors found 
that extrinsic factors relating to interaction with other nurses, doctors and healthcare 
organisations’ elements influenced nurses’ reporting habits. The authors argued that reporting 
was influenced by nurses’ intrinsic factors, which were related to their knowledge and attitudes, 
which was fundamental (De Angelis et al., 2016). Considering the complexity of internal, 
contextual and external factors, other authors have suggested exploring other possibilities for 
addressing the reporting culture other than just attitudinal surveys (McGettigan et al., 1997). 
These concepts have, therefore, been adopted to form a conceptual framework to review the 
literature on each classification. These are further elucidated on in the sections that follow. 
 
1.14.1 Intrinsic Factors 
 
Intrinsic factors refer to the core and inherent elements, which affect ADR reporting of HCPs, 
such as knowledge, awareness, attitude, perception and practice about PV and ADR reporting. 
They are considered intrinsic because they represent the innate fundamental dynamics of HCP 
behaviour, which determines their ability and willingness to identify, recognise and report 
ADRs to appropriate authorities.  
A basic Google Scholar keyword search using [Knowledge AND attitude AND practice AND 
“adverse drug reaction” AND reporting AND “healthcare professionals”] as of January 2020, 
yielded 762 references. No reviews, however, summarised the literature on the factors affecting 
reporting in Africa. The majority of studies assessing knowledge, attitude and practice (intrinsic 
factors) of ADR reporting have been conducted in Europe and Asia (Alshakka, Mohamed 
Ibrahim and Hassali, 2013; Benkirane et al., 2015; Bhagavathula et al., 2016; De Angelis et al., 
2015; Desai et al., 2011; Kamtane and Jayawardhani, 2012; Kharkar and Bowalekar, 2012; 
Lopez-Gonzalez et al., 2009). Under-reporting and the factors influencing reporting behaviours 
are therefore not adequately explored in empirical research of African studies.  A review 
conducted in India, which shares contextual similarity to Africa as a resource-limited setting, 
has reported high unawareness and poor reporting attitude among HCPs. The study showed  
that more than half of the HCPs were unaware of the PV programme and 75% never reported 
an ADR (Bhagavathula et al., 2016) which may be similar in most African studies. 
Additionally, several reviews have shown similar trends in reporting behaviours among HCPs 





Knowledge/awareness: According to the Oxford English Dictionary (OED, 2017), knowledge 
is described as “facts, information, and skills acquired through experience or education; the 
theoretical or practical understanding of a subject” or “the awareness or familiarity gained by 
experience of a fact or situation”. Even though knowledge and awareness are related, they may 
be distinct in the sense that while knowledge is based on facts through experience, education 
and training, awareness, on the other hand, is more about perceptions and consciousness of an 
individual about how things are supposed to be. For example, HCPs may be aware of the 
importance of the yellow card scheme but without any knowledge of the details required on the 
form. 
Literature shows various assessments of HCPs’ understanding of skills required to theoretically 
or practically report ADRs, but no universal tool exists to measure knowledge in PV. Most 
measurements, therefore, have been based on validated questions from previous studies, 
modified to suit research context. For example, contextually, Pulford and Malcolm’s questions 
on knowledge were based on the meaning of the black triangle in the UK yellow card scheme, 
which may have only been applicable in a UK context or other jurisdiction where they have 
the black triangle on the label of new medicines (Pulford and Malcolm, 2010). This has resulted 
in different measurement scales and parameters for quantifying PV knowledge.  
In the estimation of knowledge, while other studies have assessed knowledge using a few 
questions, others gave in-depth assessment. For example, while Almandil in her study in Saudi 
Arabia asked two questions to assess knowledge of HCPs, others asked 13 knowledge-based 
questions (Almandil, 2016; Alemu and Biru, 2019). Firstly, Almandil asked about the 
awareness of PV and ADRs followed by a question on types of ADRs and how to report them. 
She found that 62.2% were unaware of PV and 71.6% stated all types of ADR should be 
reported (Almandil, 2016). The majority of studies, however, have assessed the knowledge of 
HCPs by asking more detailed questions about the burden of ADR, where to report ADR, types 
of ADR to report, information to include in reports, responsible institutions, the yellow card 
system and PV (definition, purpose and location of WHO-IDMP) (Hajebi et al., 2010; Gupta 
and Udupa, 2011; Kharkar and Bowalekar, 2012; Bhagavathula et al., 2016).  The designs of 
the questions were usually close-ended or semi-structured questions for assessing interventions 
or cross-sectional analysis (Avery et al., 2011; Pimpalkhute et al., 2012). The level of 
knowledge among key frontline healthcare staff has also been varied.  
 
Doctors’ knowledge: Physicians and doctors play a vital role in collecting ADRs because of 
their expertise and training in medicine and their traditional role as reporters since the inception 
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of the international drug monitoring programme (Jordan, Vaismoradi and Griffiths, 2016). 
Previously, doctors were the only HCPs allowed to report suspected ADRs, but there have been 
reports of low knowledge and non-reporting among them as well (Abubakar et al., 2014a; 
Peyman et al., 2016). The majority of studies, however, have reported moderate levels of 
awareness about reporting procedures even though the majority (95%) feel they are most 
qualified to report (Kamtane and Jayawardhani, 2012; Khan et al., 2013; Daher, Ismail and 
Agarwal, 2013). For example, a comparative study in Malaysia showed significant lower 
knowledge and awareness about PV among doctors (66.9% ± 19.86) compared to pharmacists 
(76.9% ± 13.87) (Abubakar, Simbak and Haque, 2014). Even though they have a good level of 
knowledge, reports on their level of awareness differ. For example, studies in India reported 
disproportionate levels of knowledge and awareness among doctors, i.e. 60% (Kharkar and 
Bowalekar, 2012), 52.3% (Thomas, Udaykumar and Scandashree, 2013) and 66% (Chopra, 
Wardhan and Rehan, 2011). 
In a related review, seven studies reported high levels (90%) of knowledge and doctors knew 
the purpose of ADR reporting (Abubakar et al., 2014). The difference in level of awareness 
may therefore be due to a number of underlying factors relating to the level of doctors, age, 
geographical location, how data was collected and the variability in assessment tools. 
 
Pharmacists’ knowledge: Many studies have shown pharmacists to be knowledgeable and 
aware of the yellow card scheme and ADR reporting compared to other HCPs. In the UK they 
started reporting ADR independently two years before nurses, in 2000 (van Grootheest et al., 
2004), and a study by Green (2001) reports that 97.7% were aware and knowledgeable about 
the yellow card scheme before they were allowed to report (Green et al., 2001). When assessed 
alone, studies have shown lack of knowledge (30%) and low ADR reporting (Afifi et al., 2014), 
but assessing them together with other HCPs usually shows they have better knowledge. For 
example, pharmacists (60.5%) and pharmacist technicians (40%) had the highest percentage of 
PV awareness, followed by nurses (18%) and physicians (12.1%) in a study assessing ADR 
reporting among HCPs (Almandil, 2016). ADRs reported by a pharmacist are said to be of 
better quality and quantity than other healthcare professionals because of their knowledge in 
pharmacotherapy (Wilbur, 2013). 
 
Nurses’ knowledge: The role of nurses has increasingly been recognised for reporting ADRs 
because they represent the largest cadre of HCPs in most jurisdictions (NMC, 2010; Gabe et 
al., 2011; De Angelis et al., 2016; Griffith, 2013). Nurses only started to report ADRs in the 
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UK in 2002 (Ranganathan et al., 2003) and were not part of the reporting in most parts of the 
world until recently. Nonetheless, reports from studies show they have improved knowledge 
on ADRs and how to report over time. For example, studies in Sweden showed nurses had 
above average (58%) knowledge (de Langen et al., 2007), similar to studies in the UAE 
(50%) (John, 2012), and even showed better (75%) knowledge than doctors in a tertiary 
hospital in India (Rehan et al., 2012). On the contrary, other studies showed that the majority 
of nurses (71.6%) were not aware of the reporting system and did not know how to fill in the 
ADR form and the reporting system, and therefore suggested poor knowledge and attitudes (De 
Angelis et al., 2016, 2015).  
 
Attitudes: Attitudes deal with HCPs’ feelings or emotions about ADR reporting which could 
be negative or positive. Even though it may be challenging to measure emotions and feelings 
quantitatively, researchers have widely used Inman’s theoretical model of the deadly sins of 
reporting in surveys to assess HCP attitudes. This can be a good way to predict the knowledge 
of HCPs. In 1976, Inman initially presented a list of behaviours and attitudes of HCPs suspected 
to be causing low reporting of ADRs. He summarised the numerous and complex terms for 
under-reporting into seven major themes, and described them as the ‘seven deadly sins’ of ADR 
under-reporting (Table 3). Three extra factors were added in 1996, making 10 in total (Inman, 
1996). Most studies have therefore based their evaluation of attitudes of ADR under-reporting 
around these themes (Gent and Shigematsu, 1978; Hazell and Shakir, 2006; Kamtane and 
Jayawardhani, 2012; Kiguba et al., 2014; Lopez-Gonzalez et al., 2009b; Mendes Marques et 





Table 3: Attitudinal factors for under-reporting of ADR (Inman, 1996) 
Attitude Definition  
Complacency 
 
Feeling content, uncritical and encouraged by the belief that 
only safe drugs are allowed on the market. 
Fear of litigation  
 
Anxiety of being involved in legal suits from affected 
individuals or investigations by the Health Departments. 
Guilt 
 
Emotionally feeling responsible for having administered a 
treatment which has caused appreciable harm to an individual. 
Ambition 
 
The desire to collect case series and publish for personal 
recognition or other rewards. 
Defiance 
 
Disobedience by the bold resistance of reporting mere 
suspicions without causality. 
Indifference 
 
Unimportance resulting from lack of time, interest, 
procrastination; by healthcare professional towards 
contribution to the general advancement of medical 
knowledge. 
Ignorance Lack of knowledge or unawareness of the process involved in 
submitting an ADR report. 
Lethargy A combination of procrastination, lack of time, interest and 
other insubstantial excuses. 
Motivation (Financial 
Incentive) 
Any monetary gain or incentive such as lottery ticket or 
percentage increase in salary. 
Insecurity  Uncertainty about causality between a reaction and a drug. 
 
 
In a systematic review of 45 studies, the most frequent attitudes affecting ADR reporting were 
ignorance (95%), defiance (72%) and lethargy (77%) (Lopez-Gonzalez et al., 2009a). 
Ignorance, which usually reflects HCPs’ knowledge, has featured strongly as the most 
important factor for under-reporting ADRs. In a qualitative study in Ghana on ADR reporting, 
HCPs cited lethargy and lack of time as a result of high patient numbers in outpatients 
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department (OPD) as reasons for their inability to report on ADRs as shown in the following 
statement:  
“… yes, it is true, some [HCPs] don’t have the time to do education and I 
think it is OPD congestion that is causing that. Sometimes OPD will be too 
full with patients seeking healthcare services that you think if I should waste 
time doing education, I cannot finish early. I think that is the reason because 
all of us have been trained on counselling but we are not doing it because of 
pressure on us”(health worker) (Chatio et al., 2016).  
The pressure from patients gave HCPs an unfriendly attitude, keeping patients away from 
reporting ADRs to HCPs as expressed by the following patient:  
“yeah at times when you go to the health facility, they would shout at you 
and say that it is the way the drug works...if you don’t want them to shout at 
you, you will not go back and tell them and rather prefer to keep it (ADR)…” 
(Chatio et al., 2016).  
In Brazil, Varallo (2014) showed a similar trend in their study of HCPs where ignorance 
(82.7%), insecurity (82.7%) and indifference (79.3%) were ranked highly (Varallo et al., 2014). 
Many of these assessments have been explored quantitatively using structured or semi-
structured interviews (Rolfes et al., 2014). Semi-structured interviews have allowed the 
addition and explanation of HCP attitudes. For example, a study showed qualitatively that the 
word ‘report’ was misinterpreted by nurses to mean just telling a doctor or a patient, or noting 
in clinical records, rather than making sure it was forwarded to the appropriate regulatory 
authority. The authors, therefore, added other factors for under-reporting: misinterpretation of 
the meaning of ‘reporting’, unawareness of nurses’ autonomy to report ADRs and fear of 
consequences after ADR reporting (De Angelis et al., 2016). Several additional factors have 
therefore been reported based on contextual relevance. Varallo (2014) also proposed addition 
of ‘lack of training in pharmacovigilance reporting’ (Varallo et al., 2014). Attitude may, 
therefore, differ depending on the professional category, context and other inter-related factors. 
For example, doctors and nurses have similar attitudes to ADR reporting but cultural 
differences in roles are found to underpin their attitudes (Moumtzoglou, 2010). Nurses have 
been reported to have a much more positive attitude to ADR reporting than doctors (Whitaker 
and Ibrahim, 2016). This may be because nurses have a culture of following protocols, 
directives and fear of being scolded as suggested by Mirbaha and others (Mirbaha et al., 2015). 
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For example, in a study exploring doctors’ and nurses’ attitudes to reporting in Australia, a 
senior nurse said:  
“our organization tell us that we need to fill out these forms, therefore we 
do. We have a directive...” (Kingston et al., 2004).  
This has resulted in nurses preferring to report ADRs to doctors and pharmacists rather than 
the appropriate authority (Hanafi et al., 2012). Even though researchers have narrowed 
themselves to Inman’s attitudes, reasons for not reporting ADRs may still depend on complex 
inter-relations of personal barriers, contextual and extrinsic factors that need to be explored 
further. 
  
Practice: The practice of HCPs relates to the real-world application of methods for reporting 
ADR. This has been tested in cross-sectional studies using theoretical questions to assess the 
expected method of reporting ADRs. HCPs are usually asked about where reports were 
submitted, number of reports submitted in the past year or month, number of times reported, 
training on PV, types of ADR reported, types of implicated drugs and action taken (Prakasam 
et al., 2012). PV training is an important aspect, which improves knowledge, attitude and 
practice. It helps HCPs to understand where to send reports and how to report.  In Ghana, 
training for only higher rank doctors affected the reporting of junior doctors, thus a 
recommendation for more training on PV was recommended for junior doctors to increase 
ADR reports (Sabblah et al., 2014). Other studies, which did not put emphasis on training, 
noticed doctors were inclined to send ADR reports (87.7%) to pharmaceutical companies 
instead of to recommended government ADR centres (18.5%) (Kharkar and Bowalekar, 2012). 
There has been a consistent increase in the number of ADR reports submitted by nurses 
(Hawcutt et al., 2011). They form the largest cohort of HCPs in most jurisdictions and their 
contributions to ADR reporting are of immense importance (Griffith, 2013). Nurses’ ADR 
reports have been said to be comparable in quality and quantity to doctors’ (Griffith, 2013; 
Morrison-Griffiths et al., 2003). The success of the ADR reporting process, however, depends 
on the collaboration of nurses and other HCPs (Jordan et al., 2016). Nursing practice in general 
also has low ADR reporting rates compared to pharmacists. For example, a study showed that 
91% of nurses had never reported an ADR and most (87.1%) of them preferred to report to 
doctors and pharmacists in hospitals’ ADR centres rather than the ADR National Centre (1.8%) 
(Hanafi et al., 2012). 
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Pharmacists are noted in many studies for better quality and quantity of ADR reports than other 
HCPs (Wilbur, 2013) even though they are also known to have low reporting rates in practice 
(Green et al., 2001; Almandil, 2016). In other studies, when compared to doctors, pharmacists 
reported more (70.8%) ADR than doctors (51.9%) (Molokhia et al., 2016), but when evaluated 
alone in a different study, only 11.8% ever reported an ADR to authorities (Prakasam et al., 
2012). Highly specialised professionals in pharmacology are more likely to report ADR than 
other professional classes. For example, other studies have shown differences within the 
pharmacy staff sub-specialities where clinical pharmacists were noted to be more likely to 
report an ADR than dispensing pharmacists (Liu et al., 2015). Most commonly associated 
factors affecting practice were higher professional title, training on ADR reporting and access 
to forms (Liu et al., 2015). Practice can be therefore influenced by rank and class of medical 
professional, experience and training. 
 
1.14.2 Extrinsic Factors 
 
Apart from intrinsic reasons affecting ADR reporting, there are also extrinsic or distal factors. 
Extrinsic factors are external factors which relate to health system/organisation, patient 
susceptibility factors (age, sex, genetic, comorbidity), confounding HCP characteristics (age, 
sex, rank, experience and education), administrative bottlenecks and relationship with other 
stakeholders, such as regulatory authorities and pharmaceutical companies which affect ADR 
reporting by HCPs. 
 
HCP characteristics: Not many studies have reported the association between HCP 
characteristics and reporting. Older age, professional rank and longer working experience of 
an HCP is expected to influence the rate of ADR reporting positively. This has been 
demonstrated to be true in some studies (Bateman et al., 1992; Cosentino et al., 1999; Sabblah 
et al., 2014). For example, Sabblah’s study of Ghanaian doctors reported that higher-ranked 
doctors were more likely to report ADR than house officers (Sabblah et al., 2014a). However, 
other studies have found experience and older age not to be associated with better ADR reports, 
because physicians and pharmacists were unable to identify potential drug-drug interactions 
correctly (Routledge et al., 2003). HCPs who reported ADRs were rather younger practitioners 
(Tubert-Bitter et al., 1998). Other studies found no significant associations between ADR 
reporting and sex, age, number of patients seen per day and experience (Ekman et al., 2012; 
Gavaza et al., 2011; Kiguba et al., 2014; Lee et al., 1994; Sabblah et al., 2014a). Association 
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of ADR reporting with these external factors seems to vary in many studies, suggesting the 
complex nature of the factors associated with reporting at the extrinsic level. 
 
Systems and tools: Weak health systems may affect the efficiency of a reporting system. A 
major constraint to reporting ADR within the healthcare system is the unavailability of 
reporting tools (De Angelis et al., 2016; Kozamernik, 2010). In some cases, where reporting 
tools are available, the inefficiency in the reporting system could affect their reporting 
behaviour. For example, in an Iranian qualitative study, a participant stated that “Sometimes it 
takes half an hour just to fax a yellow card to ADR centre”,  which could have impacted his/her 
decision to report (Mirbaha et al., 2015a). Ability to design enabling health systems which 
ensures availability of reporting tools and improved systems is an important predictor of 
reporting and could be beneficial if developed. 
 
Workload and type of facility: Overwhelming workload or burnout have been reported as a 
common factor for HCPs’ inability to report ADR (Bateman et al., 1992; Belton et al., 1995; 
Figueiras et al., 2001; Suku et al., 2015; Sweis and Wong, 2000; Tandon et al., 2015). Several 
studies, however, have not found any association between workload and reporting rates (Lee 
et al., 1994; Bateman et al., 1992; Vallano et al., 2005; Suku et al., 2015). The type of facility 
can also have an impact on reporting and workload. Teaching hospitals may have more 
specialised cases with a high number of patients compared to a community clinic. A study in 
Kuwait also suggested doctors from private hospitals were more knowledgeable about PV and 
ADR reporting and were more likely to report than public hospitals (Alsaleh et al., 2017). Other 
underlying factors may be responsible for how ADRs are reported depending on the type of 
facility. 
 
Patient susceptibility factors: As mentioned earlier in the chapter, ADRs occur according to 
different patient factors and circumstances which are multi-factorial and differ in populations. 
These may be patient-related, drug-related or socially related (Alomar, 2014). Examples 
include comorbidity, polypharmacy, age, pregnancy, intake, race, kidney disease, gender, liver 
function, genetic disposition and clinical setting. These may be as a result of lifestyle choices 
(smoking and alcohol), which could be modified, but others (genetic factors and comorbidity) 
cannot be controlled.  Understanding the diverse effects of these factors on ADRs enables 




Relations with pharmaceutical companies: Healthcare professionals, especially doctors, 
have constant interactions with pharmaceutical companies and their representatives because 
the majority (92%) find it acceptable to try samples of new drugs (Morgan, 2006). 
Pharmaceutical companies are noted for giving HCPs gifts, continued medical education or 
conference and research sponsorship in order to promote their drugs. Even though doctors have 
denied that these incentives influence their prescriptions, rapid prescription of new drugs was 
found to be associated with samples tried (Wazana, 2000). As mentioned earlier, new 
medicines and polypharmacy may give rise to ADRs, which can lead to increased ADR reports, 
but the willingness of HCPs to report might affect the reporting rate (Kuo et al., 2012). On a 
five-point Likert scale assessing HCP reporting of ADRs, doctors (46.7%), pharmacists 
(41.4%) and nurses (33.3%) opposed reporting ADRs to the pharmaceutical industry (Shamim 
et al., 2016). A positive relationship with medical representatives, however, can be used as a 
means of increasing HCP knowledge about PV and increasing ADR reports submitted to 
regulatory authorities. For example, Indian doctors were more inclined to send ADR reports 
(87.7%) to pharmaceutical companies than government ADR centres (18.5%) because of a 
positive relationship with pharmaceutical companies (Kharkar and Bowalekar, 2012). 
 
Feedback: A functional PV system must rely on active and timely feedback between 
authorities, HCPs and patients (Yadav, 2008). This involves data sharing and actions taken on 
the basis of submitted reports. Lack of feedback from pharmaceutical companies and regulatory 
authorities, however, has been observed as a demotivation factor to reporting ADRs. In Nepal, 
even though not a regular practice, 64% of HCPs indicated they would like to receive feedback 
from the national regulatory authority (Santosh et al., 2013). Patients have also considered 
feedback important, especially from HCPs. For example, 97% of patients in a Ghanaian study 
indicated they expected feedback on ADRs they reported and 61% preferred to be called 
directly on the telephone as opposed to receiving personalised letters (3.4%) (Sabblah et al., 
2019). Feedback is therefore considered an important aspect of ADR reporting which both 




1.14.3 Contextual Factors 
 
Contextual factors refer to the background, environmental or geographical setting and 
circumstance in which the ADR reporting could be affected. ADR reporting has been identified 
in the literature to be influenced by country policies, resources, regulation, law enforcement 
strategies, stage of a drug’s life cycle, political environment to discuss ADRs and the media.  
 
Reporting policies: Even though ADR under-reporting is a global phenomenon, the measures 
to improve reporting differ. Some high-income countries, such as Sweden, Spain, France and 
Italy, have made ADR reporting by healthcare professionals mandatory (Hazell and Shakir 
2006). Such policies and laws have accounted for the high number of ADR reports generated 
by HCPs, and interventions often do not yield much effect compared to countries where 
reporting is not mandatory. For example, an educational intervention of 20–25 group sessions 
yielded a moderately positive effect but was not recommended for other geographical settings 
(Lopez Gonzales et al., 2015). Furthermore, an analysis of global reporting to the WHO 
database from 2000 to 2009, showed 85% of more than 3 million ADR reports generated 
worldwide were from the USA, UK, France, Canada, Australia and Germany (Aagaard et al., 
2012), but mainly the USA (81.8%), and less than 1% from Africa (Ampadu et al., 2016).  Most 
of the high-income countries have been members of the WHO international drug monitoring 
ince its inception, compared to African countries, which may have impacted on the ADR 
reports generated. For example, Malawi only joined in 2016, while most parts of the developed 
world have joined since 1968, creating a 48-year gap in legislation and regulatory framework. 
 
Drug’s life cycle: Newly introduced medication or treatment guidelines can also lead to an 
increased number of ADR reports, which is termed the Weber effect. The Weber effect is the 
phenomenon of spikes in reports the first two years after approval of a drug; the adverse event 
reporting increases and peaks near the end of the second year, and then reliably and rapidly 
diminishes with further time on the market (Berlin et al., 2008). As mentioned earlier, this 
effect may barely be noticed in areas where reporting is mandatory. For example, even in the 
USA where reporting is not mandatory, reporting trends still do not conform with what Weber 
described, which could be due to increased awareness about post-marketing surveillance in 
recent times (Hoffman et al., 2014). Nonetheless, studies have shown that an HCP will report 
an ADR for patient safety reasons, if the condition is serious and if the drug is new (Bäckström 




Media publicity: ADR reporting can also be influenced by publicity. Dr William McBride’s 
publicity about thalidomide curtailed further administration of the drug and increased reports. 
New changes to medicines also tend to have publicity and awareness, which can influence the 
rate at which ADRs are reported. For example, the Ghana FDA recorded an increase in ADR 
reports when a WHO new treatment guideline for antimalarial prophylaxis was introduced in 
children (Chatio et al., 2016). Also, media awareness about the neuropsychiatric effects of 
mefloquine in the UK led to a six-fold increase in reporting rates (Nevin and Croft, 2016; 
Schlagenhauf, 1996). Changes in the packaging of Thyrax®  from a brown glass bottle to a 
blister in the Netherlands drew media attention which saw ADR reports increase by 85%. These 
media reports were carried out in newspapers and on television (Rolfes et al., 2016). A study 
by the New Zealand Centre for Adverse Reactions Monitoring, measuring the impact of 
television on adverse reports submitted after formulation change of Eltroxin (thyroxin), also 
saw a significant increase in ADR reporting rates (Faasse et al., 2012). Other examples include 
breast implants in the USA (Brown et al., 2001), paroxetine in the UK (Martin et al., 2006) and 
the rotavirus (Danovaro-Holliday, 2002). 
 
1.15 Interventions to Improve Reporting of ADRs 
 
Globally, various interventions have been used to address the problems faced by under-
reporting of ADRs, targeting doctors (Abubakar et al., 2014), nurses (Hazell and Shakir, 
2006a), pharmacists (Pande et al., 2013) and patients (Inch et al., 2012). Previous studies have 
shown that interventions can increase the number and quality of ADR reports (Gonzalez-
Gonzalez et al., 2013; Molokhia et al., 2009; Pagotto et al., 2013; Ribeiro-Vaz et al., 2016). 
Many of these interventions have been empirical research evaluating the use of educational 
interventions (Pagotto et al., 2013), awareness workshops (Alraie et al., 2016; Herdeiro et al., 
2012), information communication technology (Ribeiro-Vaz et al., 2016), increasing yellow 
card availability (Avery et al., 2011), training on ADRs (Morrison-Griffiths et al., 2003),  and 
even a dropbox (Amit and Rataboli, 2008), as measures for improving ADR reporting. Despite 
the implementation of all these interventions, there is still general under-reporting of ADRs, 
and failure to recognise them when they occur seems to be a key area of deficiency (Carleton 
and Smith, 2006). 
Reviewing the literature on interventions to improve reporting showed that the majority of 
interventions were educational, implemented passively or actively. Active educational sessions 
 
 39 
included face-to-face lectures, workshops, training, PowerPoint presentations and meetings 
about PV and ADRs (Bisht et al., 2014; Figueiras et al., 2006; Jha et al., 2014; Lopez-Gonzalez 
et al., 2015; Mendes Marques et al., 2016; Stoynova et al., 2013). There were also passive 
educational interventions, which included self-study, self-study educational materials, 
brochures, poster displays, monthly bulletins and email reminders. Others include monitoring 
visits, incentives, making forms available and reporting using electronic or web-based services. 
The incentives included certification, a lottery ticket and percentage salary given as cash. 
Overall, active educational interventions, which included regular monitoring visits, were 
shown to have a better outcome in increasing ADR reports by 25.5% (Gony et al., 2010), 
compared to less interactive approaches, such as self-study and one-off training, which resulted 
in a 0.6% increase in reports post-study (Stoynova et al., 2013). It was noted that the effect of 
the interventions, especially educational interventions, often reduced with time after 








1.16 Pharmacovigilance (PV) and Reporting of Adverse Drug Reactions (ADRs) in 
Ghana 
 
In this sub-section, the focus shifts from the broader literature and evidence relating to PV, 
ADRs and associated reporting globally, to the more specific issue of this topic in the Ghanaian 
setting of West Africa. The content of this chapter will be used to provide evidence that ADR 
reporting in Ghana is considerably below what is recommended, thus justifying the current 
research. To do this, an initial overview of current PV and ADR processes and governance in 
this setting is provided, and reports about reporting are reviewed. 
 
1.17 The Ghanaian PV System 
 
The Food and Drugs Authority (FDA) is an autonomous government agency of the Ministry 
of Health (MOH), which has oversight responsibility for PV activities in Ghana. A safety 
monitoring unit within the FDA coordinates the National Pharmacovigilance Centre (NPC). 
PV activities are decentralised from the national to the regional level through regional PV 
officers who are linked to Institutional Contact Persons (ICP) in healthcare facilities locally. 
The FDA has wider responsibility for the regulation and safety of food, drugs, food 
supplements, herbal and homoeopathic medicines, veterinary medicines, cosmetics, medical 
devices, household chemical substances, and tobacco and tobacco products, as mandated by 
the Public Health Act, 2012 (Act 851).  
 
Ghana joined the WHO PIDM in Uppsala, Sweden (UMC) in 2001 as its 65th member and the 
first in a West African country, but the country still lacks the legal provision to enforce PV 
laws. A subsequent designation of the University of Ghana Centre for Tropical Clinical 
Pharmacology and Therapeutics as a WHO collaborating centre for advocacy and training in 
PV further enhanced the course of providing PV training and building capacity in the country 
and Africa at large. The FDA facilitates routine PV sensitisation and training of stakeholders 
to raise awareness about PV. Even though the dedicated but limited budget for PV activity is 
available at the national level and public health programmes, healthcare facilities may not have 
such budgets. A decentralised PV system is helping to improve stakeholder communication 
 
 41 
and coordination through regional FDA offices which serve as regional PV centres. They 
facilitate the circulation of safety newsletters, safety warnings and public awareness. The 
channels for receiving ADR information have been through consumers/patients, HCPs and 
MAH. The FDA encourages the reporting of all suspected reactions, including for herbal 
medicines, vaccines and over-the-counter drugs. The main tool for reporting ADRs by HCPs 
has been the yellow form or the ADR reporting form (Appendix I), which is used to report 
medication-related problems, soliciting basic information about the patient, suspected drug, 
reaction and reporter details. Different forms are available for patients (blue form) (Appendix 
J/K) and also for public health programmes, such as the Adverse Effects Following 
Immunisation (AEFI) (Appendix Q). All these forms can either be filled out manually or 
electronically from the FDA website. The HCPs’ electronic platform uses the Safety Watch 
System (Appendix L). Through collaborative efforts, the blue form mobile application 
(Appendix N) was recently launched in Ghana by the FDA to facilitate ADR reporting.  Details 
of basic requirements may differ based on needs. For example, the AEFI form (Appendix Q) 
requires more detail than the normal adverse reaction forms (Appendices I/J/K). Country 
regulations may also differ, for example, the USA requires extra patient data on height, weight 
and ethnic origin, whereas Denmark, Ireland and Norway do not include these on their 
reporting forms (WHO, 1972). Forms may be modified to suit country-specific needs, for 
example, Chan (2008) suggested adding details about Chinese herbal medicinal products on 
the Australian ADR forms. 
 
1.18 ADR Reporting Trends in Ghana 
 
The FDA is the primary steward of ADR reports in Ghana. ADR reporting has improved over 
the years compared to global trends. Reports from the FDA newsletter, DrugLens, were 
reviewed from 2008 to 2018 and showed an increase from 108 reports to 3,729. Figure 3 shows 
a decade of cumulative trajectory of ADR reports, with a sharp increase in reports, especially 
from 2014 (Figure 3). This increase could be attributed to increased awareness, government 
policies, mass drug administration, public health interventions and introduction to a new 
reporting system and tools.  These reports are often reviewed and forwarded to the WHO 
Global ADR database: the Vigibase. A review of paediatric data on the Vigibase between 1999 
and 2012 showed a corresponding increase in reports to the WHO monitoring centre, with an 
average reporting rate of 2.5 reports per million children per year (Cliff-Eribo et al., 2015).  In 
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2017, the Safety Watch System, an electronic reporting system, was launched which further 
increased reporting of HCPs as shown in Figure 3.  
 
Figure 3: Graph of ADR reports received from 2008 to 2018 by the FDA in Ghana 
 
 
1.19 Healthcare Professionals’ Reports 
 
The majority of ADR reports sent to the FDA have been from HCPs, followed by MAH and 
consumers/patients. For example, in 2015, only 0.4% (3/809) of reports were direct 
consumer/patient reports (DrugLens Issue 5, 2016). Doctors, nurses and pharmacists are often 
the HCPs who most commonly send ADR reports. Among HCPs, pharmacists are noted to send 
the most reports, peaking at 64.4% of reports in 2014 and decreasing to 32.8% in 2018 (Figure 
4). A similar decline in reports is noted for doctors, who also peaked at 18.6% in 2014 but 
decreased to 7.8% in 2018. Nurses, however, have been increasing consistently from 8.1% in 
2013 to 23% in 2018 (Figure 4). A report from Cliff-Eribo (2015) on paediatric reports between 
1999 and 2012 in the Vigibase suggests that nurses submitted 50% of the reports, followed by 
pharmacists (23%) and physicians (15%) before 2012 (Cliff-Eribo et al., 2015). This, therefore, 





















Year reports were collected 
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Figure 4: Graph of percentage of ADR reports sent by healthcare professionals
 
 
1.20 Patient/Consumer Reports 
 
Direct patient or consumer reporting is infrequent in many jurisdictions. Few studies have 
explored consumer reporting, but consumer reports show a potential of identifying possible 
new ADRs that were not previously captured by HCPs and should be explored (Cox, 2009). 
Even though patients trust their HCPs to report, they would report themselves if they thought 
the HCP paid no attention to their concerns (Blenkinsopp et al., 2007). Patients may usually 
passively receive care, without asserting themselves to their HCPs because of power relations. 
Chatio (2016) identified that patients felt HCPs did not provide them with adverse effect 
information, were unfriendly, and coupled with long queues, this has resulted in non-reporting 
of adverse effects in Ghana (Chatio et al., 2016). The Ghana FDA has therefore recognised the 
need to capture patient/consumer reports by undertaking more education, and in 2019 
introduced a mobile reporting app – the blue form app – targeting both patient and HCP reports 
(Appendices M/N). A study of 28 healthcare facilities in Ghana reported that only 3% of 
patients were aware of the FDA patient reporting system, thus the majority (68%) reported 
their ADR experiences to doctors (Jacobs et al., 2018). Community pharmacists have also been 
targeted by the FDA as stakeholders, because self-medication is widespread (Bennadi, 2014) 
and they have the potential to send reports on patients who visit them. The FDA has therefore 




1.21 MAH (Reports from Pharmaceutical Companies) 
 
Laws govern the operations of pharmaceutical companies to ensure the safety of medicinal 
products in Ghana.  According to the Ghana FDA, MAH are required by the FDA to report all 
adverse reactions through a designated Qualified Person for Pharmacovigilance (QPPV), 
usually an HCP who represents the pharmaceutical company. They are also legally mandated 
to conduct post-marketing surveillance. Surveillance activities, however, have been 
inadequately defined and implemented. Most MAH have relied heavily on the reports from 
HCPs with little efforts to facilitate reporting. Additionally, herbal medicinal product 
registration has also increased, creating a vigilance gap (Ghana FDA, 2016). 
 
1.22 International Stakeholders 
 
Similar reporting processes and regulations exist in other parts of the world, such as the UK, 
USA and Australia. National regulatory authorities that enable the general population to 
spontaneously report MRPs include the USA’s MedWatch Adverse Event Reporting 
Programme, the UK’s MHRA ‘yellow card’ system and Australia’s Adverse Drug Reaction 
Advisory Committee (ADRAC) ‘blue card’ system (Chan et al., 2008). These schemes are used 
to report all suspected ADRs including incidents from fake or defective medicine, medical 
devices, and serious ADRs from blood and blood components.  
After approval of a drug, an MAH is required to submit a Periodic Safety Update Report 
(PSUR), which is a PV requirement intended to provide an evaluation of the risk-benefit 
balance of a medicinal product at defined time points post-authorisation (Ebbers et al., 2010; 
Ebbers et al., 2013). This regulatory requirement differs from country to country. For example, 
in the USA, quarterly reports must be submitted in the first three years, followed by yearly 
reports. In the EU, the requirement is every six months in the first two years, annually for the 
next two years, and then at three-year intervals, at the time of renewal of registration. Even 
though operations and regulatory requirements of PV differ between countries, the basic 
principles are the same (Jeetu and Anusha, 2010). For example, the Australian ADRAC 
operates under a different name – the ‘blue card’ system – based on the same principles as the 
UK yellow card scheme (Chan, 2008).  
In addition, regional agencies and blocks such as the European Medicines Agency (EMA) 
support MAH on applications to change a marketing authorisation, submit product data and 
report product defects or recalls collaboratively with other countries. For example, haemolytic 
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anaemia was found in using intravenous artesunate for treating malaria in Europe, which was 
never noted in the drug development process (Mehta et al., 2007). This information, although 
generated in Europe, ought to have beneficial implications for malaria treatment in Africa and 
signifies the need for intense surveillance in all populations (Mehta et al., 2007).  There are 
agencies present in 150 countries globally which collaborate with the WHO-PIDM to ensure 
safe medicine use and patient safety. Such safety information allows regulatory authorities to 
make important changes, such as withdrawal or changes to labelling, dosage or mode of 
administration (Hajebi et al., 2010). There is, therefore, the need for international 
communication, collaboration and use of efficient methods in monitoring, identifying and 
reporting ADRs. 
 
1.23 Reporting Process 
 
Having clarified various definitions, terminology and related concepts, it is important to 
understand how ADRs are reported in Ghana, the stakeholders involved and action taken after 
assessment. Previously, reporting ADRs was restricted to only doctors, but now other 
healthcare professional cadres, pharmaceutical representatives, Public Health Programmes 
(PHPs) and patients can also report directly. As mentioned earlier, the primary source of ADR 
data in Ghana is from HCPs.  
Efforts are being made to encourage consumer or patient reporting. Sending reports to a 
regulatory agency or MAH involves the use of multiple communication channels including 
electronic mail, online reporting forms, telephone, mobile applications and facsimile. All data 
collated from the primary stakeholders are forwarded to the external stakeholders, such as the 
FDA/MOH and MAH. The national regulator liaises with the WHO-International Drug 
Monitoring Programme (IDMP) and MAH to send the data to the international database of the 
WHO-IDMP, Vigibase. The reports are analysed (Vigilized) using the WHO causality 
assessment criteria for detecting ADR and also the Naranjo algorithm/scale, which was 
developed to estimate the probability of an ADR occurring based on a 10-point question criteria 
(Naranjo et al., 1981). This was often used in clinical trials and has also been widely adopted 
for routine clinical practice for the assessment of causality. Following analysis, if a signal is 
confirmed, regulatory actions are taken; the drug can be withdrawn, formulation changed, 
warnings added and HCPs informed. HCPs can report ADRs to reference centres or designated 





























In Ghana, some of these strategies have been used in an attempt to enhance reporting. They 
include the use of the mobile application, electronic reporting, workshops, incentives and 
distribution of forms, but no studies have scientifically explored the impact of these interventions 
on reporting. 
 
In summary, this second section (B) of the first chapter has advanced the discussion of ADRs in 
relation to an overview of the factors responsible for reporting in terms of contextual issues, and 
extrinsic and intrinsic issues associated with reporting. It has attempted to explore important 
concepts of pharmacovigilance and ADRs, and also the interventions which are used to improve 
reporting, and also a more specific focus is given on the Ghanaian setting, and the existing PV 
and ADR reporting processes in this West African setting, where it will be argued that research 
is needed. It has been noted in the general review of the literature that studies in Africa on the 
topic were scant. The next chapter therefore rapidly scopes specific ADR reporting studies in 





A NARRATIVE REVIEW OF THE FACTORS INFLUENCING ADR 
REPORTING IN AFRICA 
2.0 Introduction  
 
Having presented the literature more generally on ADR reporting in chapter 1, with a section 
on factors influencing reporting, it was noted that the literature on ADR reporting in Africa 
was scant. This chapter will therefore focus more on a narrative review of African-specific 
literature on the factors influencing ADR reporting within that context. The conceptual 
framework by Obonyo (2014) was adopted to organise and guide the review. The review 
question was, “What is the scope of literature on ADR reporting among frontline healthcare 
professionals in Africa?”. The rationale of the study is to give an overview of the research on 
this topic using already identified factors in the previous review into whether they are intrinsic, 
extrinsic and contextual factors. There was no formal quality assessment of individual studies 
and the narrative lacks a comprehensive synthesis of the quantitative findings. 
 
2.1 Sources of the Literature 
 
Searches were conducted in PsychInfo, EMBASE, MEDLINE and Google Scholar using a 
combination of search terms. The searches were conducted from June 2019 and updated in 
January 2020, and include studies published from 1960 to date. Search terms combinations 
include [Doctors OR Medical Practitioners OR health professions] AND [Nurses OR Nursing 
Officers OR health professionals] AND [Pharmacist OR Pharmacist Officers OR health 
professionals] AND Hospital AND “ADR reporting” AND attitude AND practice AND 
knowledge OR awareness AND Africa (detailed search strategy in Appendix T). 
 
2.2 Selection of Literature for Inclusion 
 
Studies were included if they focused on 1) adverse drug reaction reporting; 2) population: 
healthcare professionals, i.e. medical (doctors/physicians), nursing (general/specialised) and 
pharmacy staff (pharmacists/technicians), and setting: African studies conducted in hospitals 
and clinics.  Studies which did not meet the inclusion criteria were excluded. Using the 
inclusion criteria described above, the lead researcher screened all the studies retrieved from 
the databases, first by titles, followed by abstracts and full text articles. The process was 
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repeated to ensure that all relevant studies were considered. Where there was any doubt, 
supervisors were consulted and asked to crosscheck the selection. The aim was to ensure that 
the selection was carried out appropriately, and that there was no selection bias.   
 
2.3 Data Extraction and Synthesis  
 
Relevant data were extracted using a data extraction form. All full text articles that met the 
inclusion criteria were downloaded and read, and the important information needed for this 
review extracted onto the data extraction form. Information extracted include author, country, 
sample, type of healthcare professional and healthcare facility (Table 20). The data was then 
analysed and the findings of the factors influencing ADR reporting narratively presented into 
intrinsic, extrinsic and contextual factors.  
 
2.4 Search Results 
 
A total of 2,052 (Ovid Medline 81, Embase 268, PsychInfo 943, Google Scholar 760) African 
studies were retrieved following the database searches. After screening, 80 full abstracts were 
retained, 46 full papers were eligible for full text review, and a final 29 studies met the selection 
criteria and were included. The majority of the studies were excluded at title screening stage 
(n=1,972). At the abstract stage, because of time and resources, papers were excluded if full 
versions were not available online or information was only on closely related topics such as 
medication errors and adverse medical events. Additionally, studies were excluded if they 
focused on other health professionals but not specifically on doctors, pharmacists and nurses, 
and interventions studies not designed to address only ADR reporting problems.  
 
2.5 Study Setting 
 
Scope of the evidence 
 
The studies retrieved were conducted between 2004 and 2019 in only nine African countries 
representing 17% (9/54) of the countries in Africa. More than half of the selected studies were 
undertaken in Nigeria (31%, 9) and Ethiopia (24%, 7), and the rest were in Ghana (3), 










The total number of participants in the 29 studies were 6,705 healthcare professionals, of which 
the majority were nurses (2,995). Medical staff (2,597), pharmacy staff (680) and ancillary 
staff (i.e. dentists, health workers (unspecified), community health workers etc) (433) followed 
this. The smallest number of participants was 35 HCPs and the highest was 1,345. The average 
response rate was 80.3% even though nine studies did not report on this. The following table 
(Table 4) summarises the characteristics of the included studies. A detailed summary of papers 
can be found in Appendix U.
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Ezeuko et al., 2015  Nigeria 372 109 241 22 NA NA 
Nde et al., 2015  Cameroon 149 85 34 18 12 NA 
Katusiime et al., 2015  Uganda 223 95 120 8 NA 1THCF 
Ameade et al., 2014  Ghana 125 NA 125 NA NA 1THCF, 2PHCF 
Bello and Umar, 2011 Nigeria 61 61 NA NA NA 1THCF, 3PHCF 
Kiguba et al., 2014  Uganda 1345 275 792 84 194 7 (THCF, PHCF, PVCF) 
Sabblah et al., 2014  Ghana 259 259 NA NA NA 23PHCF (inclusion 6 private facilities) 
*Tesfa and Wabe, 2012  Ethiopia 82 15 49 21 NA 1THCF, 3PHCF 
Awodele et al., 2011  Nigeria 251 251 NA NA NA PVCF 
Ohaju-Obodo and Iribhogbe, 2010)  Nigeria 330 330 NA NA NA 4THCF 
Elnour et al., 2009  Sudan 475 175 200 100 NA 6THCF, 2PHCF 
*Oshikoya and Awobusuyi, 2009)  Nigeria 99 120 NA NA NA 1THCF 
Okezie and Olufunmilayo, 2008) Nigeria 192 192 NA NA NA 1THCF 
Adedeji et al., 2013  Nigeria 35 35 NA NA NA 1THCF 
Seid et al., 2018  Ethiopia 102 NA 61 25 16 8PHCF 
Muringazuva et al., 2017 Zimbabwe 47 NA 30 NA 17 6 HCF* 
Mulatu and Worku, 2014  Ethiopia 625 101 430 94 NA 9HCF 
*Shanko and Abdela, 2018  Ethiopia 297 44 230 21 NA 1THCF 
Kefale et al., 2017  Ethiopia 213 5 161 27 20 1THCF 
Khoza et al., 2004  Zimbabwe 144 35 74 16 19 1THCF 
Gurmesa and Dedefo, 2016  Ethiopia 133 19 70 19 25 1HCF 
Fadare et al., 2011a Nigeria 65 43 20 2 NA 1THCF 
Terblanche et al., 2017  South Africa 132 31 77 24 NA 1THCF 
Kamal et al., 2014 Egypt 211 211 NA NA NA THCF 
*Charles et al., 2017  Cameroon 188 50 122 1 13 THCF, SHCF, PHCF, CMTY PHM 
*Alemu and Biru, 2019 Ethiopia 114 26 49 17 12 SHCF and PHCF 
*Amedome and Dadson, 2017) Ghana 145 30 110 15 NA SHCF 
Udoye et al., 2018 Nigeria 169 NA NA 108 61 2THCF and CMTY PHM  
Joubert and Naidoo, 2016 South Africa 102 NA NA 58 44 NA 








Knowledge was explored differently in the 29 studies. Knowledge and awareness were used 
synonymously to refer to the level of familiarity with information on the PV system and ADR 
reporting. The most common knowledge-based questions examined were on the definition of 
PV, ADR, the difference between ADR and side effects, and the purpose of reporting (Kamal 
et al., 2014; Kefale et al., 2017; Khoza et al., 2004; Muringazuva et al., 2017; Mulatu and 
Worku, 2014; Oshikoya and Awobusuyi, 2009; Seid et al., 2018; Shanko and Abdela, 2018), 
awareness about reporting locally or nationally to ADR reporting centres (Udoye et al., 2018; 
Oreagba et al., 2013; Nde et al., 2015; Khoza et al., 2004; Oshikoya and Awobusuyi, 2009; 
Katusiime et al., 2015; Terblanche et al., 2017) and also awareness about the yellow form and 
ADR forms in general (Adedeji et al., 2013; Ohaju-Obodo and Iribhogbe, 2010; Angamo et 
al., 2012; Fadare et al., 2011; Nwalwu and Harrison, 2015).  
Despite the differences in the types of questions asked on knowledge, Seid (2018), Mulatu 
(2014) and Kefale (2017) reported an aggregated knowledge score of  52.9%, 34.2% and 33% 
respectively among HCPs, which indicated a moderate to low level (Kefale et al., 2017; Mulatu 
and Worku, 2014; Seid et al., 2018). Pharmacy staff, however, showed better knowledge and 
awareness of ADRs and PV in a Nigerian study by Udoye (2018), where they showed 100% 
awareness of PV and ADR reporting (Udoye et al., 2018). The lowest reported level of 
knowledge was a South African study by Terblanche (2017) where the general knowledge was 
only 17.5% (Terblanche et al., 2017). 
Angamo et al. (2012) reported an average of 75.6% of HCPs who were unaware of the national 
reporting centre and the yellow card system. In Nigeria, 78% of doctors self-assessed and 
indicated they had adequate knowledge, but further assessment showed 47.4% were not aware 
of the PV process (Ohaju-Obodo and Iribhogbe, 2010). In Ghana, a small number of studies 
on the subject of ADR reported high levels of knowledge among doctors (88.8%), nurses (78%) 
and pharmacists (92.2%) when asked about PV, awareness of ADR reporting and its purpose 
(Amedome and Dadson, 2017). This high level of knowledge was supported by a study of 
doctors in Accra where more than half showed good knowledge (Sabblah et al., 2014). 
High levels of knowledge among HCPs did not reflect positively on their practice; under-
reporting was observed to still be high. For example, a study of doctors, nurses and pharmacy 
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staff reported that even though they had adequate knowledge (23.1%) and positive attitude 
(75%), in practice no HCP either reported (0%) or noted (0%) ADRs (Angamo et al., 2012). 
Attitudinal behaviour of participants was positive in the majority of the studies. Attitudinal 
assessments varied between studies but were largely based on Inman’s (1996) perceived 
attitudinal behaviours for non-reporting. Even though Inman’s original research focused on 
doctors, the theory of the ‘seven deadly sins’ of under-reporting has been widely explored and 
modified to suit different settings and different healthcare professionals. There was generally 
a positive attitude because at least eight of the studies reported that ADR reporting was 
necessary or part of HCPs’ duty or professional obligation (Mulatu and Worku, 2014; Shanko 
and Abdela, 2018; Kamal et al., 2014; Terblanche et al., 2017; Kiguba et al., 2014; Oshikoya 
and Awobusuyi, 2009; Khoza et al., 2004). Litigation was explored in only four of the selected 
studies (Jarrett et al., 2013; Mulatu and Worku, 2014; Kamal et al., 2014; Ezeuko et al., 2015). 
Opinions about litigation varied among HCPs – while the majority agreed legal liability issues 
affect reporting in Ethiopia (Mulatu and Worku, 2014), only 14.3% thought litigation could 
affect reporting in Nigeria (Adedeji et al., 2013). Lethargy was reported in various forms 
among the studies which are related to fatigue, lack of time, burnout and workload. 
There were contradictory reports among HCPs. Eight studies reported lack of time to report 
ADRs, but the majority of HCPs disagreed with this. For example, HCPs in three studies 
(Kiguba et al., 2014; Oshikoya et al., 2011; Joubert and Naidoo, 2016) disagreed that lack of 
time discouraged reporting, while fewer HCPs reported having no time to report (i.e. 16%, 
37.1%, 46%). On the contrary, more than half (57%) of the HCPs in Uganda did not report 
because of lack of time. A closely related theme which was reported was workload, which was 
referred to in three studies. For example, while some HCPs suggested reporting created 
workload in Ethiopia (51.2%) (Angamo et al., 2012), others (62.1%) in the same country 
(Shanko et al., 2018) suggested otherwise. Adedeji (2013) in Nigeria reported a much lower 
percentage in a study of doctors where only 17% felt reporting created extra workload and only 
8.6% specifically reported it was time-consuming (Adedeji et al., 2013).  Ambition, 
complacency and guilt were not reported, but diffidence and ignorance were featured. 
Diffidence, which Inman (1996) referred to as hesitance of reporting mere causality, was 
observed in three studies with varied opinions and phrased as uncertainty about causality. The 
reports indicated that uncertainty about when, who and how to report was a limiting factor to 
reporting in seven studies (Gurmesa and Dedefo, 2016; Terblanche et al., 2017; Kamal et al., 
2014; Shanko and Abdela, 2018; Necho Mulatu, 2014; Okezie and Olufunmilayo, 2008; Kefale 
et al., 2017). For example, Kefale (2017), in Ethiopia, reported that 77% of HCPs wanted to 
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establish causality before reporting an ADR, while in South Africa, the most common reasons 
for non-reporting were uncertainty about how, where and when to report (54.5%). Ignorance 
about the need to report or the reporting system, which is linked to knowledge and awareness, 
was reported in three studies (Fadare et al., 2011; Ezeuko et al., 2015; Charles, 2017). More 





Other external factors which influenced reporting were the poor feedback, lack of feedback, 
and no feedback from external national reporting centres and internal stakeholders, such as the 
heads of departments. This was reported in seven studies where HCPs indicated that poor 
feedback, or the lack of it, affected their reporting. Kiguba (2014) reported that feedback to 
public health programmes in Uganda was much higher (60%) than from the national centre 
(23%) or medical superintendents (39%) (Kiguba et al., 2014). HCPs had varied responses 
about lack of feedback. For example, 59% in South Africa (Joubert and Naidoo, 2016) in 
contrast to 6.1% reported (Terblanche et al., 2017), 48% in Uganda (Katusiime et al., 2015), 
62.8% in Cameroon (Charles, 2017), 55.8% in Sudan (Elnour et al., 2009), 47.1% and 58.8% 
in Ethiopia (Kassa Alemu and Biru, 2019; Seid et al., 2018). The majority of HCPs reported 
that lack of feedback affected their reporting significantly and therefore suggested improved 
feedback from stakeholders. 
HCPs’ personal and professional characteristics influenced ADR reporting. Among the studies 
reviewed, at least nine studies reported on the association of HCPs’ background characteristics 
to ADR reporting. Fewer females engaged with pharmaceutical companies (Bello and Umar, 
2011) or private practice (Awodele et al., 2011). There was also a lower likelihood of reporting 
ADRs from private health facilities compared to public ones (Kiguba et al., 2014). This was 
further supported in Ghana where a study showed that doctors from government and quasi-
government hospitals were 1.26 to 5 times more likely to report ADRs than private hospitals 
(Sabblah et al., 2014). In terms of age, responses were varied: in Uganda, HCPs aged 36 to 65 
years were three times more likely to report ADRs than those aged 21 to 35 years (Katusiime 
et al., 2015). Kiguba (2014) also reported that HCPs who were 30 years and older were less 
likely to report. Participants aged 40 and over were reported to have a better attitude and 20 to 




Years of experience and higher qualifications were reported to be associated with knowledge, 
attitude and practice. For example, HCPs with 10 years’ experience and a PhD were 11.1 times 
more likely to have satisfactory knowledge, and those with the same number of years of 
experience were 1.7 times likely to have a satisfactory attitude as well (Kamal et al., 2014). 
Also in Uganda, HCPs with 10 years’ experience were four times more likely to report ADRs 
than those with five years or less experience (Katusiime et al., 2015). Additionally, two studies 
reported that medical faculties or departments were more likely to observe and report an ADR 
than surgical or other departments (Okezie and Olufunmilayo, 2008; Kiguba et al., 2014). 
  
Contextual factors 
Only one study reported on policy in Sudan where the majority of participants in the facilities 
surveyed had reported that there was no policy in place for the detection (60%), investigation 
(62.1%) or reporting (50.3%) of ADRs (Elnour et al., 2009). In addition, media was only 
reported in one study to solicit where ADR knowledge is acquired. Only 7.2% acquired 
knowledge about ADRs and how to report through media. HCPs, however, suggest the media 
could improve reporting with varying levels of positive responses: 8.6% (Adedeji et al., 2013), 




This is the first review exploring the scope of literature on ADR reporting in Africa. Only three 
studies were identified in the Ghanaian context and no qualitative studies were retrieved from 
the literature searches to the best of our knowledge. In assessing the factors influencing ADR 
reporting, intrinsic characteristics of knowledge, attitude and practice were common methods 
of assessment, but the parameters for measurements were varied. No standard scale or index 
for measuring any of the variables exists. The majority of studies adopted Inman’s (1996) 
‘seven deadly sins’ modified to the local context of the research with varied responses. Some 
of the factors proposed by Inman, such as ambition, complacency and guilt, were not reported, 
probably because they were not applicable to the African setting due to the differences in the 
health system’s culture and practice. Extrinsic and contextual factors were least explored and 
responses showed variation in responses with regards to these factors.
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2.9 PhD Study Rationale 
 
The literature review has justified the need for further research on ADR reporting because of 
continuous poor HCP practice and scant studies on the topic in Ghana. Studies undertaken 
elsewhere have had gaps in generalisability and variable interpretations of results. As 
mentioned earlier, ADRs cause significant morbidity, mortality and increased healthcare costs 
(Wiffen et al., 2002; Elliot et al., 2018). Several studies have shown the impact of ADRs and 
associated non-reporting of events on healthcare systems (Aagaard et al., 2012; Hazell and 
Shakir, 2006a, 2006b; Pagotto et al., 2013; Wiffen et al., 2002) with only a small number of 
reports from Africa. Contextually relevant data is important to understand HCP reporting 
behaviour. Reporting of ADRs is indeed a vital component of PV to ensure the safe use of 
medicines in routine care. Healthcare professionals are identified as sending the most ADRs 
reported to regulatory authorities. Doctors, nurses and pharmacists form the primary cohort of 
HCPs who are frequently involved in ADR reporting compared to patients and other 
stakeholders. Targeting this group is therefore important in providing multi-level perspectives 
about factors influencing ADR reporting. McGettigan et al. (1997) suggest exploring other 
avenues to understand the reporting culture rather than just attitudinal surveys. Circumstances 
and context may differ, thus the need to explore these factors more holistically is important for 
understanding ADR reporting, especially in a Ghanaian context.  
Globally, and particularly in Africa, ADR reporting has been met with low interest, and ADRs 
are not reported due to several factors which have been identified in the literature, including 
lack of time, ignorance and lack of reporting tools (De Angelis et al., 2016; Griffith, 2013; 
Gupta and Udupa, 2011; Irujo et al., 2007; Lopez-Gonzalez et al., 2009a; Sevene et al., 2008). 
The majority of studies exploring these factors have, however, been skewed towards the 
internal or personal factors of HCPs’ knowledge, attitude and perceptions, without adequately 
exploring other possibly related factors, such as national regulation, media, policies, health 
systems, patients, relationships with pharmaceutical companies and other organisational 
related factors.  
The FDA ARS in Ghana has consistently been reporting below the WHO recommendation of 
200 reports per million population (WHO-IPDM, 2000), even though reporting generally has 
been on the increase in recent times. Few of the studies that have explored factors affecting 
ADR reporting in Ghanaian hospitals have been quantitative (Chatio et al., 2016; Franklin et 
al., 2014; Paul et al., 2014; Sabblah et al., 2014; Amedome and Dadson, 2017). The choice of 
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study participants was also either narrow, e.g. exploring only doctors (Sabblah et al., 2014), or 
too broad, e.g. patients and public health programmes (Chatio et al., 2016; Suku et al., 2015; 
Yamoah et al., 2019). This study therefore seeks to focus on the key frontline HCPs (i.e. 
doctors, nurses and pharmacists) working in routine clinical practice in hospital settings. In the 
review of databases during the literature review, no qualitative studies addressing the issue of 
ADR reporting among Ghanaian HCPs were found. There is a need to explore specific factors 
affecting ADR reporting in a Ghanaian context, with more emphasis on the qualitative. 
The methodological distinction between this study and other studies, which have explored 
similar research questions, will be the use of a mixed methods approach. The rationale for using 
this approach is that neither quantitative nor qualitative methods generally are sufficient to 
capture the trends and details of a phenomenon of interest, i.e. ADR reporting (Ivankova et al., 
2006). It is therefore important to explore the topic using mixed methods where the strengths 
of each design can be maximised. In this way, HCP-specific factors can be identified for the 
development of recommendations and targeted interventions to improve ADR reporting in the 
















2.10 Aim and Research Questions 
 
Based on these reviews of the ADR reporting literature, the proposed aims of this study are to 
explore factors associated with spontaneous ADR reporting by HCPs in Ghana. The following 
associated research questions are proposed: 
 
1 What are the perceived factors associated with spontaneous ADR reporting by HCPs in 
Ghanaian hospitals?  
In addition, the sub-aims are to understand why such factors are considered relevant, and to 
explore any associations between such perceived factors and HCPs’ characteristics. The way 
in which ADR reporting is undertaken in Ghana will also be explored and, finally, this study 
will also seek to understand HCPs’ views as to what could be done to increase ADR reporting. 
These are represented in the following secondary research questions: 
2 Why do HCPs consider factors associated with ADR reporting to be important? 
3 How is ADR reporting undertaken by HCPs in Ghana? 
4 What associations are there between HCP characteristics and perceptions about ADR 
reporting? 





METHODOLOGY AND METHODS 
 
 3.0 Overview of the Chapter 
 
This chapter provides a description of the methodology and methods selected to answer the 
research questions. The first section of this chapter gives the background of the epistemological 
underpinnings of the research methodology and builds an argument for choosing a concurrent 
mixed methods design. This is followed by a detailed description of the research methods used 
to collect and analyse data. Overall, this study used concurrent mixed methods, and each 
approach is described in the following sections in line with best practices for presenting mixed 
methods research (Meissner et al., 2011; NIH, 2019).  
 
3.1 Epistemology and Ontology 
 
Epistemology and ontology refer to two different philosophical ways of viewing the nature of 
research. Ontology refers to the nature of being or study of reality, while epistemology refers 
to our theory of how knowledge is created and what underpins the theoretical perspective of 
research (Patel, 2018). In research, ontology helps researchers to be more certain about the 
nature of the subject they are researching, while epistemology is concerned with all aspects and 
processes of acquiring, producing and transferring knowledge in a credible way (Marsh, and 
Stoker, 2011; Patel, 2018). It is therefore important to reflect on and be guided by this ideology 
of knowledge production. Epistemological debates about knowledge creation and assumptions 




The two traditionally dominant worldviews of the construction of knowledge have been those 
of positivism and constructivism, which underpin quantitative and qualitative methodologies 
respectively (Cracknell, 1994; Walker and Baxter, 2019). Proponents of the positivist approach 
advocate for understanding nature through hypothesis testing, causal explanations and 
empiricism which is thought to form the basis of knowledge (Clark and Creswell, 2008). The 
nature of reality is specifically perceived and created by using valid and reliable tools.  
Interpretivists/constructivists, in contrast, are proponents of the view that knowledge is based 
on concepts such as humanism, culture and idealism, which have been described as the best 
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ways of understanding human behaviour (Tashakkori and Teddlie, 2003). Interpretivism 
(constructivism) refers to a phenomenon where individuals create the nature of reality or 
groups, which can be best understood by exploring events and activities.  
In addition, a third paradigm relating to realism has gained popularity in recent years, this is 
based on a pragmatic methodology which propounds that reality can be interpreted in light of 
its usefulness and what works best (Tashakkori and Teddlie, 2003; O’Cathain, 2010). This has 
given rise to mixed methods research, which will be considered and argued for, and represented 
as the most appropriate in this research. Justification of the suitability of a mixed-methods 
approach for this research is described further.  
 
3.3 Mixed Methods Approach 
 
The importance of mixed methods research has gained popularity in the last decade, redirecting 
the discussion about epistemological incompatibility towards appreciating the potential value 
of blending both qualitative and quantitative methods into a single study (O’Cathain and 
Nicholl, 2008). A mixed-methods design is described as a procedure of collecting, analysing 
and ‘mixing’ both quantitative and qualitative data at some stage of the research process within 
a single study, to understand a research problem completely (Tashakkori and Teddlie, 2006). 
Also, the explanation of a mixed methods research design is based on a pragmatic approach 
which balances the two extremes of qualitative and quantitative data to form a third paradigm 
(Gunasekare, 2015). It falls neither within a positivist or constructivist epistemological stance 
but adopts an entirely new model (Subedi, 2016). It is based on the premise that the truth is not 
determined once and for all but can be both objective and subjective in our search for 
knowledge. The immediate goal of this approach, therefore, is “to make warranted assertions 
and to produce pragmatic/workable solutions for valued ends” (Denzin, 2012). The style of 
presentation of the report of this mixed methods study followed the recommendations proposed 












Table 5: Good reporting of mixed methods approach 
 
Good Reporting of a Mixed Methods Study 
(GRAMMS) 
 
Where addressed in this research 
Describe the justification for using a mixed 
methods approach to the research question 
Methodological justification 
Describe the design in terms of the purpose, 
priority and sequence of methods 
 
General methodology (dominance and 
sequence) 
Describe each method in terms of sampling, data 
collection and analysis 
 
Methodological process: data collection, data 
analysis 
Describe where integration has occurred, how it 
has occurred and who has participated in it 
 
Integration/triangulation section 
Describe any limitation of one method associated 
with the presence of the other method 
 
Strengths and limitations section 






3.4 Methodological Justification 
 
Previous studies have not sufficiently explored the trends and peculiarities of ADR reporting 
among HCPs in Ghana. Research on ADR reporting in Africa has predominantly been 
quantitative (Fadare et al., 2011; Kamal et al., 2014; Katusiime et al., 2015; Oreagba et al., 
2011; Ameade et al., 2014; Sabblah et al., 2014; Terblanche, 2018; Bello et al., 2016), with 
only a few writters exploring the subject either qualitatively or using mixed methods (Chatio 
et al., 2016; Jacobs, Ampadu et al.,2018) and these were on patient perspectives in Ghana. A 
combination of both quantitative and qualitative methods would therefore produce a 
comprehensive account which allows a complete analysis of the research problem, maximising 
the strengths of each approach (Creswell, 2009; Denzin, 2012; Greene and Caracelli, 1997). 
No studies have explored the issue using a multi-method approach based on multi-perspectives 
of healthcare professionals. The few mixed methods spotted in the literature have only focused 
on nurse’s perspective of reporting (De Angelis et al., 2016; Lobo et al., 2013). Creswell notes 
that the two most compelling reasons for using mixed methods are when researchers require 
multiple perspectives from participants to give a complete understanding by merging 
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qualitative and quantitative measures to confirm a phenomenon (Creswell, 2013). The 
justification is therefore to confirm or otherwise the few quantitative studies found in Ghana, 
while embellishing them with the qualitative approach. Furthermore, comprehensively 
merging the two methods increases confidence in the findings by ensuring that marginalised 
(especially junior staff) voices are heard (Mertens, 2003). Also, combining the two methods 
produces more contextually relevant knowledge than two independent research paradigms or 
studies would (O’Cathain et al., 2007; Shneerson and Gale, 2015). This will be the first time a 
mixed methods study has been undertaken on the topic, to the best of our knowledge, among 
key healthcare professionals in Ghana. Ultimately, the outcome will provide a multilevel 
perspective of the problem based on contextual relevance. 
 
3.5 Mixed Methods Design 
 
There are several types of mixed method designs, with some authors suggesting up to forty 
different types of mixed methods designs in the literature (Ivankova et al, 2006; Palaiologou, 
2016; Clark and Ivankova, 2018).  
The mixed methods design commonly referred to are six which are designed based on four 
considerations: priority, implementation, integration and a theoretical perspective (Creswell, 
2003).  In this study, priority was given to the qualitative phase, which aimed to give a deeper 
understanding and complete picture of ADR reporting among HCPs. Priority refers to which 
method, either quantitative or qualitative, is given more emphasis in the study. Implementation 
refers to whether the quantitative and qualitative data collection and analysis comes in sequence 
or in chronological stages, one following another, or in parallel or concurrently. Integration 
also refers to the phase in the research process where the mixing or connecting of quantitative 
and qualitative data occurs (Creswell et al., 2003). This study therefore reflects on these 
important aspects of mixed methods, which are incorporated in the design and implementation 
stages. 
 
3.6 Concurrent versus Sequential Designs 
 
The commonly used types are the concurrent and sequential mixed methods designs, even 
though there are several variants of these two forms (Cresswell, et al., 2003; Terrell, 2012). 
These have been further differentiated into six, namely sequential explanatory, sequential 
exploratory, sequential transformative, concurrent triangulation, concurrent nested 
(embedded), and concurrent transformative (Creswell and Clark, 2011). The choice of 
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approach depends on the research questions, time, and resources. For the purpose of this study, 
a concurrent triangulation was used to complement the outcomes of the two data sources and 
to make judicious use of limited time and resources (Farmer et al., 2006). Even though a 
sequential explanatory approach (i.e. analysed quantitative data informs qualitative phase) 
could have worked as well, this would have had an impact on time and resources, and thus was 
considered inappropriate. 
 
3.7 The Concurrent Triangulation Method 
 
The concurrent triangulation mixed methods (CTMM) design has been used widely in mixed 
methods (Onwuegbuzie, and Jiao, 2007; Jang et al., 2008; Östlund et al., 2011) where both 
qualitative and quantitative study designs are implemented and completed within a short 
timeframe independent of each other (Bryman, 2016). Several synonyms of concurrent 
triangulation design have been found in the literature; these include simultaneous triangulation, 
parallel study, and convergent parallel study (Hadi, et al., 2013; Morse, 2010; Östlund et al., 
2011). In this study none of these synonyms are used; the term concurrent triangulation mixed 
method is used throughout. 
CTMM is used when qualitative and quantitative methods are incorporated into a single study 
by a researcher and implemented at the same time, with the objective of confirming, cross-
validating or corroborating findings. The strength of employing this method stems from the 
fact that it offsets the limitation of individual studies while building on individual strengths 
within a short data collection time frame (Castro, et al., 2010; Östlund et al., 2011). 
Convergence or divergence of findings can, therefore, strengthen knowledge claims and can 
be better explained when compared (Creswell 2004). In this research, the comparison and 
integration were implemented during the discussion of final findings.  
In implementing a CTMM, the possibility of bias is likely to occur while collecting both 
qualitative and quantitative data at the same time (Collins et al., 2007). This was minimised in 
this study by collecting data simultaneously and independently on identical samples, i.e. in 
each hospital, quantitative data was collected, followed by the qualitative data within the same 




3.8 Prioritising Dominance and Sequence 
 
Prioritising is important in mixed methods research because it places emphasis on which 
method to emphasise. Dominance and sequence ascertain the primacy and order in which the 
research is undertaken. Dominance relates to the relative weighting of the importance of one 
method over another or which method is more central to the research (Creswell and Clark, 
2011). Sequence, on the other hand, refers to questions of method order, the most basic being 
whether methods are implemented simultaneously or sequentially. The way research is 
designed can influence dominance (Morgan, 2013). In the implementation of a concurrent 
triangulation design such as this one, priority is usually the same but can favour either 
qualitative or quantitative dominance (Schoonenboom and Johnson, 2017; Walker and Baxter, 
2019). Usually shown in literature as quant + QUAL., where capital letters indicate 
the dominant method, lowercase represents the less dominant method, and “+” is concurrence 
(Hesse-Biber and Johnson, 2015).   
In this research, the qualitative phase was given priority (quant + QUAL) because of the 
saturation of quantitative studies in the literature on ADR reporting (Kharkar and Bowalekar, 
2012; Abubakar, et al., 2014a; Sanghavi Dhara et al., 2014; De Angelis et al., 2015; Marques 
et al., 2016; Udoye, et al.,2018; Opadeyi et al., 2019). No qualitative study has been conducted 
on this topic in the study context, and thus a complete understanding of ADR reporting 
behaviours and practices is lacking. A dominant qualitative approach would, therefore, provide 
complementary evidence to affirm and otherwise the quantitative results. The sequence of 
implementation was influenced by resource and time constraints, hence the justification for a 







Even though there are no generally accepted methods for implementing dominance, this study 
was guided by the Dominance in Mixed Methods Assessment (DIMMA) model (Walker and 
Baxter, 2019). In this model, three fundamental principles were used to judge dominance (i.e. 
sequence of qualitative and quantitative methods in each publication), whether any method 
dominates the paper as a whole, and how the method dominance potentially relates to method 
sequence. In conclusion, studies which used convergent designs had a wide variation in terms 
of dominance and sequence.  
This research, however, initiated a dominant qualitative approach, and subsequent comparison 
of the respective word count in the results chapter showed 78% of results reported were based 
on the qualitative findings, with a sampling ratio of 386: 51 (8:1) for quantitative and 
qualitative research participants respectively. This represented a significant amount of 









Figure 8: Methodological process of concurrent triangulation mixed methods design 









Integration is a vital aspect of mixed methods research, which essentially brings the same 
participant data from two studies undertaken independently, within a project, as one to increase  
the overall knowledge generated. Jang (2008) describes it as “the interaction or conversation 
between the qualitative and quantitative components of the study” (Jang et al., 2008). 
Researchers have proposed three integration techniques to consider in mixed methods, i.e. 
using a triangulation protocol (Farmer et al.,, 2006), following a thread (Adamson, et. al., 
2009), and using mixed methods matrix-based (Wendler, 2001). O’Cathain (2010) has further 
suggested presenting a detailed procedural information. In this study design, a triangulation 
protocol (Farmer et al., 2006) was used and reported in the discussion chapter (Table 25). 
 
3.11 Triangulation Protocol 
 
A triangulation protocol in the mixed methods approach is used to corroborate two sets of 
findings at the data interpretation stage, after they have been analysed to gain a complete picture 
of a phenomenon (O’Cathain et al., 2010). During integration, researchers list findings from 
each component, and identify and compare where the convergence, complementarity and 
discrepancies are inherent (Farmer et al., 2006). Denzin (2009) identified four aspects of mixed 
methods which could be used individually or combined at various levels (i.e. methodological, 
data, theoretical or investigator level) to facilitate triangulation. Methodological triangulation 
involves using multiple data collection methods (qualitative and quantitative), while data 
triangulation requires using multiple sources (HCPs) which inform the research question 
(Östlund et al., 2011). Using a substantive theory to explain research questions refers to 
theoretical triangulation, while investigator triangulation entails using two or more researchers 
in the analysis (Farmer et al., 2006; Denzin, 2012, 2009). Achieving integration, therefore, 
involved adopting methodological, data, and investigator triangulation techniques to explore 
in-depth views of HCPs on ADR reporting. This was deployed during the collection of survey 




3.11 Study Setting and Demographics 
 
The study was conducted in Tamale, Ghana. Ghana is located off the Atlantic Ocean on the 
west coast of Africa (Figure 9). It has an estimated population of 29,767108 (2018) according 
to World Bank estimates (World Bank 2019) and a growth rate of 2.5% according to the 2010 
population and housing census estimations (PHC, 2012). The country has been demarcated into 
16 administrative regions. The north of the country has some of the lowest health indicators in 
the country (UNFPA, 2011) and has recently, geographically divided into five administrative 
regions i.e. Upper West Region, Upper East, Northern Region, Savannah Region and North 
East Region. The study location (Northern region) comprises 26 administrative districts 
operating at decentralised levels for efficient healthcare delivery (PHC, 2012).   At the time of 
data collection (2017), the Northern Region and its capital city, Tamale, were the most 
populous in the north of Ghana, with estimated population of 2,935,622 and 269,227 












Table 6: Demography and vital statistics of the Northern Region (GHS, 2018). 
 
INDICATORS Frequency  
Population with no 
education 
 
Male (47.7%) - 
Female (65.8%) - 
Critical staff Pharmacists 36 
Pharmacist Technicians 47 
Medical officers 216 
Medical officer(consultants) 2 
Medical officer(specialists) 44 
Medical/physician assistants 131 
General nurses/Midwives 2,999 
Community health nurses 1032 
Enrolled nurses 3040 
Lab. Technicians 100 
Public Health Officers 22 
HCP to patient ratio Doctor: patient 269:11,130 (1:41) 
Nurse: patient 6,248:479 (1:13) 






Outpatient  1,876,818 
Inpatient  179,351 
Health infrastructure 
*incomplete data for 
private and quasi 
government hospitals 




District hospitals 17 
Health centres 105 
General hospitals 16 
Maternity homes 8 




These health facilities and human resources are sited in 26 districts (PHC, 2012). In addition, 
in terms of health work force training, the Tamale metropolis has one university teaching 
hospital, a community health nurses training school and one nursing training college, where 
the majority of the health human resource of the setting received their training.  
 









3.12 The Ghanaian Healthcare System 
 
Structure of the health delivery system 
 
The Ministry of Health (MOH) has oversight responsibility for the provision of quality 
healthcare through adequate financing of the health system, provision of logistics for health 
education, training, development, provision of hospitals and management of health services in 
general. The Ghana Health Service (GHS) has been vested with the mandate for provision of 
health services through promotion, curative and rehabilitative care. The MoH therefore 
formulates policies, while GHS sees to the autonomous implementation of government policies 
on health in both the public and private sectors. 
MOH/GHS is a WHO development partner and has a comparatively well-developed healthcare 
system compared to the sub-region (Drislane et al., 2014). It operates a decentralised healthcare 
administrative structure which functions in four tiers i.e. national, regional, district and sub-
district/community level. 
The primary point of contact is at the sub-district/community level, where clinics and 
community-based health planning and services (CHPS) are managed by nurses and physician 
assistants. Secondary points of care are the district and some regional health centres/hospitals, 
which are usually managed by specialist doctors and nurses. Tertiary care services are offered 
at some regional and national hospitals where specialists doctors manage advanced cases. Most 
of these hospitals are government/public owned and are often referred to as referral 
centres/hospitals and are currently located in only five of the 16 regions: Northern, Ashanti 
Greater Accra, Volta and Central regions.  
The healthcare sector is financed largely by the government (39%) to support the National 
Health Insurance Scheme which finances affordable health for all (Schieber et al., 2012). 
The coverage of the scheme as at the end of 2017 was estimated to be about 18 million, with 
only 10.57 million active members (nhis.gov.gh). In-patient and outpatient visits have 





3.13 Study Sites 
 
Hospitals: Five hospitals were selected as sites for this study: The Tamale Teaching Hospital 
(TTH), Tamale Central Hospital (TCH), Tamale West Hospital (TWH), Seventh Day Adventist 
Hospital (SDA) and Kabsad Scientific Hospital (pilot hospital). Selection of hospitals were 
based on the following justification: 
 
1. The TTH is the largest tertiary referral hospital in the north of Ghana, and it serves as 
the teaching hospital for the University for Development Studies.   
2. The TCH and TWH are the two main primary care hospitals in the metropolis, 
providing general primary healthcare services to the central and western parts of the metropolis 
while receiving referrals from sub-district clinics.  
3. The SDA hospital is a mission hospital run by a faith-based organisation offering 
primary care services in the Tamale metropolis.  
4. KABSAD is a private hospital offering secondary care and essential services to 
individuals who opt for private care services. Kabsad was deemed suitable for piloting the 
study because it shared similar characteristics to the main study sites. 
 
The five selected healthcare facilities were the most patronised and were within a 4 to 8km 
radius of the metropolis (Figure 10). The Tamale meterpolis is estimated to be 646.90180sqkm 
with 115 communities and 223,252 inhabitants (PHC., 2010). Notwithstanding the availability 
of community, district and other private clinics, the selected study sites were the most 
pertronised and cater for the healthcare needs of majority of the population. Patients also travel 
form outside the metropolis to assess specialist care especially at TTH which is a referal 
hospital. The diversity in sample of study sites therefore offered a multi-level perspective from 











In this section, the qualitative phase of study is described. Participant recruitment, selection, 
data collection and analysis are described. Trustworthiness which is an important aspect of 




The target population of both phases of the research were healthcare professionals i.e. nursing, 
pharmacy, and medical staff, who were among the core clinical team working at the five 
selected hospitals in the Tamale Metropolis.  A diverse group of health professionals was 
considered based on a report from the Food and Drugs Agency (FDA), which suggested that 
medical, nursing and pharmacy staff are the most frequent ADR reporters (Darko and Sabblah, 
2016; FDA, 2018).  
Participants included general nurses and specialities such as midwives, emergency care nurses, 
nurse prescribers, public health nurses, and enrolled nurses, who consented to be part of the 
study. Pharmacy staff included pharmacists and pharmacy technicians, while medical staff 
included doctors and medical officers of various specialities and seniority levels, as well as 
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physician assistants.Dentists, physiotherapists, laboratory and biomedical staff, radiologists, 
technical officers, environmental health officers, dispensing assistants, optometrists, and ward 
assistants were not considered for this study as they are less likely to be involved in ADR 
reporting.  
In addition, non-clinical HCPs who were not frontline medical staff (administrators and 
management staff) were excluded. 
 
3.13.2 Sample Size 
 
The qualitative sample was selected mainly from respondents of the quantitative survey and 
pilot study. An open invitation was sent along with survey questionnaires for participants to 
indicate their interest to participate in either the FGD or in-depth interview. Out of 386 
invitations, 70 expressed interest and 51 invitations were accepted (including pilot study). A 
total of five FGDs (19 nurses) and 32 in-depth interviews (medical, pharmacy and nursing 
staff) were undertaken. In FGDs, a sample of four to ten participants is usually recommended 
(Bryman, 2012; Barbour, 2005), so 14 participants were targeted per group in case of attrition. 
The pilot study had only three participants because of practical limitations. Data saturation was 
considered an important concept, which helps the researcher to curtail further sampling when 
no new information is being generated (Glaser and Strauss 1967). Identifying the required 
sample size for the perceived data saturation limit was based on previous studies elsewhere 
(Mirbaha et al., 2015; Williams et al., 2013; Kingston et al., 2004; Nichols et al., 2009), 
because there were no studies in the local context to base the sample on. For example, while 
Kingston (2004) and colleagues sampled between 4 to 11 for their FGD, Mirbaha et al., (2015) 




Participants were approached by invitation to opt in for either an in-depth interview or a focus 
group discussion (Appendix B) to further understand the central phenomenon of ADR 
reporting in their various facilities after the survey. Information sheets about the qualitative 
study were also made available at various departments and units. Even though there was a high 
response rate from the invitation letters (Appendix E), gatekeepers recommended specific 
individuals, departments or units to approach in order to capture the contextual relevance of 
the topic. With participant permission, contact details of participants who were sent an 
invitation letter (Appendix E) were collected for future correspondence and appointments. 
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Participants who honoured the final SMS notification of invitation reminders, follow-up phone 
calls, and who consented, participated in the study.   
 
3.14 Qualitative Pilot Study 
 
The study site (Kabsad Scientific Hospital) was purposively selected because it is located in 
the same study area and comparable to the selected hospitals in the main study. The rationale 
of the pilot was to trial the study methods within the study population (HCPs) in an environment 
similar to the main study. Permission was sought from the hospital administration and 
purposive sampling techniques were used to recruit nursing and medical staff. The process was 
used to test interview protocols, strengthen interviewer skills and to identify the practical issues 
in the research beforehand (Kim, 2011).  The transcripts from in-depth interviews, focus group 
and field notes were analysed and added to the main study. This was because qualitative 
interviews are progressive and continuously improve as the study progresses, thus some have 
argued for pilot studies to be an integral part of the main study rather than separated from it 
(Holloway, 1997). Throughout the interviewing process, the researcher gained confidence and 
insights as a novice researcher. Insights into improving interview schedules, line of questioning 
and introduction of the issues, were gained in the process. 
The qualitative pilot phase identified a number of ethical, technical, cultural, social and 
professional challenges associated with the data collection. Measures were therefore put in 
place to limit occurrences in the main study.  
 
1. Getting a suitable place and time for conducting interviews with those who had 
consented to participate in the study was challenging. For example, a scheduled interview 
session with a doctor in his consulting room was constantly interrupted by visitors. Some nurses 
who were interviewed in their staff common room were interrupted by colleagues and friends. 
This created a noisy environment which affected the quality of the recording. Locating a quiet 
environment was therefore an important measure taken in the main study, to reduce external 
disturbance. 
2. Participants routinely excused themselves from the interviews to perform work-related 
tasks, which often disrupted the flow of the interview. 
3. Piloted audio-recording of participants signalled poor audio quality. This indicated the 
need to request recordings to be conducted in a designated closed meeting area such as the staff 
room or consulting rooms, when no other patients or staff were present. In addition, 
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manipulation of the recording device was also challenging, especially in terms of positioning 
the device to be able to capture the best audio quality, and when the audio had to be paused 
and recording continued later. 
4. The facility was informed, and access sought from hospital administration. A purposive 
sampling technique was used to sample key informants through a gatekeeper. This was a 
challenge however because the gatekeeper informed participants of the study but there were no 
direct or personal introductions. Coupled with the busy schedules and unfamiliarity with 
scientific research, this was a challenge. The success of the responses and data collected 
therefore depended on the researcher’s inter-personal skills (Kim, 2011). 
5. The researcher’s own knowledge and expectations implicitly created a bias. It is 
important to block these biases and assumptions then explain the phenomenon of ADR 
reporting in terms of its inherent systems and meaning to the healthcare professional by 
maintaining the epoche process (Kim, 2011). Epoche helps the researcher maintain a position 
of uncertainty, suspend their judgement and refrain from any premature conclusions.  On a few 
occasions at the initial stages of the interviews, it was noticed that leading questions were being 
asked, which made it difficult to maintain the epoche. This process was mastered process 
through practice, where reflections and self-awareness were used to better the researchers 
interviewing skills. The practice helped gain insight from an emic perspective while trying not 
to impose their own views on participants, as suggested by Seidman (2006). 
6. There were instances where the researcher was asked questions by the interviewees, for 
example, the researcher, in trying to assess participants’ knowledge, asked: “What is 
pharmacovigilance?” After a few seconds of silence, the participant asked the researcher the 
same question. This necessitated rephrasing of the interview question to include alternative 




3.15 Data Collection 
 
The data was collected between September and November 2017. The qualitative approach 
permitted an in-depth exploration of the rich accounts of the study participants’ experiences. 
This was achieved using multiple strategies including key-informant interviews, in-depth 
interviews, focus group discussions, and analysis of open-ended questions. The process 
ensured data triangulation, giving a detailed and comprehensive view of the phenomenon 
(Sargeant, 2012) while increasing the validity and reliability of the study (Plano Clark and 
Creswell, 2008). The focus group discussion (FGD) in particular ensured interaction between 
participants, which reduced recall bias (Vaivio, 2012). Additionally, it facilitated inter and intra 
HCP comparisons in their natural setting where sensitive issues were discussed in a supportive 
environment. Participants who opted for in-depth interviews were followed up at a time and 
location most convenient to them for a recorded interview session.  
 
3.15.1 Interview Guide and Procedure  
A semi-structured topic guide by Kingston (2004) on incident reporting by doctors and nurses 
in Australia was modified, based on the current research context and questions, to facilitate the 
in-depth interviews and focus group discussion in this study (Kingston et al., 2004). The topic 
guide from Kingston (2004) had the following questions:  
● What comes to mind when you hear the word “incident reporting”?  
● What is the current reporting process in your organisation?  
● Can you think of any positive things that have occurred as a result of completing an incident 
report? Can you think of any negative things?  
● How would you rate the current reporting system?  











● How many times a year, on average, do people in your position fill out incident reports?  
● Why do people decide to complete an incident report?  
● How do you think people feel when they complete an incident report?  
● Based on your experience, how many times a year should people in your position fill out 
an incident report?  
● What makes people in your position decide not to complete a report?  
● Does the seriousness of the situation have any bearing on whether an incident report is 
made, or not?  
● On the sheet, I have listed some of the obstacles to reporting. Do you have any comments? 
Which of these do you regard as the really big issues? Are there any other obstacles?  
● Would having a form with the option of not identifying the reporter make a difference?  
● Is there anything else we should have discussed that we haven’t touched on yet?  
The questions were then modified into an introductory part, the main questions, and conclusion 
(Table 7). The introductory part was about the study, participant and researcher background. 
Some of the main questions included: what factors affected adverse reaction reporting among 
healthcare professionals, how adverse drug reactions were reported, and how adverse drug 
reaction reporting could be improved. The questioning was flexible, allowing use of several 
probing and follow-up questions. To conclude, the opportunity was also given at the end of 
each session for participants to give any additional viewpoints.  
Through the qualitative data collection phase, participants were able to contribute to 
discussions and express their views. Through the discussion, participants learnt a lot and 
medication safety was also promoted. Prompts and images were used to facilitate discussion 
about ADR reporting. For example, pie charts and a newsletter from the Food and Drugs 
Authority (Darko and Sabblah, 2016) were shown to participants to facilitate discussion points. 





Table 7 Modification of the interview topic guide 
 
PILOT INTERVIEW FINAL INTERVIEW GUIDE SUMMARY OF CHANGES 
1. Introduction (researcher and research 
purpose) 
1. Introduction of researcher and research 
purpose. 
The question was rephrased to allow more time during 
the icebreakers to introduce myself, build rapport and 
also hear the background of the participant. In the pilot, 
I only mentioned my first name and delved into the first 
question on pharmacovigilance (PV). 
2. Tell me about yourself and how long you 
have been practising. 
             
3. Can you please tell me briefly what you know 
about pharmacovigilance; what is your 
general understanding about 
pharmacovigilance? 
 
 3a. What is an ADR? 
2. What is pharmacovigilance?  This question was rephrased to take a step back to 
understand whether HCPs had basic knowledge about 
the phenomenon. Provision was made for using 
alternative terms such as ‘medication safety’ or ‘drug 
safety’ in case the participant had never heard of the 
term pharmacovigilance (PV). The hypothesis was that 
they had at least heard about PV already before the 
interviews. 
3. How is the current reporting process in your 
facility? 
4. Have you had some experience with adverse drug 
reactions from patients?  
If yes, tell me about your experience and how you 
reported it; if no, tell me why. 
It was also presumed that HCPs would have 
encountered at least one ADR in their practice. The 
pilot, however, showed otherwise. Questions were 
therefore restructured to ask about their experience 
with ADRs and how they are reported incidences. It 
4. Can you think of any negative or positive that 




 was noticed that pilot questions 5 and 6 only generated 
very short responses. Asking about their reporting 
experience and the reporting process generated more 
conversation. 
5. How would you rate the current reporting 
system? 
 
6. How many times do people in your position fill 
out a form? 
7. Why do people decide to complete the ADR 
forms? 
 
5. Looking at the FDA Drug Lens newsletter 
(show participant a copy), reporting in this 
region is the worst in the country – why do you 
think reporting is low? 
Using the pilot questions 7, 8, 9 and 10 experienced 
short responses and moments of awkward silence. To 
avoid this in the main interview available data on ADR 
reporting from the FDA was used as a prop to facilitate 
discussion about why ADR reporting was low. Even 
though pilot questions 7, 8, 9 and 10 were merged, they 
were used to prompt participants if they failed to speak 
about them eventually. 
8. How do you feel when you complete a form? 
 
9. Examples of your experiences – in what 
situation would you be compelled to report? 
 
10. Roles and responsibility of providing forms. 
 
11. Does the seriousness of an event affect whether 
an ADR would be reported?  
6. How likely are you to report the following 
types of reactions on a scale of 1 to 5 where 1 
is ‘would definitely report’, and 5 is ‘would 
definitely not report’? Explain your choice of 
response. 
● Any adverse reaction 
● The patient died as a result of the reaction 
● The reaction caused the patient to be 
hospitalised or needing significant medical 
treatment 
● The reaction included in the product 
information is a known adverse reaction for 
the drug 
● The reaction followed a vaccination 
● The reaction followed use of a biological 
product 
● The reaction followed use of new medicine 
 
This question was rephrased to solicit the best response 
to the underlying factors which motivate HCPs to 
report ADR. The piloted question gave shorter 
responses and required further probing and prompting 
to solicit the required response. 
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12. Suggestions for improving reporting. 
 
7. If you were the manager and had money to 
invest, what barriers do you think – if they are 
addressed – ADR reporting would improve, 
especially in your facility? 
Pilot question 12 was rephrased into a preamble to get 
the participant involved from a point of power and to 
discuss what they think would work. Question 13 was 
asked as a follow-up question if it was not discussed. 




14. Can I have your final words to conclude? 8. If there are any other issues, I have not raised 
that you would like to comment on, you are 
most welcome to give your final comments. 
This was rephrased to present a polite conclusion, but 
this did not change the meaning of the question asked. 




3.15.2 Instruments and Interview Records 
 
Interactions were facilitated which created a context in which the participant could relate to 
thereby generating data through important probing questions as suggested by Chenail (2011). 
As the researcher becomes the main data collection instrument in qualitative research it is 
important to develop the appropriate attributes (Sandelowski, 2000). Questioning and listening 
skills acquired were leveraged to give the participants a platform to express their opinions, as 
it is thought to have a therapeutic effect on participants when their views are listened to 
(Poggenpoel and Myburgh, 2003). 
All in-depth and key informant interviews were audio-recorded and transcribed verbatim, as 
described in later sections. With the written consent of the research participants, an encrypted 
digital audio recorder was used for the data collection. All data was safely stored on the 
university drive. After data collection, a transcription software (Express Scribe 6.05) was used 
for dictation and transcription of audio files into word files. For participants who agreed to be 
interviewed but did not permit digital voice-recording, permission was sought for notes to be 
taken and crosschecked with the participant to maintain the accuracy of notes after interviews. 
Member checking is an important quality control measure, which allows participants to review 
the accuracy of their statements (Harper and Cole, 2014). All interviews were recorded at the 
hospital facilities, at times and places convenient to the researcher and participant and where 
there were minimal disruptions and apparent high sound quality.  
 
3.15.3 Open-ended Question Analysis  
 
An additional justification for qualitative dominance was further exploration of participant 
views using open-ended questions in the quantitative survey. Questions 1, 3, 5, 7 and 8 (see 
text box) were analysed as follow-up questions to augment questions, which preceded them. 
For example, question 1 followed a set of Likert-type questions about suggested methods of 
improving ADR reporting. This allowed scope for a deeper understanding of the discovery of 
diverse perspectives (Gillham, 2000). Open-ended questions were analysed by undertaking a 
content analysis (Erlingsson and Brysiewicz, 2017) where data extracts were condensed, 




Text box of open questions analysed 
 
  
Could you suggest other ways of improving ADR reporting in your healthcare 
facility?...................................................................... 
 
Do you read the FDAs newsletter, the DrugLens? Yes/no 
 
If yes where do you get your copy from? ..........................................     
 
In which department or unit do you mainly work?....................................................... 
 
Highest Level of education 
Masters  Degree  [   ] 
Bachelors Degree   [   ] 
Diploma    [   ] 
Certificate    [   ] 
Other………………..  [    ]  (please state)…………………….. 
How many ADRs have you reported this year (select one option) 
0                   [     ]  
1-5                       [     ]  
6-10                     [     ]  
11- 20                  [     ]  
More than 20       [     ] 
 
Whom did you report to?................... 
 





3.16 Thematic Data Analysis 
 
Unlike quantitative methods, qualitative data analysis is not straightforward because there are 
few well-established acceptable rules to guide analysis. As mentioned earlier, qualitative 
inquiry usually generates large amounts of data, which is often challenging to analyse, thus 
described by Miles (1979) as an attractive nuisance. There is often the fear of failing to carry 
out a true analysis due to the complexity of the data.  It is therefore recommended that data 
collection and analysis proceed simultaneously (Merriam and Merriam, 1998). Simultaneous 
analysis however was not practical because of resources and time, but data analysis 
commenced immediately after collection, from December 2017 to September 2018.  
Analysing quantitative data aims to understand the underlying patterns, trends and relationships 
revealed in the numerical data about a phenomenon to help draw a valid conclusion (Albers, 
2017). Describing the process helps the reader to understand how the results culminated from 
raw data into useful information. Thematic analysis has become a popular strategy and useful 
strategy for analysing qualitative research, and can be adopted in different contexts of analysis, 
such as critical discourse (Burman and Parker, 1993) and narrative and content analysis, even 
though they are unique strategies in their own right. A classic thematic analysis strategy was 
adopted which was guided by the research questions. The decision was influenced by my stance 
as a pragmatic researcher, as I sought to utilise what works best based on research design and 
the data collected. Even though thematic analysis is criticised as not being robust and lacking 
sophistication (Smith and Firth, 2011), it is widely used and novice researchers find it useful 
in learning “core skills that will be useful for conducting many other forms of qualitative 
analysis” (Braun and Clarke, 2006, p.78). Through a non-linear step-by-step reiterative 
process, important themes were identified and used for analysis. A theme is described as a 
category identified by an analyst, informed by data, which relates to his/her research 
focus/question; codes identified in transcripts/field notes provide the researcher with the basis 
for theoretically understanding the data, which can make theoretical contributions to the 
literature relating to the research focus.  
When analysing themes, it is advisable to look out for repetitions, indigenous typologies, 
metaphors, analogies, transitions, similarities, differences, linguistic connections, missing data 
and theory related to the material (Bryman, 2015). It is important to see through the 
“participant’s eye”, hence the need for abductive reasoning, which is a type of inductive 
reasoning that relies on explanations and understanding of the participants’ world view 
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explained by the researcher. The FGDs and in-depth interviews were analysed deductively 
using the six-stage thematic analysis process described by Braun and Clarke (2012) (Figure 
11). Although rarely a linear process, it systematically guides the data analysis process. 
 
Figure 11: A six-phase thematic analysis format (Braun and Clarke, 2012) 
 
Step 1 
Data familiarisation: To make meaningful inductions, it is important to be familiar with the 
whole data corpus. Data obtained through the interviews were transcribed verbatim using the 
NCH transcription software, Express Scribe, and double-checked for accuracy. Field notes 
were typed and stored in Microsoft Word. Important emerging ideas were highlighted at this 
stage and noted. Even though time consuming, transcribing data, reading and re-reading the 
data, and noting down and highlighting initial ideas further deepened the familiarisation 
process, helping the researcher to become immersed, knowing the depth and breadth of the data 
corpus (Braun and Clarke, 2006). 
 
Step 2 
Initial code generation: It is important to code interesting features of the data in a systematic 
fashion across the entire data set, collating data relevant to each code. This can reduce chunks 
of data into manageable amounts. Initial codes were generated by the researcher in the first 
instance through open coding, and their appropriateness was discussed further with the 
supervisory team. Open coding involves reading through the data several times and creating 
tentative labels for chunks of the data which show interesting concepts. The open coding was 
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followed by axial coding, which allowed the identification of relationships between the codes. 
Transcribed data was coded and analysed both manually and using NVivo version 12. All files 
were transferred to NVivo and initial codes, generated based on ideas from familiarisation of 
the data and from the general literature. Manually, pen and paper were used to sketch ideas 
from codes and to create mind maps (Figure 12). A memo of coding was kept to document the 
coding process and emerging ideas. The style of coding usually depends on the research 
standpoint and questions. An inductive approach was used to narrow the research scope to 
explore a new phenomenon, rather than a deductive approach which is usually driven by a 
hypothesis and establishing causality.  
 







Searching for themes: This stage involved collation and sorting of codes, and further 
development of the mind maps into potential themes (Figure 14). Gathering all data relevant to 
each potential theme was achieved by observing repeated patterns and building a visual 
narrative. At this stage, repetitions are an important way of identifying themes or trends in data 
but may not necessarily mean anything, especially if they do not relate to the research focus or 
questions of interest (Patton, 2002). According to Bazeley (2013), it is important to justify how 
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themes emerged or were identified (Bazeley, 2013). He argues that presenting themes and 
illustrative quotes is not sufficient in qualitative research, but that the themes need to be 
weighted to show the significance of one over the other. NVivo software was therefore used as 
a supplementary tool for coding the searching codes and identifying and prioritising themes. It 
helped to identify important themes based on the number of reference hits made in a file. For 
example, Figure 13 shows highlighted themes based on the level of importance, from 
transcripts of nurses’ data. The code name ‘availability of forms’ (highlighted) shows 11 
reference hits in three files. This shows the importance of the code and possible inclusion in 
subsequent themes. For example, ‘defensive medical practice’(highlighted) shows it has not 
been referenced in any files among nurses, and thus is less important. Such codes were either 
merged or disregarded based on perceived relevance. 
 


















Reviewing themes: After collating codes and searching all the emerging themes, they were 
crosschecked to ensure they were close-fitting in relation to the coded extracts (step 1) and the 
entire data set (stage 2) to generate a comprehensive thematic map of the analysis. This process 
entailed many reiterations and discussions with the supervisory team finding the linkages 
between themes and codes, clarifying ambiguity and weighting importance of themes. This 
was prepared by printing on A3 sheets (Figure 15) where themes and codes were reviewed and 














Figure 15: Picture of reiterations from supervisory team crosschecking relevance of 






Defining and naming themes: There was ongoing analysis to redefine the specifics of each 
theme, and the overall story the analysis tells was initiated in this step. Clear definitions were 
generated, and refined names of each theme created. The links and interconnections between 
themes and subthemes were examined as proposed by Attride-Sterling (2001) and Grogran, et 
al. 2014. After weighting themes according to importance, two main themes emerged i.e. 
system and human factors, which resulted in internal/external factors and patient/HCP factors 
respectively. These were presented pictorially in a diagram (Figure 16) showing subthemes and 




Figure 16; Initial organisation themes 
ADR not reported









































































































































































































Write-up: This step presents the final opportunity for analysis. Themes are meaningless if they 
are not expounded to show their inter-relatedness and how interesting they are (Bryman, 2016). 
The themes were linked back to the research questions and literature to draw inference and 
implication for the study. This process comprised selection of vivid, compelling extract 
examples, analysis of selected extracts and production of a scholarly report of the analysis. 
Continuous reiterations from the researcher and supervisory team produced succinct 





In this section, the quantitative research phase including the quantitative research design, the 
techniques for participant recruitment, data collection, and analysis are described. The section 
begins with the rationale for this component of the study design, before moving on to describe 
the key stages of the research process. Validity and reliability, which are important aspects of 
ensuring quality in quantitative research, will be discussed separately under 3.26 
 
3.17 Study Design 
 
The quantitative phase of the study employed a descriptive cross-sectional study design with 
the mixed methods study to provide snapshot evidence about ADR reporting practices among 
HCPs in Tamale, Ghana. As mentioned earlier, only one study utilised a quantitative approach 
to investigate ADR reporting among nurses in Tamale city (Ameade et al., 2014). Sabblah 
(2014) also focused on doctors in Accra, and a third study focused on doctors, nurses and 
pharmacists in the Volta region. This study design therefore aimed to offer comparability and 
multiple perspectives of different categories of HCPs in the context of Tamale city, which is 





3.18 Study Participants 
 
As in the qualitative study, the study participants were healthcare professionals: medical, 
nursing and pharmacy staff. 
 
3.19 Inclusion and Exclusion Criteria 
 
Participants were invited to take part in the study if they were directly involved in patient care 
and clerking. Nursing staff included enrolled nurses, midwives, general nurses, nurse 
practitioners (prescribers) – and other specialised categories such as eye, ear, nose and throat, 
paediatric care, emergency care and mental health. Medical staff comprised house officers, 
medical officers, medical/physician assistants, consultant physicians and specialist doctors, 
while pharmacy staff included all ranks of pharmacists and pharmacy technicians. Clinical staff 
who had additional responsibilities such as clinical, administrative support, and hospital 
management, were also included. 
Dentists, physiotherapists, laboratory and biomedical staff, radiologists, technical officers, 
environmental health officers, dispensing assistants, optometrists and ward assistants were 
excluded from this study. In addition, non-clinical HCPs who were not front-line medical staff 
(administrators and management staff) were also excluded. 
 
3.20 Participant Selection 
 
As mentioned previously, participants were selected from five hospitals in the Tamale 
metropolis, i.e. Kabsad Scientific Hospital, SDA Hospital, Tamale Teaching Hospital, Tamale 
West Hospital and Tamale Central Hospital (Figure 17). The selection of study hospitals was 
purposive while selection of study participants used random stratified sampling. The 
stratification was based on hospital department and units. Ten main departmental units were 
purposively selected, and participants were selected from these units by simple random 
sampling. Departmental unit heads used the staff list, and participants who were selected 
consented and were issued the questionnaire. It was important to maintain diversity across 
participant characteristics representing nurses, doctors and pharmacists. Selection strategy 
ensured adequate representation of departments and units, and healthcare professions of 
interest (Palinkas et al., 2015).  
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3.21 Sample Size 
 
As mentioned earlier, the purpose of the quantitative phase is to provide supplementary 
evidence to the main qualitative findings. There is therefore no prerequisite to produce a formal 
statement on statistical generalisability because it only serves as a supportive element of the 
study, as suggested by Morgan (2013). 
A sample size was, however, calculated based on a sampling frame (Table 8) of the population 
of 2,060 medical, nursing and pharmacy staff from the selected hospitals. The sample size was 
determined by using freely available online sample size calculator software (raosoft.com). The 
online model used was based on the following formulae using estimated sample size (n) and 
margin of error (E). 
 
Where  
N = population size (2060) 
r = fraction of response that you are interested in (50%) 
Z(c/100) = critical value for the confidence level C (90%) 
 
With an acceptable margin of error (E) of 5%, at a 90% confidence interval and a 50% response 
distribution, the recommended sample sizes (n) for a population of 1,716 nurses, 286 medical 
staff and 62 pharmacy staff in four hospitals were calculated as 234, 140 and 51 respectively. 
Proportions of each HCP within each hospital were estimated based on the total population of 
HCPs within the hospital facility. The total estimated sample size was therefore 425.  Attrition 
of healthcare professionals was expected due to the nature of their work. Previous studies in 
similar settings estimated the unit non-response rate to be between 5% to 15% (Sabblah et al., 
2014; Fadare et al., 2011; Ezeuko et al., 2015). Additionally, 25 (6%) survey questionnaires 
were included to mitigate attrition and non-response.  
  
x = Z(c/100)2r(100-r) 
 
n = N x/((N-1) E2 + x) 
 






Table 8: Sampling frame and selection of study participants 
 
 
3.22 Data Collection 
 
Questionnaires were handed in person to HCPs and largely self-administered and returned by 
participants themselves at their convenience. Some participants however requested guidance 
and clarification in which they were supported under the supervision of the researcher. 
Considering the time constraints in the study, this method was cheaper and quicker to 
administer. Moreover, it was a more inclusive strategy than the postal or mail system of self-
administration suggested by Bryman (2016), which was not applicable in the context of this 
study (Bryman, 2016). The survey was administered face-to-face by the researcher only when 
HCPs consented to do so, because they felt would not have time to do it later. Even though 
responses were higher for those who consented to be guided through the questionnaire, the 
presence of the interviewer had a tendency to bias responses. As suggested by Tourangeau 
(2013), self-administered web surveys are likely to present sensitive information spontaneously 
if the researcher is absent (Tourangeau et al 2013). This was confirmed in a study comparing 
the trustworthiness of face-to-face and postal responses, which showed that postal responses 
were more likely to retrieve honest responses than face-to-face (Preisendörfer and Wolter, 
2014). In both Tourangeau and Preisendorfer’s cases the absence of the researcher avoided 
socially desirable responses. In this study, where applicable face-to-face interviews was 
avoided and used only when it took several reminders to retrieve some of the questionnaires, 
to reduce loss to follow-ups.  
Hospital 
  



























929(54.0) 256(89.0) 41(66.13) 1226 126 125 34 285 
Tamale Central 
Hospital 
387(22.9) 10(4.3) 7(11.29) 404 54 6 6 63 
Tamale West 
Hospital 
260(15.0) 12(4.3) 4(6.45) 276 35 6 3 44 
Seventh Day 
Adventist (SDA) 
140(8.1) 4(2.40) 10(16.13) 154 19 3 8 30 
Total 1,716(100) 286(100) 62(100) 2060 234 140 51 425 




3.23 Data Collection Instrument  
 
The data collection instrument for the survey was a structured, self-administered questionnaire 
with integrated open-ended responses described in the qualitative section (Appendix P). The 
instrument had a clear presentation and instructions on how to complete it. Ambiguity, long 
and double-barrelled questions were avoided as suggested by Bryman (20012). The items on 
the questionnaire were adopted and modified for a Ghanaian context from tested and validated 
previous studies (Bello and Umar, 2011; Ameade et al., 2014; Sabblah et al., 2014; Ezeuko et 
al., 2015). The instrument was in six parts comprising 67 items. Participants were surveyed on 
questions related to practice (16 questions), and contextual/external issues (six questions). 
Additionally, five questions were aimed at establishing knowledge of healthcare professionals, 
which comprised five questions for which correct responses reflected participants’ knowledge 
on ADR reporting. Part 1 omprised demographic and background characteristics of study 
participants; this was followed by the second phase, which considered the current practices of 
ADR reporting. Part 3 pecifically focused on contextual questions. Part 4 assessed ADR 
reporting knowledge, while Part 5 consisted of multiple-choice answers and some Likert-type 
questions on HCP reporting attitudes, based on Inman’s typologies (Inman, 1996). Likert-type 
questions on suggested ways to improve ADR reporting were asked in Part 6.  
 
3.24 Questionnaire Piloting  
 
Similar to the quality phase of the research, the questionnaire which was adapted and modified 
to collect data from the research participants was administered to a small sample of participants 
in a small-scale pilot study. The participants were recruited from a private hospital (Kabsad 
Scientific Hospital) which shares similar characteristic, in terms of the population studied, with 
the 4 hospitals sampled for the main study.  A pilot study is considered an integral part of any 
research process. It is described as a small-scale methodological test conducted to prepare for 
a main study and is intended to ensure that methods or ideas would work in practice (Kim, 
2011). Hassan et al. (2006, p.70) described this as a: “small study to test research protocols, 
data collection instrument, sample recruitment     strategies and other research techniques in 
preparation for the main study” (Hassan et al., 2006). The pilot study helped the researcher to 
practise the research instruments at first hand and re-strategise. Unlike the qualitative phase, 
where the data from the pilot study were included in the final analysis, the data from, 
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quantitative pilot were excluded from the analysis, because the purpose of the pilot was to 
validate the adapted revised questionnaires.  
Some of the challenges encountered in the pilot study, which were used to improve the final 
instrument, include the following: 
 
1. Participants complained that there were too many questions, and it took several follow-ups 
to retrieve the questionnaires. This was addressed by reducing the number of items in the survey 
instrument and rewording some questions to ensure clarity.  
2. Administering the questionnaires face-to-face did not work well because participants had 
busy schedules and preferred to complete them in their own time. A flexible approach was used 
in the main study, whereby participants who had time filled in the questionnaire and others 
returned it at their convenience before the end of the study. 
3. Some questions seemed to be misunderstood and were often left blank or ticked incorrectly, 
especially Q29, Q31, Q37 and Q75. According to Bryman’s guidelines for designing 
questionnaires, questions in a forced-choice format where the instructions stated, “please tick 
all that apply” would yield superior responses if provided with “yes” and “no” options 
(EXAMPLE 2) for each response rather than a single option (EXAMPLE 1) (Bryman, 2015).  
 
Even though this approach has been advocated by Dillman (2007) and Dillman et al. (2014), it 
was not practical to self-administer questionnaires in the context of this study; participants were 
often confused and left the questions blank. These types of questions were therefore rephrased 
in the final survey. 
There was less variability in the six questions which assessed knowledge in the survey. 95% 
of participants selected the “don’t know” option. Questions were re-structured, and one 




3.25 Quantitative Data Analysis 
 
After data collection, Google forms were created to enter the data. Data were converted to 
Microsoft Excel spreadsheets and checked for missing data, incomplete responses and data 
inconsistencies. Errors which were identified were corrected, deleted or left unchanged 
depending on the gravity or the error, i.e. extreme or normal, as suggested by Van Den Broeck 
et al. (2005). Three participants’ data was completely deleted because of incomplete data, 
participants who did not follow skip-patterns in the questionaire were coded as missing data, 
and some missing data which were not correctly coded, were corrected. After cleaning the data, 
the data of 386 participants were imported into IBM SPSS version 24 to perform descriptive 
and inferential analysis. 
Preceding analysis, the data were defined in SPSS, suggesting variable names, labels and value 
labels, and coding for missing values. Recoding some variables was necessary to meet the 
SPSS formatting requirement. For example, interval data such as 20-30, 31-40 and 40+ were 
recorded as 1, 2 and 3 respectively. Selected variables were also regrouped and coded because 
of missing values or fewer responses, which made analysis problematic. For example, 
healthcare professionals were grouped into three main groups, i.e. nursing staff, medical staff 
and pharmacy staff, for analysis purposes.  
In the original data, the different HCP categories required grouping midwives, mental health 
nurses, public health nurses and nursing specialities as nursing staff. The medical staff 
comprised physicians, physician/medical assistants and medical doctors (various specialities), 
while pharmacy staff were grouped as pharmacy technicians and pharmacists (various 
specialities). These were therefore grouped to aid analysis. Other variables aggregated included 
age, frequency of reporting and observing whether daily, weekly and monthly options recorded 




Table 9:  Examples of aggregated data from survey. 
 
Question from sample Original data Aggregated data 





Years of experience 0-5 ≤5years 











How often do you observe ADR? Daily Daily/weekly/monthly 
Weekly 
Monthly 
Every 3months  Every 3-6months 
6 months 
Once a year  Once a year  
Never  Never  
Can’t tell  Can’t tell  
How often do you report ADR? Daily At least once a year 
Weekly Never 
Monthly Can’t tell 
Every3 months  
Every6 months  
Once a year  
Never  
Can’t tell  
How many ADRs reported in this 
year?  
0 0 No 









The questions were recoded into “correct” or “positive” response = 1 and “incorrect” or 
“negative” responses = 0 and analysed accordingly. In a similar fashion, all Likert-type 
responses were given assigned numerical values to support SPSS data analysis i.e. strongly 
disagree = 1, disagree = 2, neither = 3, strongly agree = 4, and strongly disagree = 5. Thirteen 
Likert type questions were addressed HCP attitudes, while twelve Likert type questions also 
addressed suggested methods for improving ADR reporting.  
Likert-type questions have been distinguished from Likert scales by Clason and Dormody 
(1994). Likert-type questions have been described as a set of single questions which does not 
aim to combine items into a composite score scale, as opposed to an actual Likert scale in 
which items can be quantified into a measure for a characteristic, behaviour or trait (Boone and 
Boone, 2012).  The Likert-type questions used were unique and unrelated and were not 
intended to estimate a composite score for attitude because standardised scales for measuring 
attitudes to reporting ADR are unavailable in the literature.  
There has also been debate about analysing Likert scales using parametric or non-parametric 
methods and whether they can be treated as interval rather than ordinal data to support 
parametric tests, which has more statistical power (Maydeu-Olivares, 2005). Data was 
therefore analysed using non-parametric analysis where mode and median were used as 
measures of central tendency, and frequencies were used to measure variability. Using a non-
parametric method for analysis was justified because the data were largely categorical, ordinal 
(‘Likert-type’ responses, ADR reporting rates, etc), and nominal (sex, grade, department, HCP 




3.26 QUALITY OF RESEARCH 
 
This section describes the theoretical underpinnings of undertaking a research project of high 
quality, with practical examples of steps which were taken to ensure this. This therefore 
encompasses what strategies were used in terms of the qualitative (trustworthiness), 
quantitative (validity and reliability), and mixed methods (legitimization) in undertaking this 
research. 
 
3.26.1 Trustworthiness in Qualitative Research  
 
Lincoln and Guba (1994) suggested that the primary methods of assessment in qualitative 
research should focus on trustworthiness and authenticity of a study. As mentioned earlier, the 
quantitative terms of reliability and validity in qualitative research rather focuses on the aspects 
of trustworthiness and authenticity. This study was guided by Lincoln and Guba’s constructs 
of credibility, transferability, dependability and confirmability, which confirms, the 
trustworthiness of the research (Guba and Lincoln, 1994).  
Credibility and transferability are synonymous with the quantitative criteria of internal and 
external validity (generalisability) respectively. Credibility refers to emphasis on multiple 
accounts to establish social reality, while transferability refers to the production of rich and 
detailed accounts of a culture (Geertz, 1973). Mixed methods equivalents such as multiple 
validity, insider-outside and political approaches were considered as ways to legitimise the 
research to emphasise multiple accounts and rich detailed accounts. Participants therefore gave 
accounts from different categories of healthcare professionals (i.e. medical, nursing and 
pharmacy perspective) and also different health facilities, including a teaching hospital, private 
hospital, primary and secondary care hospitals. The findings can therefore be credible and 
transferable in the context of the research.    
Dependability and confirmability parallel the quantitative equivalent of reliability and 
objectivity respectively. Dependability refers to keeping a complete audit trail of all phases of 
the research process, while confirmability suggests not allowing personal values to influence 
the conduct of the research. To draw credible inference from the mixed methods, weakness 
minimisation, sequence, sample integration, commensurability and conversion were issues 
which were reflected on by the researcher. The researcher influences and bias were  
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acknowledged through personal reflections, and every step of the research process was 
documented by keeping a field notebook and comprehensively reporting the process details to 
justify the methods used. 
In addition to the criteria proposed by Lincoln and Guba, an additional issue of authenticity 
explores the wider political impact, which is similar to the legitimation issues of multiple 
validity and political impact to ensure credibility of a mixed methods research (Onwuegbuzie, 
Johnson and Collins, 2011). The wider political impact of this study was seen as a form of 
awareness creation about the topic of ADR, in which participants suggested they learnt 
something new which generated discussion among colleagues. Authenticity further seeks to 
infer how educative the concepts are in the sense of helping to understand different perspectives 
of other members of the society (educative authenticity), how change in circumstances can be 
enforced (catalytic authenticity), and empowering members to take action (tactical 
authenticity). Even though taught, provoking the implementation of authenticity in practice has 
been said to be controversial (Bryman, 2016, p.386). The potential wider political impact and 
authenticity of this research would help start conversations about ADR and possibly develop 
appropriate training and future actions.  
To validate the findings and determine the credibility of the information and whether it matches 
reality (Merriam, 1988), four primary forms were used in qualitative, phase of the study: (1) 
triangulation – converging different sources of information (interviews, documents, pictures) 
and making meaning; (2) member checking – getting feedback from the participants on the 
accuracy of the identified categories and themes; (3) providing rich, thick description to convey 
the findings; and (4) external audit – asking a person outside the project to conduct a thorough 
review of the study and report back (Creswell, 2003; Creswell and Miller, 2002). This was 
undertaken by cross-checking with participants and getting feedback from colleagues through 
external audits.  
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3.26.2 Validity and Reliability 
 
Reliability and validity are traditionally quantitative ideas of measuring the quality of a piece 
of research, as mentioned earlier. Pilot testing a survey data collection instrument is therefore 
considered essential and, widely advocated of enhancing both the validity and reliability of a 
questionnaire (Bowling, 2014; Bryman, 2016; Creswell, 2013; Denzin and Lincoln (1994); 
Oppenheim, 1992). 
Reliability issues include stability, internal and inter-rater reliability (Bryman, 2016). A 
measure can be tested for stability by the test-retest method, i.e. administering a test to the same 
sample twice on different occasions. This study relied on questions which were already tested 
and had been used in previous studies (Adedeji et al., 2013; Ezeuko et al., 2015; Nde et al., 
2015; Oshikoya et al., 2011; Sabblah et al., 2014; Angamo et al., 2012).  
Using multiple indicator measures, such as Likert-type responses, required checking for the 
internal reliability of the instrument. The internal reliability refers to whether the indicators 
which make up the scale or index are consistent and can result in the same findings if reanalysed 
by an independent researcher (Burns, 1999, p.21). The review of literature showed no existing 
reliable scales for measuring parameters of interest such as knowledge, attitude and perceptions 
of healthcare professionals. To guard against threats of internal reliability, the study was 
implemented using peer examination (utilising other researchers’ findings), mechanically 
recorded data (keeping a detailed account of the data), multiple researchers (involving my 
supervisory team) and low inference descriptors (ideas that can be easily quantified), as 
suggested by LeCompte and Goetz (1982). 
The Likert-type responses used in this study were modified and used as an index to assess HCP 
attitudes and also to explore suggested ways of improving ADR reporting. The internal 
reliability was retested by measuring the indices used, using SPSS Cronbach’s alpha test for 
reliability. As a rule of thumb, the acceptable alpha level is set at 0.80, but some studies have 
accepted a much lower figure. For example, Berthoud (2000, p.169) writes that a minimum 
alpha level of 0.60 is ‘good’. After modification of Likert-type items from previous studies, an 
alpha of 0.62 for 14 items on attitude was achieved, while 0.82 was found for 13 items on 




Several other methods of exploring validity have also been reported in literature, including face 
validity, concurrent validity, predictive validity, construct validity, and convergent validity. In 
the context of this study, only face validity was explored. Face validity is considered an 
essential intuitive process where a researcher tries to establish that the measure of interest is 
actually reflected in the content. Local experts were contacted for expert judgement of the 
survey instrument, and the final instrument was reworded to reflect the language, which was 
understood by participants. Additionally, the supervisory team provided guidance and 
reiterations until the final survey instrument was ready. 
While validity and reliability may be of importance, and a common discussion in quantitative 
research, it is less pronounced in qualitative research, where the primary focus is to capture 
real-life experiences of participants.  
3.26.3 Mixed Methods (Legitimation) 
 
To measure the strength and quality of a mixed methods study, the most recommended term 
used instead of validity is legitimation which uses a bilingual nomenclature and can be adopted 
by both qualitative and quantitative studies (Onwuegbuzie, Johnson, and Collins, 2011). Other 
authors prefer to use quality inference to refer to issues of reliability, trustworthiness and 
validity in mixed methods (Subedi, 2016). 
Legitimation is where the researcher draws inferences that are credible, trustworthy, 
dependable, transferable and confirmable in a mixed methods study. Nine types of legitimation 
discussed in literature include: (1) sample integration – yielding quality meta-inference; (2) 
inside-outside – accurate and appropriate utilisation of insider (group member) and observer 
view (researcher) in explaining or describing ADR reporting; (3) weakness minimisation – 
balancing the strengths and weaknesses of each approach; (4) sequential – minimising the 
effect on meta-inference by not trying to reverse the quantitative and qualitative sequence; (5) 
conversion – the extent to which data conversion techniques can lead to interpretable and high-
quality inference data; (6) paradigmatic mixing – the extent to which different researchers’ 
paradigms, epistemological and ontological underpinnings blend and combine; (7) multiple 
validity – the extent to which quantitative and qualitative research strategies are utilised for 
high yielding meta-inference; (8) commensurability – ensuring meta-inferences reflect a mixed 
worldview based on the cognitive process of Gestalt switching and integration; and (9) political 
– and extent to which and audience or consumers of mixed methods research value the meta-
inference from both quantitative and qualitative components (Clark and Creswell, 2008).  
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The study took into account these important underpinnings to ensure that the research process 
was trustworthy, reliable, valid and legitimate in understanding ADR reporting among 
healthcare professionals. 
 
3.27 ETHICAL CONSIDERATIONS 
 
 3.27.1 General Considerations 
 
Consideration of ethical principles and how robustly the related procedures are undertaken is 
an important aspect of any research involving human participants (Bryman, 2016). This section 
will examine how the study adhered to ethical guidelines during recruitment, data collection, 
data storage and analysis. The standard theoretical framework from which to analyse ethical 
situations in medical research generally stems from Beauchamp and Childress’s literature on 
the ethics of biomedical literature (Beauchamp and Childress, 2019). They provide basic 
universal guidelines for the conduct of human research internationally, ensuring the core 
principles of autonomy, justice, beneficence and non-maleficence, confirming that harm does 
not occur or is minimised for participants. These have however been modified to country-
specific recommendations based on these principles. It is important to ensure that research is 
transparent, and procedures acknowledged to authorities and participants alike. The 
significance of adhering to honesty, rigour, respect and scientific integrity in the whole research 
process are widely discussed in literature (Brinkmann and Kvale, 2008; de Vaus, 2002; Iphofen 
and Tolich, 2019).  
As a researcher at the University of Sheffield (UoS), the university policy guidance requires 
researchers to undertake recommended training on ethics and submit research proposals for 
ethical review approval before any research can be undertaken. The researcher therefore 
undertook the required module on Research Ethics and Integrity (FCS6100) to ensure that the 




In addition, the University’s ethics policy governing research involving human participants, 
personal data and human tissue required submission of the research proposal to the University 
Research Ethics Committee (UREC) for ethical approval. The research was however 
undertaken in Ghana, and The University of Sheffield Research and Innovation Services (RIS) 
recognises the ethical review process of the Ghana Health Service (GHS) Ethics Review 
committee (ERC). The Ghana Health Service is on the list of “organisations overseas that are 
recognised by the University of Sheffield’s Research Ethics Committee as having in place 
sufficiently robust ethics review procedures.” It was therefore passed as a recognised 
Alternative Ethics Review Procedure by Univeristy of Sheffield. As such, this means that a 
separate application to an internal University of Sheffield departmental research ethics review 
was not required. 
A study protocol was therefore submitted for ethical approval to the Ghana Health Service 
Ethics Review Committee.  Recommendation for conditional approval was given, subject to 
the requested modifications incorporated into the main protocol (ID NO: GHSERC001/07/17). 
After addressing queries on the main protocol, elaborating on ethical considerations, informed 
consent and seeking a local supervisor for the research project, a final approval decision was 
granted to commence the study from 31st August 2017 to 30th August 2018 (Appendix O).  
Literature suggests that engaging effectively with the research setting and being sensitive to 
the organisational hierarchy and structure, particularly getting clearance from gatekeepers, is 
critical for success of the study (Ritchie et al., 2014; Snape and Spencer, 2003). After ethical 
approval at the national level, written permission to assess study sites was therefore also 
requested locally from the Northern Regional Health Directorate of the GHS (Appendix D). 
After approval (Appendix H), an additional certificate of authorisation  (Appendix R)  was 
requested and received from Tamale Teaching Hospital’s administration to have access to units 
and departments, because of its autonomous administrative nature compared to other GHS 
facilities.
 
3.27.2 Specific Considerations 
 
Specific features and how they were addressed have been elaborated in table 10. Because this 
study was a mixed methods study, the procedures differed even though they were based on the 
same ethical principles, and additional comments have been provided.
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HOW IT WAS ADDRESSED 








Participating in in-depth interviews, key 
informant interviews and focus group 
discussion required demands on HCPs time. 
Participants chose a time and a place which 
was convenient for discussions, which were 
kept brief and concise with minimal 
disruptions. They could also choose to either 
be part of a focus group discussion or an in-
depth interview. After interviews, invited 
participants were acknowledged via SMS for 
their time, while drinks and snacks were 
provided, especially for those who participated 
in focus group discussions. 
The number of items on the survey 
questionnaire was reduced to 
decrease the time spent on a 
questionnaire, considering the busy 
schedules of HCPs. They were also 
offered the opportunity to self-
administer the survey questions at 
their own convenience and for 
completed questionnaire to be 
collected later at a time and place 
convenient to them. Participants 
were also given University of 
Sheffield labelled pens as souvenirs 
to show appreciation for their time 
after the survey. 
Firstly, it was established earlier during the 
upgrade of the PhD that the study was 
worthwhile and would not make 
unreasonable demands on participants. This 
was justified by passing the upgrade review.  
 
Secondly, ethical approval from GHS-ERC 
further confirmed the research was within 
scope and did not undermine research 
participants. As a mixed methods research, it 
was likely the research placed a higher 
burden and time constraints on those who 
participated in both qualitative and 
quantitative phases. This was addressed by 
appreciating their time and providing snacks 
and drinks during focus group discussions. 
Using both (Qual./Quant.) approaches was 
worthwhile as it provided greater research 














HOW IT WAS ADDRESSED 
 Qualitative Phase Quantitative Phase Additional comments 
Participation in 
research should 
be based on 
informed 
consent 
(Appendix A).  
Informed consent is an important basic 
principle and best practices were adopted for 
this study (Bryman, 2016; Ritchie et al., 2014). 
Participants who responded to the study’s 
invitation to participate in either an in-depth 
interview (IDI) or focus group discussion 
(FGD) were presented with an informed 
consent. They read the information sheet 
specific to IDI or FGD and asked questions 
(Appendix B). The informed consent also 
contained summary of the study (Appendix A) 
including; contact information of researcher, 
affiliated institution, research aims and 
purpose, potential risk and benefits, 
anonymity, confidentiality of data including 
personal information, required data to be 
collected, autonomy and ability to withdraw 
from the research at any time. Participants 
were also given details about approximate 
duration of interviews. They were given the 
opportunity to ask questions and seek further 
clarification and participated in the study based 




Verbally accepting to be part of the 
study was the first stage of consent. 
The second stage involved 
presentation of a detailed participant 
information sheet for the survey 
(Appendix V) similar to the 
qualitative phase to make an 
informed choice to proceed with the 
survey or not. Once willingness to 
participate was confirmed, a consent 
form was signed and dated 
(Appendix A). Some participants 
declined to be part of the qualitative 
phase after the survey. 
 
 
The study information was presented to 
HCPs at staff meetings to advertise the 
research, indicating who the researcher is, 
why the research is being carried out, what 
the researcher will be doing and who will be 
involved. 
A two-stage informed consent process was 
employed. HCPs who agreed to participate in 
the research were first to consent for the 
survey (Appendix V), invited to the 
qualitative phase (Appendix E) and if they 
agreed to be contacted, they consent again for 
either a focus group discussion or in-depth 






















HOW IT WAS ADDRESSED 







Participants were well informed during the 
consent process to exercise their autonomy. 
They were also given the opportunity to 
withdraw at any point, since the consent 
process is a dynamic and evolving process 
(Pope and Mays, 2006). Even though drinks 
and snacks were provided during the 
qualitative phase, this was an act of good will, 
which was offered to participants as a gesture 
of appreciation for their time after the sessions 





As mentioned in the qualitative 
phase, the quantitative phase 
provided explicit information in the 
informed consent. Even though both 
parties signed it, the researcher 
respected the participant’s decision 
to participate in the study and 
provided gentle reminders to 
participants who self-administered 
the survey questionnaire. There was 
no pressure on participants to 
participate. Participants were lost to 
follow-up if they failed to return the 
questionnaire before the close of 
study. University labelled pens were 
given to participants as a gesture of 









Recruiting participants through gatekeepers 
who were heads of departments or units may 
have threatened their voluntariness but 
having a face-to-face information session 








HOW IT WAS ADDRESSED 






risks of harm 
known 
Non-favourable or derogatory responses by 
participants about ADR procedures in a facility 
could lead to rebuke from superiors especially 
during focus group discussion and in-depth 
interviews. Recall of traumatising personal 
events in hospital was also considered a 
potential psychological risk to participants. 
Also, risks of confidentiality in focus group 
discussions were of concern. 
Personal data were therefore anonymised and 
delinked from interviews, and focus groups 
were homogenous (i.e. same cadre and same 
rank of staff), to manage and ensure 
appropriate protection and well-being of the 
participants. 
 Participants were informed and reassured 
about the purpose of the study, which was not 
to audit their practice but to understand their 
perceptions of the problems of ADRs reporting 
and ways to improve the current system. An 
information sheet included contact information 
of researcher, affiliated institution, research 
aims and purpose, potential risk and benefits, 
anonymity, confidentiality of data including 
In order to avoid the risk of work-
related queries from superiors, the 
researcher avoided administering 
the survey to HCPs during working 
times. The stress of completing the 
questionnaire was also considered. 
Participants were given ample time 
to respond to the survey, in order to 
avoid psychological trauma and 
burnout already compounded by 
work related stress. 
Generally anticipated harm for both methods 
was perceived as minimal (if any). Potential 
harm to research participants can be queries 
from superiors and dismissal if appropriate 
organisation guidelines were not followed. 
Permission was therefore sought from the 
management of the facility to ensure research 
procedures and protocols were in line with 
the organisation's policy so that the job of 

















personal information, required data to be 
collected, autonomy, and ability to withdraw 










HOW IT WAS ADDRESSED 





As mentioned before, there was risk of 
participants not respecting the confidentiality 
of what was discussed or of disagreement 
issues during the focus group discussions, 
which are challenging to control (Ritchie et al., 
2014). Then participants were informed about 
data confidentiality in the participant 
information sheet (Appendix B). This was 
further addressed by effective moderation of 
the session. Even though interviews were face-
to-face, participants’ transcribed data were 
anonymised, and any reference directly linked 
to any personal identification were removed 
from results presented or for future 
publications. Personal data such as phone 
numbers, which were collected to arrange 
interviews, member check and send 
appreciative messages, were collected for the 
purpose of the research only and would not be 
shared with any third party. All data would be 
stored safely and destroyed two years after the 
Survey questionnaires were 
anonymised without any reference 
or trace linking to personal data 
(person or hospital name, 
department, location etc.).  Contact 
details of participants who opted to 
be part of the qualitative study were 
collected after the survey and 
retained for further correspondence 
purpose only. 
Electronic data (files and folders) 
were stored on an encrypted pass 
worded electronic storage device for 
reuse indefinitely. Further details 
about data management were 
stipulated on the participant 
information sheet (Appendix V). 
Hard copies of survey materials 
were stored in a secured cabinet 
under lock and key to be destroyed 
two years after study closure. 
Some types of integration in mixed methods 
research allow the researcher to trace back to 
participants’ data to identify where the 
discrepancies may lie (O’Cathain et al., 
2010). The analysis strategy of this 
concurrent mixed method was at the analysis 
stage and did not require tracing back to 
particular research participants. Participant 
details in both phases of the study were 
therefore confidential and not traceable. 
Access to the data was restricted to the 
research team only. The University of 
Sheffield’s ‘Udrive’ was used as backup 
storage for both survey data and audio files.   
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end of study. Anonymised data would however 
be stored safely indefinitely and perhaps used 






Positionaility refers to “the stance or positioning of the researcher in relation to the social and 
political context of the study, the community, the organisation or the participant group” they 
plan to understudy (Coghlan and Brydon-Miller 2014). As the researcher becomes the data 
collection tool in qualitative research, it is important to discuss how the researcher’s 
relationship with his research environment influenced the research outcome. This ensures 
quality control and a realistic presentation of data that is thrustworthy. It is therefore essential 
for the researcher to understand the effect of their personal circumstances in the study. 
Furthermore, being self-critical and aware of oneself in the research is paramount in ensuring 
that our backgrounds or positionality does not bias our findings.  
I come from the northern part of Ghana and my educational background originally is a 
bachelor’s in Applied Biology following which I worked briefly in a biomedical laboratory. I 
went ahead to study for a master’s degree in Clinical Trials, with the aim of enhancing my 
laboratory career, but my faith changed. I worked as a social development officer instead in 
poor rural setting of northern Ghana. It was during this time I developed an interest in exploring 
people’s experiences, perspectives and beliefs about life.  
Even though I enjoyed working as a social development officer, my duties became routine, and 
I wanted something more challenging. It brought me to the realisation that I needed to 
undertake a PhD. The choice of interest in my topic was based on earlier interest from my MSc. 
course in clinical trials at the University of Ghana. It was during this time I became intrested 
in Phase IV trials and post authorisation studies, which are the final stage of the drug 
development process, usually focused on the safe use of the medicines. Even though I wanted 
to undertake research on that topic for my masters’ level dessertation, I was disappointed about 
the lack of data on safety monitoring in routine clinical practice. I became interested in 
pharmacovigilance and wanted to understand challenges in this crucial aspect of health. Having 
enjoyed my time exploring people's views in my earlier work, I envisaged part of my study 
would be a qualitative study. This background therefore influenced my choice of the study site, 
research participants and study design. On going awareness of my perpective helped to ensure 









            This chapter presents details of findings from the qualitative stage of the study, which as noted 
in chapter three represented the dominant methodology in this exploratory descriptive study 
(Walker and Baxter, 2019). There are no gold standards or guidelines on how to present a 
qualitative-dominant mixed methods study. This thesis therefore firstly presents the findings 
from the qualitative phase, followed by presentation of quantitative findings in the next chapter. 
The chapter begins with the description of participant demographics and later presentation of 
emerging themes from focus group discussions and in-depth interviews of healthcare 
professionals. As described in the earlier chapter, these were data collected from a sample of 
five healthcare facilities in the Tamale metropolitan area of Ghana. The participants were 
medical staff (doctors and physician assistants), pharmacy staff (pharmacists and pharmacy 
technicians) and nursing staff (general nurses and specialised nurses). Data from the surveys 
will be reported in the next chapter both descriptively and using inferential statistical analysis 
to explore associations between responses and a variety of factors relating to ADR reporting. 
The open-ended questions on suggestions to improve ADR reporting is presented as part of the 
qualitative findings in the chapter.  The overall research aim was to investigate the factors 
influencing adverse drug reaction reporting among healthcare professionals in Ghana. As a 
reminder, the qualitative phase sought to explore the main questions of what the perceived 
factors influencing ADR reporting are but specifically focusing on the following questions: 
 
1) What are the factors associated with ADR reporting, and why do HCPs consider them 
important? 
2) How is ADR reporting undertaken by HCPs in Ghana? 





4.1 Participant Demographics  
 
Data was collected from a total of 51 healthcare professionals (28 females and 23 males) who 
were interviewed from 5 healthcare facilities (the pilot study sample was added to the main 
study). Additionally, findings were based on data from discussions and personal reflections of 
individuals who did not wish to be voice recorded but were knowledgeable about the reporting 
process and were willing to contribute. The healthcare facilities comprised one tertiary care 
facility, two primary care facilities, one non-governmental primary healthcare facility, and one 
non-governmental secondary care facility. Thirty-two healthcare professionals participated in 
the in-depth interviews (IDI) and 19 participated in the focus group discussions (FGD). The 
justification for combining both IDIs and FGDs was to enhance data richness. Among the in-
depth interview participants 12 were nursing staff, 9 were medical staff and 11 were pharmacy 
staff (Table 11). There were also four FGDs comprising only nurses; six in group 1, five in 
group 2, three in group 4 and four in group 5 as shown in table 12. The interview process, notes 
taking, and voice recording was moderated by the investigator. 
 






Facility Sex Department Years of 
Practice 
Nursing Staff 
1. Nurse practitioner PCF Female OPD 8 
2. Nurse  TCF Female ICU 6 
3. Nurse practitioner PCF* Female OPD 10 
4. Nurse PCF Female Paediatric 5 
5. Nurse PCF Female Psychiatry 11 
6. Nurse practitioner PCF Female Psychiatry 6 
7. Nurse PCF Female Medical 20 
8. Nurse PCF Female Paediatric 16 
9. Nurse PCF Male Paediatric 7 
10. Nurse practitioner PCF* Female OPD 8 
11. Nurse Manager PCF Female Administration 33 
12. Nurse Manager PCF* Male Administration 9 
Medical Staff 
1. Doctor PCF Male General 22 
2. Doctor PCF Male Surgery 10 
3. Doctor PCF Male General 9 
4. Doctor PCF Male General 5 
5. Doctor SCF* Male General  7 
6. Doctor SCF* Male General 5 





PCF* Female General 20 
9. Physician 
Assistant 




1. Pharmacist TCF Male OPD 6 
2. Pharmacy 
technician 
TCF Male Paediatric 6 
3. Pharmacy 
technician 
TCF Male Ear, Nose and Throat 4 
4. Pharmacist  PCF Male Administration (HOD) 15 
5. Pharmacist PCF* Male General 7 
6. Pharmacist TCF Male Obstetric and 
gyaenacology 
6 
7. Pharmacist TCF Male OPD 4 
8. Pharmacist TCF Female ICU 8 
9. Pharmacy 
Technician 
PCF Female Paediatric Unit 2 
10. Pharmacist PCF Male Administration (HOD) 21 
11. Pharmacy 
Technician 
PCF Female General 13 
 
Abbreviations  
Non-Governmental Facility, PCF_ Primary Care Facility, SCF_ Secondary Care Facility, 
TCF_ Tertiary Care Facility, OandG_Obsterics And Gyaenacology, OPD_Outpatient 










4.2 Overview of Emerging Themes. 
 
As summarised in figure 17, the qualitative data analysis revealed two central themes; system 
factors and human factors. These were considered in light of other sub-themes which emerged; 
the system factors comprised of both internal and external aspects, which in turn were 
represented by specific factors identified to influence these sub-themes. Similarly, the human 
factors could be distinguished in terms of healthcare professional perceptions about themselves 
as HCPs and patients. As Figure 17 illustrates, the interviews revealed considerable complexity 
and depth to the perceived issues relevant to ADR reporting in Ghanaian hospitals. These 
factors are now considered in more detail terms, with quotations used to illustrate and support 
the various themes. It is also noteworthy that these themes emerged from the initial organisation 




Healthcare Professional Sex Department Approximate Years 
of Practice 
NON-GOVERNMENTAL PRIMARY CARE FACILITY  (PCF*)_GROUP1 
1 Nurse Male Paediatric 1 
2 Nurse Male Emergency 0.5 
3 Nurse Female Antenatal 0.5 
4 Nurse Female Male Medical 5 
5 Nurse Male Emergency 1 
6 Nurse female Paediatric 0.5 
NON-GOVERNMENTAL SECONDARY CARE FACILITY  (PSF*)_GROUP2 
7 Nurse Female OPD 3 
8 Nurse Female OPD 2 
9 Nurse Female OPD 4 
GOVERNMENTAL PRIMARY CARE FACILITY  (GPCF)_GROUP 3 
10 Nurse Female OPD 10 
11 Nurse Female Surgical 6 
12 Nurse Female Surgical  15 
13 Nurse Female OPD 13 
14 Nurse Female Psychiatry 10 
GOVERNMENTAL PRIMARY CARE FACILITY  (GPCF)_GROUP 4 
15 Nurse  Female  Theatre 9 
16 Nurse Male Male medical 1 
17 Nurse Female Theatre 14 
18 Nurse Female Theatre 3 





 SYSTEM FACTORS 
 
System factors are divided into internal and external system factors based on what HCPs 
considered as important factors influencing their reporting behaviour. 
Previously studies have reported on human factors such as knowledge, attitudes and practice 
of ADR reporting. In this section, the themes reported show that the majority of emerging 
themes related to system factors which refered to various internal and external systems, 
whether this was within the hospital itself or beyond, and these are now considered in more 
detail as follows. 
 
4.3 Internal Factors 
 
Analysis of interviews revealed various internal factors, which could also be understood in 
terms of organisational level factors. These were often attributed to the administration of 
healthcare facilities, which were affected by either the official reporting process or institutional 
performance of the hospital. The instituted reporting process was affected by availability of 
forms, severity, hierarchy and power relations, while the performance of the hospital was 
affected by finance, management and leadership, communication, and technical issues. The 
reporting process and submission of completed forms to relevant authorities such as the FDA 
was perceived to be affected by three main internal system factors: availability of forms, 








4.3.1 Reporting Process 
 
In all the study hospitals (Tamale Teaching Hospital (TTH), Tamale West Hospital (TWH), 
Tamale Central Hospital (TCH), Seventh Day Adventist Hospital (SDA) and Kabsad Scientific 
Hospital (KSH), only one facility (TTH) had a drug information centre/pharmacovigilance unit 
led by a pharmacist. The reporting process differed between hospitals and appeared to be 
influenced primarily by the availability of pharmacy staff. TTH was the largest hospital and 
had more staff, with at least one clinical pharmacist in each department. In contrast, TWH, 
TCH, KSH and SDA were smaller facilities, which sometimes had one pharmacist responsible 
for the whole facility. As will be shown in subsequent sections, pharmacy staff were the lead 
persons identified by participants as being responsible for coordinating the ADR reporting 
process and assisting in medication-related problems in all facilities. Complaints and reports 
from other HCPs in various wards and units were channelled to the pharmacist, who then 
completed the ADR forms.  
 
Figure 18 summarises the five-stage reporting process in the healthcare facilities sampled. 
Stage 1: ADRs were initially identified at ward level, usually by medical or nursing staff. Stage 
2: The report would then take either a formal or an informal route depending on severity of the 
incident. If the incident was considered a normal reaction, the informal route was used, which 
involved a verbal report of the incident to officers in charge, treating the patient and discharging 
with no further action. In this case, reports were lost because of improper documentation. In 
instances where doctors and nurses were able to manage the reaction at the ward level without 
the need of a pharmacist, a patient could be treated and discharged without any further action. 
On the other hand, a formal route would be activated if a serious ADR required the assessment 









Stage 3: Through the formal route, a clinical pharmacist may be involved to assess and 
document the reaction. Further documentation may be detailed in the patient folder or nurses’ 
notes. If forms are unavailable, the patient is treated and discharged without further action. 
Stage 4: If a form is available, the reaction is documented by completing the yellow form. 
Stage 5: Forms from the various departments, units and wards are compiled by the pharmacist 
for collection by the FDA. 
 
The FDA was responsible for the distribution and collection of completed forms, and the 
primary points of contact with the FDA were the hospital pharmacy units; the decision to 
distribute them to various units and wards or to keep them at the pharmacy were at the 




4.3.2 Familiarity with the Reporting Process 
 
A drug information centre/pharmacovigilance unit was already established in one of the study 
hospitals. The reporting process therefore was to report ADRs to the designated contact person 
(pharmacist). They collated reports and were responsible for informing the FDA about a 
subsequent collection. A pharmacist describes the process as follows: 
 
“…well we have forms from the FDA that we are supposed to document. So, what we 
usually do is that we may ask the patient to stop the medication and recall whatever 
medication has been given. So, in the form we have to write the name of the patient, the 
drug that the patient took, the dose and then the harmful effect that occurred or the 
ADR that occurred you document that one. And you the person filling the form should 
sign. And usually what we do is that we keep it for a couple of days and we inform the 
FDA to come and pick it up[...]” Pharmacist 1 
 
Some pharmacists and medical officers were, however, not aware of the reporting process in 
their places of work. This was a key theme that will be considered in the next section on human 
factors and HCP knowledge. A doctor shared his lack of awareness about instituted reporting 
channels n in the following quote: 
 
“… I am not aware of any official communication channel. For instance, should a 
patient react we would probably see (treat) them but I am not aware of any official 





Although TTH had a drug information unit where all pharmacy staff were supposed to send 
completed ADR reports, most HCPs were not aware of this arrangement. This lack of 
awareness was common among the different HCP staff. There was the tendency for HCPs to 
be reliant on the pharmacist for information about ADR reporting. Some pharmacists, however, 
were not well informed about the process. At a different unit of work in the same hospital, a 
pharmacist shared his uncertainty about who to send the reports to: 
 
“… according to one of my colleagues, there is someone who is suppose to collate 
(ADR forms) but I don’t know of this arrangement. Actually, myself, I don’t know of it, 
so the form I filled is even still with me…” Pharmacist 6 
 
Some medical staff were equally not certain about the reporting process in their hospital 
although they felt verbally reporting to the pharmacist to take further action was appropriate. 
 
“I do not know if at the pharmacist they will have something in place to key in the 
complaints. But if you’re going to report, going directly to the person reporting verbally 
if you have to sign that…or if the pharmacist will enter something that is needed in the 
report [...] but having to write a report like written report and presenting it I think 
would not be very convenient.  People will end up not reporting…” Doctor 7 
 
HCPs therefore viewed reporting as not only completing the required form but also relaying 
the information to the officer or supervisor in charge. 
 
4.3.3 Verbal Reporting 
 
Analysis revealed that the preferred mode of reporting ADR was verbal. ‘Reporting’ was 
largely understood as merely telling a person in charge rather than completing the required 
form. So, when asked about the ADR reporting process in facilities where HCPs worked, most 
participants – depending on rank of officer – said they informed their supervisor about the ADR 
or referred to ADR reporting as the work of the pharmacist. Cases of ADRs encountered at the 
ward level were usually managed by telling the immediate supervisor and changing the 
medication while drawing it to the attention of a supervisor. Any changes to medications were 
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recorded in the patient folder but not in designated ADR forms, which were usually kept with 
the pharmacist. 
 
“…the channel actually […] here we don’t have anything like a pharmacovigilance 
[…] something like a unit or maybe some forms to report. We don’t have anything like 
that so when it comes, when we get cases like that, we either change the medication for 
them then we draw the pharmacist attention […] but we don’t have anything like a unit 
we report to. Usually that’s what happens [...]” Nurse 1 
 
Most pharmacy staff also agreed reporting was their primary role and responsibility, which 
unconsciously encouraged verbal reporting. The following quotation illustrates their role in the 
reporting process. 
 
“…the nurses administer the medication for patients. So, when they administer the 
medication and there is any suspected ADR, they report to me […] as I said the form is 
here at the pharmacy and I am in charge of the filling. But what happens is that…you 
know because mostly it’s the nurses who administer the medications, the reports usually 
emanate from the nurses…” Pharmacist 7 
 
4.3.4 Documentation Fatigue 
 
Unlike medical staff, nurses – by virtue of their role in the clinical team – were often in a 
position to observe at first-hand medication-related harm, including ADRs. Cases were, 
however, often not reported because of the procedure of completing a form. Most nurses 
perceived the official reporting procedure as complicated. They preferred to report their 
observation verbally to their immediate supervisor or the pharmacist, without having to 
complete a form. The following nurse describes one of the barriers to reporting saying; 
 
“…because it entails filling a form, that is why people don’t … sometimes if you 
observe, you will see that things that you report verbally, people prefer doing that. But 
anything that entails…they say ‘go and write’ people try to shy away from it …yes and 





Their perception of filling in additional documentation made them distance themselves from 
having to complete an ADR form, thereby relegating it to be the duty of a pharmacist. Nurses 
viewed officially reporting an ADR or medication-related cases as not part of their core 
mandate, as captured in the following quote. They viewed their role as one of observation or 
being vigilant to spot and draw attention to further action to be taken by either a doctor or a 
pharmacist. The following nurse was surprised when she saw a chart showing the Northern 
region with the lowest ADR reporting rates nationally, because she had reported (verbally) 
incidences in the past: 
 
“…I think as nurses, ours is to report to the [pharmacist] because in this facility, it is 
the pharmacist… our duty is to report to them, and it is their duty to also forward to 
whoever. As you are saying I am also surprised, because I know we have reported such 
incidents in the past to the pharmacies[...]” Nurse 12 
 
Overall, the reporting process as described by participants showed verbal reporting to be the 
common practice preferred by many, because of the challenges in reporting officially to a 
competent authority using the required forms. Their motivation to report depended on their 
level of awareness about PV and ADR reporting, and on other prevailing factors such as 
availability of forms. 
 
4.3.5 Unavailability of Forms  
 
Issues relating to the availability of ADR forms were considered a major impediment to the 
ADR reporting process. Though forms were distributed in some units, most HCPs could not 
locate the forms when asked about them.  Unavailability of forms at unit level resulted in delays 
and non-reporting.  Forms were often not readily available even at the pharmacy unit where 
HCPs trusted they could find some. Even though the following pharmacist indicated forms 
were available, they could not find a sample form to show when asked about the availability of 
the form: 
 
“[…] we have the forms; the forms are available […] right now I do not have a sample 
here but normally they are available. So that if you suspect you just go there you pick 
a form and you just fill it. But however, at times they do give samples. They do give 




Unavailability of forms further complicated the reporting process, deterring HCPs from 
reporting. The following doctor points out that the unavailability of the form coupled with 
workload prevented him from reporting: 
 
“…In fact, there is a lot that we don’t get to report [...]. Because erm like I said the 
forms may not be readily available and the workload may not allow you to want to go 
back and want to fill a form and the pharmacist does the necessary things on the 
form…” Doctor 3 
 
The standard practice, however, was to keep forms at the pharmacy unit even though they 
occasionally distributed them to other units or consulting rooms. Most nurses were not familiar 
with the reporting of ADRs using the required forms when asked. 
 
“[…] the form I have never seen one before. Me, I have never seen anything like that. 
But I know sometimes they (ADR reporting) are just oral communications…  
(Investigator: have you ever reported to the Food and Drugs Authority; have you seen 
the ADR form before?) […] no, we haven’t crossed that limit yet, just within just 
within…no, I think the facility should provide these things [ADR forms]?” Nurse 7 
 
Even though there was basic training and education from nursing school about 
pharmacovigilance and the importance of ADR reporting, availability of forms seemed to be a 
barrier to reporting. The quotation that follows is from a nurse who expounds the disconnect 
between theory and practice:  
 
“[...] I think the first and last time I saw one was when I was in school. FDA had a forum 
with us in school, on pharmacovigilance [...] they came with some forms and said since 
we are about to go out into the job market…we were in our final year… these are some of 
the issues we will be faced with. People will take medication and come with adverse side 
effects. So in case we encounter such, these are the forms. We should fill and submit to 






4.3.6 Policy Issues  
 
The lack of policy guidance on ADR reporting made HCPs pay critical attention only in 
situations where incidences were life-threatening. Most healthcare facilities lacked protocols 
for reporting ADR. High patient numbers in consulting rooms made prescribers pay attention 
to only serious incidents, as quoted by the nurse practitioner as follows: 
 
“…So when you get the situation and it is not something that is so disastrous to life you 
just try to handle it and carry on. That’s what often times we do but there is [...] like 
erm a laid down[...]what do I say [...]protocol[...] in the facility that when you get a 
drug reaction this is the channel this is the protocol do this do that, report to this person, 
draw the attention of so and so. There is no such laid down rules…ahaa… so we are 
practising as individuals though collectively our interest is a patient should not suffer 
the consequences of or otherwise…of any of the medical prescribers…” Nurse 10 
 
In the delivery of healthcare by HCPs, SOPs and internal guidelines for reporting ADRs were 
absent in facilities and this affected the practice. 
 
“…probably that will make us bring them out. Maybe some see and they don’t mind 
because it is not[...] like they are not even aware of it because it is not a policy in the 
hospital as part of our practice that when you see an ADR, document it or report it. So 
maybe that one could have helped…” Nurse 8 
 
HCPs were unaware of any policy guidelines and of the recommended protocols instituted by 
management to ensure reporting of ADRs or medication related incidents. 
 
“…I don’t know of any policy at the hospital level where there is a framework for 
reporting. Even if it’s in the books it is not made known to us. I don’t remember it being 
mentioned when I was employed and oriented…” Pharmacist 10 
 
Lack of enforcement by the Ministry of Health (MOH)/GHS caused reporting not to be of 
priority or importance to participants. Even though HCPs felt it was important to report, there 




“… it is not happening, why because it is not mandatory. Are you getting it? And as I 
said if you leave human beings to do what they like certainly you won’t get results… 
here you know we want to do something but we do not have… you see human beings 
naturally will not just do something unless there is a little pressure. Unless there must 
be a force. That will compel you whether you like it or not to do…” Pharmacist 4 
 
4.3.7 Hospital Administrative Issues 
 
Key indicators to effective functioning and optimal performance of healthcare facilities were 
identified as being linked to the problem of reporting. Fundamental among them were 
management and leadership, communication barriers, technical issues, incomplete patient data, 
funding, and training, which were identified as important factors affecting ADR reporting. 
 
4.3.8 Management and leadership 
 
HCPs were concerned with the way ADR issues were managed administratively. MOH or GHS 
annual review meetings seldom featured the pharmacist and ADR issues. Pharmacy staff 
criticised the way invitation letters to such meetings and workshops were often addressed 
requesting either the pharmacist or the matron, instead of inviting both to attend. 
 
“… here in the region in particular, it’s pathetic. I will give you a classical 
example…their [Ghana Health Service] annual review meetings for example. They will 
send out information and say med. sup, administrator, matron or pharmacist…it means 
we are not getting it right. Are you saying the matron can go and handle 
pharmaceutical issues like the way the pharmacist runs [...] no no no. Are you saying 
the pharmacist can go and handle the issues about nursing? [...] and you don’t 
understand it…and these things keep happening and I will be asking ‘aah what is wrong 
with us’…so some people [hospital management] sit somewhere, do not think it’s [ADR 
reporting] important…[...]once you have one of these people [nurse or pharmacist] 
that it’s ok [laughing] [...] yeah so structurally we have fundamental issues and those 
people at leadership positions are not seeing too [...] I mean not getting it right. And 
these things are compounding the problem…” Pharmacist 4 
 
From personal reflections and interviews, it was observed that the FDA’s invitations to HCPs 
to attend training on some occasions were often received and attended by administrators instead 
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of selected clinicians. HCPs were of the view that administrators who went for these training 
sessions or orientation on ADR reporting often came back without cascading the training.  
 
“[…] I think the FDA should give training directly to HCPs rather than administrators. 
Most of these trainings administrators go for them, come back to sit with the knowledge 
[…]” Nurse 11 (FGD) 
 
Despite better understanding and training opportunities, senior level staff – especially nurses – 
were less likely to directly observe an ADR in inpatient departments at first-hand; they were 
often involved in administrative duties. They relied on junior officers who were at the bedside 
of patients but were less likely to be knowledgeable about the reporting processes. 
 
In addition, high staff turnover created human resource constraints, which affected reporting. 
Hospital management were challenged by staff shortages due to attrition of HCPs for further 
education and retirement of HCPs, exacerbated by high patient attendance. The following nurse 
describes how reporting declined when a person responsible for the coordination of reports was 
moved; 
 
“…ahhh, because our place the drug [...] immediately anything happens, small thing 
and they are sending it. Ahaa and that guy makes sure that they have focal persons in 
the wards. But I think he has joined some NGO [...] it’s like he has left. At least he 
should be for two years [...] but at least he has prepared the grounds before leaving…” 
Nurse 1 
 
4.3.9 Bureaucracies  
 
An important factor influencing the reporting process was the perceived need of participants to 
conform to an established hierarchy. They often required a second opinion and further 
assessment to establish some sort of causality before reporting an ADR. After assessment, and 
if deemed worthy of reporting, all HCPs expected the pharmacist to contact the regulatory 
agency or pharmaceutical company to report the case officially. Bureaucratic reporting 
processes influenced the reporting process, as described earlier. The informal hierarchy in place 
was for nurses to report to doctors and doctors to pharmacists. Within each professional 




HCPs could also complete a form and directly report to the FDA if they felt confident to do so. 
This was, however, a rare occurrence.  Conversely, if an ADR was considered not serious by 
the HCP it was reported to the next in charge and managed within the core clinical team (nurses 
and doctors). No action or further reports were sent to external stakeholders (pharmaceutical 
company or the FDA) for ADRs considered non-serious. 
 
As mentioned earlier, verbal reporting was considered convenient for nurses and junior officers 
because of fear of blame and the bureaucracy of the process. According to participants, only 
doctors were allowed to write in patient folders, while nurses were not permited. This 
arrangement therefore created a barrier to reporting, and instead of nurses documenting an 
incident when they observed it, they had to wait and verbally report to the doctor. The doctor 
then decided to either note it in the patient folder or consider it as non-serious. Even though 
nurses sometimes observed cases, it was impossible to document them in the patient folder for 
fear of being blamed or reprimanded.  
Nurses within their professional category preferred to verbally report to their in-charge, the in-
charge to the matron, and the matron may report to the doctor. The doctor may then involve 
the pharmacist to further assess the case and take notes. Reporting ADR to the authorities was 
often left in the care of the pharmacist, and pharmacy staff also preferred to send these reports 
through their superiors before they went out to the authorities. For example, a pharmacy 
technician may inform his/her supervisor (clinical pharmacist) before a completed form is 
submitted to the authorities. The pharmacist quoted in the following passage has eight years’ 
experience and was asked if he had ever sent a report directly to the authorities; he responded 
in the negative, citing bureaucracies and hierarchies inherent at his place of work as factors 
affecting reporting. 
 
“[...] have not sent a report but erm when we get the [...] erm when we come across 
some of those cases the in-charges (senior pharmacist) take it up. And from there I 
don’t know what happens. You see if you are working with someone [...]a senior 
colleague. You understand. If there is something you have to channel it through him. 
So those are some of the things.  You can’t go behind your boss and do anything. When 
it happens that way (ADR incident) he takes it up and you don’t see anything or any 




It was also common for junior officers to expect senior officers to take action on reporting 
ADR, which was done to respect hierarchy and avoid blame. The following pharmacist was 
asked about an occasion when he observed an ADR and what action he took. He indicated in 
the following quotation that he had to wait for his superior to come and do the documentation 
and after the documentation, he received no feedback. 
 
“[…] He is my boss erm he did most of the questioning and filling of those things and 
trying to find out other details. So that was what we did we followed up filling these 
details and submitting it to the erm the one in charge…  from there I don’t know what 
happens. You see if you are working with someone … a senior colleague. You 
understand. If there is something you have to channel it through him. So those are some 
of the things.  You can’t go behind your boss and do anything. When it happens that 
way, he can take it up […]” Pharmacist 27 
 
Nurses did not feel confident about reporting ADRs directly; they often wanted validation from 
a pharmacist, doctor or a senior colleague before reporting. This was seen as respecting 
protocol and not wanting to over-step responsibility, because they were unsure about the 
recommended procedure. 
 
“… it is not our duty as nurses to go straight and report to FDA, it should pass through 
a channel. Yes! And the highest channel should report it to the FDA [...]” Nurse 3 
 
“…the reporting channel should be through the in-charge to the pharmacist and he will 
now forward the report to the FDA. But if there is a way to send it directly too would 
be better[...]” Nurse 9 
 
Even though some nurses felt they could report directly, it was often not the practice and they 
relied on multiple opinions before sending a report. 
 
“…I think you can go straight to report or if there’s a doctor on ward rounds at that 
particular time you tell the doctor that, this is what I have observed, then he can also 




Organisational hierarchies and inherent power relations between HCP categories as well as 
within cadres influenced bureaucracies related to ADR reporting. 
 
4.3.10 Hierarchies and Power 
 
HCPs felt incompetent because superiors influence on their reporting. Senior staff made it 
unlikely for subordinate HCPs to report ADRs. Power relations within professional categories 
and between HCP cadres played a major role in getting ADRs reported.  
It was perceived that the hierarchy and power between HCPs made it a challenge to discuss 
clinical issues together. Superiors often seemed to dominate, listening less to the opinion of 
junior officers. This imbalance created a communication gap between junior officers and senior 
officers. It was less likely for junior officers to report ADRs and medication safety concerns, 
as suggested by the nurse in the following quotation: 
 
“… But sometimes the superior [senior officers] always sit down and think that yes 
they are above and we the rest we [junior officers] are below, so whatever you [junior 
officers] say will be pushed aside. So how then do I report such issues to such a person. 
Because look as we were just saying now if […] they [authorities] come and say ‘oo 
how come the child’s condition has deteriorated’… how do I report it?[...] I will never 
do it…” Nurse 7 (FGD) 
 
From personal reflections and opinion of nurses, there were hierarchy and power dynamics 
among the core clinical staff.  A hierarchy was evident, with nurses being considered the lowest 
in terms of authority and power, followed by pharmacy staff, with doctors being considered to 
be most senior and influential. Junior nurses felt they were not confident enough to challenge 
the clinical decisions of doctors or prescribers due to an inferiority complex. For example, 
sometimes nurses felt antibiotics were overprescribed for children by doctors but could not 
challenge or assert themselves. It was therefore often difficult to complete a form in such a 
situation and also to identify which antibiotic was causing the reaction, as this quote illustrates: 
 
“These are all antibiotics[...]overloading the system but if you go to tell the prescriber, 
this is what is happening, they will say ‘ooh you don’t know anything’…that it’s their 




There was also perceived fear of consequencies from colleagues or superiors for exposing 
wrongdoing. HCPs did not want to be seen in their teams as ‘bad people’ for reporting a safety 
issue which has resulted in an ADR. This could be linked to fear of ADR reporting and 
consequences of reporting, as captured earlier. The following quote illustrates this factor better: 
 
“[…] We will be looked down upon and if anything at all comes they will quickly ask 
you, so when you went to her and this and that happened who did you report to? There 
is nothing. We are sitting down here we don’t have a medical sup. So if an MA [medical 
assistant] does something wrong, the next person you should have reported to should 
have been the medical superintendent. Here we don’t have a medical sup. And I can’t 
report an MA to my matron. You see the problem? So sometimes you the nurse you also 
have the fear that you will bring this thing forward and people will tag you as a bad 
person. You see the problem…so this hospital, inferiority complex. I know what I am 
doing but because I am a junior, I can’t say it. I fear to approach. You understand […]” 
Nurse 5 (FGD) 
 
4.3.11 Inferiority Complex 
 
Within professional categories, it was common to observe junior officers feeling inadequate 
and, likely to be reprimanded by senior staff. An imbalance of power and the manner in which 
senior staff members managed this relationship made junior officers feel inferior.  
The following nurse describes situations in which they find it challenging to report issues to 
their supervisors because of the power imbalance and fear of consequences.  
 
“…sometimes the superiors always look down on the lower ranks[...]so you see 
sometimes that’s what we are just saying, so if it was her (superior) that I am supposed 
to report to her, now she is the one who has prescribed it, I have gone to you, you are 
even prescribing it […] If the side effects come, how do I report to you? You see what 
we are saying. So basic thing that we know, as we have learnt, you might have your 
Master’s, I might have a certificate, but I know what you don’t know. You see, so it 




Between HCP cadres, it was observed that nurses were more likely to feel an inferiority 
complex than other HCPs.  These affected inter-personal relations, resulting in inter-
professional conflict and distrust. 
 
4.3.12 Communication Barriers 
 
Ineffective communication contributed negatively to ADR reporting to a large extent. As noted 
earlier, internal communication channels at various health facilities were complicated, and 
HCPs were often not aware of the channels of communication. Also, when issues were raised, 
feedback was delayed and was often not received by reporters. FDA communications with 
healthcare facilities were usually only directed or communicated to pharmacy staff or contact 
persons. The FDA established cordial relationships with individual clinical pharmacy staff and 
contacted them directly with medication safety-related issues. They often bypassed 
administrative bureaucracies which created communication challenges among hospital 
administrators, medical superintendents and pharmacy staff.  
 
“…erm I still think that the FDA should be more proactive than they are. I think they 
should interact with us [administrators/hospital managers] more often…and me if they 
continue with that am sure we will turn around. I tend to hear their meetings after the 
meetings have passed, because they tend to communicate with the pharmacist directly. 
Instead of getting through to[...]at least as a manager I should know when… if you are 
going to hold a meeting of such things maybe I would want to add some of my clinicians 
to go and listen to it… but if you call pharmacist alone to go and sit down, expecting 
that they will also come and bring it out. This newsletter you talked about, I came and 
saw it lying on my desk I don’t know who brought it… yes, so it should involve more of 
managers and clinicians not just pharmacy staff…” Doctor 7 
 
Internal communication between healthcare professionals was also weak. Pharmacy staff found 
it difficult to get feedback from their superiors and from nurses who were at the frontline of 
healthcare delivery to patients.  
 
“…this hospital our channel of communication is very poor…when you first started I 
told you that our communication system is very poor…at times you can even send a 
problem to the bosses but at the end you will never get the feedback. That’s our problem 
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here, communication is very bad, it’s very very poor.  (Investigator: “So I was just 
wondering what could be some of the problems”)… you see those at the wards, the 
nurses at the wards, they will have been the best people to be giving us the [...] those 
informations (sic) but we never hear anything from them…” Pharmacist 10 
 
4.3.13 Technical and Logistic 
 
Logistic and technical challenges were also perceived to obstruct the efforts of the FDA in the 
distribution of forms and creation of an electronic platform. It was noted that internet 
connectivity at all healthcare facilities was unstable. The FDA made efforts to set up an 
electronic system and train HCPs, but they were unable to use the system due to technical 
challenges.  
 
“[...] the last meeting we had at one of the venues in Tamale here they talked about 
having a platform. That is web-based platform where we were supposed to be signed 
on and such that when the case comes you can just log in and deliver it 
directly[...]yes[...]but you know how our internet system is[...] unfortunately, even 
before we left the meeting [...] they (FDA) couldn’t set us up there because of 
challenges…” Pharmacist 4 
 
The basic infrastructure was in place in the various hospitals, but HCPs were challenged by 
broken equipment, poor Wi-Fi connection, lack of a common software platform and 
management of information systems, making digitalisation problematic.  
 
“…now naturally in Tamale here, the internet is not perfect but as a regional hospital, 
the Metro hospitals within the Metro and even some of the district hospitals all have 
internet access. They can all be hooked on. So, if as a nation we are cautious about 
these things[...] yes, the CHIPS [Community Health Improvement Services] 
compounds, the health centres if it is not possible let’s leave those ones now. But the 
teaching the teacher in the secondary to primary levels that can be put onto this system 
should have a common platform…” Pharmacist 4 
 
“Here we have HAMS [Hospital Administration and Management Systems Software] 
the HAMS we have we are not even [...] exploring it fully. We still use manual folders 
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[laughing][...]But it can be folder-less… So that is where the problem is you see and 
this hospital is using HAMS  (software), another person is using this, another person is 
using that, another person is using that, at the end of the day everybody is doing different 
things…and some as at now are not even using any software… they are not interested 
in going folder-less because is demanding people have to sit down and type in the only 
thing that you see is that drugs and diagnosis[...]” Pharmacist 4 
 
Patient record-keeping was based on a manual folder system even though efforts were being 
made in hospitals and the National Health Insurance Scheme to create electronic patient 
records. The objective of keeping electronic patient records was, however, for the purpose of 
managing insurance claims electronically, rather than for medication safety purposes. Some 
management information systems’ software had the ability to compile ADRs from electronic 
patient records, but this was underutilised. Among HCPs, it was observed that only pharmacy 
staff could access these electronic interfaces for health insurance claims-related purposes. 
HCPs lamented the lack of a common electronic platform to coordinate or harmonise the 
activities of ADR reporting. 
 
“…Well you know one of the biggest challenges we have here in this country is that we 
haven’t really done due diligence with regards to harmonising the way we work. Till 
date health insurance has come to stay, we have to manage our claims. Every facility 
has to struggle on its own and acquire any software that they come across that they 
think it’s good and all these software’s have their deficiencies they might not be 
compatible like talking about data because we as Ghana Health Service knowing what 






4.3.14 Sociotechnical Constraints 
 
HCPs were also concerned that the FDA electronic reporting system was not user-friendly. The 
high workload, coupled with technical difficulties faced by HCPs in using the system, 
discouraged them from completing ADR forms, especially using the electronic system. They 
perceived the process of reporting an ADR electronically to be a long process which required 
logging onto a website before submitting a form. Older staff were also perceived to be more 
challenged with computer assited reporting. This process made HCPs passive about reporting. 
 
“[...] now there’s a problem (ADR) or even if I have internet, I have to go to your 
(FDA) own website go and search for it and now sit down and begin to type a whole lot 






4.3.15 Incomplete Patient Data 
 
Incomplete patient information was a major concern for HCPs, especially pharmacists who 
were often tasked with reporting incidences of ADR or medication-related issues. 
 
“…but the patient maybe is discharged, and it’s gone…so how do you complete a 
form… then always you find out that is always half half (incomplete) you are unable to 
gather the data…” Pharmacist 5 
 
Cases were also lost because some HCPs usually insisted on waiting for the clinical pharmacist 
to collect patient details, because they considered ADR reporting as not part of their core duty. 
Pharmacy staff also blamed the issue of incomplete data on the inability of nurses, doctors and 
prescribers to document detailed enough patient information to complete an ADR report form. 
By the time the pharmacist is available to collect the details it is often challenging to complete 
patient information. 
 
 “…so quite recently there was a case, was it a few months ago, I wasn’t around. They 
only came to tell me later and that the patient is even gone so we couldn’t document it. 
The other day I gave the form, there for them to document… I don’t know if I can trace 
the leaflet. They brought the thing [making faces] [...] It’s like …I don’t know…” 
Pharmacist 10 
 
“…That’s the bottom line is not in existence look a patient will even suffers ADR he 
will pick the folder and will know that much from the folder. They are not going to make 
any conscious effort to chronicle the event in there… ’ooo he reacted to this maybe it’s 
done’. Or maybe withdrawn or stopped the treatment. So, you even pick the folder and 
its useless[...]now the patient too is gone so …these are the real issues, so you see when 
you are asking the people to provide the data…from where? Where are they picking it 
from? Do we have one? I doubt it we don’t…yes let’s be fair[...]I am telling you these 
are the facts on the ground, we don’t. So, when it happened and the person who is to 
document it is not there, there and then and approach the case then it becomes a 
difficult one. You will hear about it, but the folder will not be able to help you to do the 
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capture and write up the details, because they will not find any details like that in the 
folder. You may just find one or two sentences that talk about it, but they might not even 
bother much to even I mean chronicle the event…” Pharmacist 4 
 
4.3.16 Complicated Form and Reporting System 
 
Despite efforts by the FDA to keep the form to two pages and make it as simple as possible, 
HCPs – especially nurses – still found it complicated. They were not acquainted with the 
reporting system.  
 
“…and the constraints too sometimes complicated administrative or reporting 
procedure, sometimes the booklets for reporting is so cumbersome you open here right 
now the questions so many things like you are in class…you have to go through a whole 
lot of …they should make it simple, a simplified something…” Nurse 8 
 
They were often not aware of where to report ADRs and who specifically to report to. 
 
“…even the channel of reporting is actually difficult we don’t even know where to 
report it and who to report to. So what we do is that once the doctor comes around we 
just tell the doctor your observation, what you noticed and if there is the need for the 
person (doctor) to change the drug then the person will change the drug. But we don’t 
usually go further to see what really happened…” Nurse 4 
 
4.3.17 Funding and Training 
 
External factors such as the stakeholders, i.e. FDA, MOH, and pharmaceutical companies, 
provided limited budgetary allocation for promoting ADR reporting. Similarly, internal 
elements such as hospital administration, management and leadership provided no internal 
budgetary allocation. Financial administrative decisions taken by the internal management and 
leadership were dependent on finance from stakeholders. Limited funding therefore affected 
the education, training and sensitisation on ADR. It was perceived that lack of funding affected 




“[...] if you want people to do a job you have to make sure they are well trained, and 
they understand what exactly you want them to do. So they will do it but you see these 
things sadly, here is when we say that we are supposed to come and cascade the training 
but you know it’s a system […] you take one or two people you send them you train 
them and they come and they are in the system [...] but no money no money syndrome 
and things like that[...] people are not prepared to organise trainings, you see in Ghana 
here one of our biggest challenge is that, everything you want somebody to come and 
sponsor. Oo that’s so so and so erm global fund has given some money to do what…[...] 
so why can’t we ourselves make money and make it regional thing[...]” Pharmacist 10 
  
“…I think FDA should continue to do the sensitisation, especially adverts in local 
dialect. That one is very necessary. But they will tell you they don’t have money because 
when they do the adverts they have to pay. So, the sensitisation should be there to 
patients and caregivers. That if you take any medications and you have any issues 
report to FDA[...]” Pharmacist 2 
 
4.4 External Factors  
 
External factors were described as factors which were distal, and beyond the immediate control 
of the HCPs. These elements were identified to be influenced by the social, economic, political 
and environmental activities, which were distal, and beyond the hospital setting directly but 
were still considered to have an effect on ADR reporting. The three external factors identified 
were infrastructural issues, media publicity, and stakeholder contribution. 
 
4.4.1 Infrastructural Issues  
 
These were factors participants described as socio-political and physical geographical barriers, 
which hindered efficient and effective collation of ADR reports. Poor road network, 
communication network and lack of social amenities in remote communities hindered 
reporting. The perceived inability of leadership to release resources meant barriers to work in 
these communities was further compounded due to political reasons. Even though nurses were 





“… You see sometimes there are certain things you are not supposed to say. But like 
everything in Ghana or Northern region in particular, it’s politicised in the sense that 
maybe somebody was paid to do that job. The fellow doesn’t belong to this [...] so you 
are not allowed to do that […] (‘they will side-line you…’ Nurse 4) [...]. You are willing 
to do it but there are no resources for you to do it. Imagine you are to leave here and 
have to go to somewhere Santani […] overseas community (remote community) […] 
you have to use your motorbike, pick a boat and cross. So, like, you are risking your 
own life. Meanwhile the money has been sent to somebody’s account. To release it to 
do that work yet is not there […]” Nurse 5 (FGD) 
 
Getting core HCPs to these remote locations was a disincentive due to a lack of basic social 
amenities in these locations. HCPs therefore often refused postings in the past, which has had 
a ripple effect on the current reporting situation in the region.  
 
“[...] these are the facts on the ground[...] There are still districts without pharmacist[...] 
not even a technician […] a pharmacy technician […]” Pharmacist 3 
 
4.4.2 Media Publicity 
 
Dissemination of relevant health-related topics, especially in local dialects, had a positive 
impact on reporting medication-related problems. Lack of funds for adverts on TV, radio and 
print negatively affected this initiative. Environmental factors affected media publicity. The 
dispersed geography of communities limited their access to some types of information. The 
most popular were TV and radio. Previous radio announcements resulted in patients visiting 
healthcare facilities to report medication safety-related issues to healthcare professionals. 
 
“[…] one day I was sitting here, and somebody came and said he heard some 
announcement on radio that they said if you have a mental problem you should come to 
the hospital. That announcement was actually meant for Upper East, but he had it and he 
came. And we attended to him and give him medication and he went […]” Nurse 7 
 
In public health interventions, the involvement of media increased consumer awareness about 




“[...] I remember some time back when they started taking SP (Sulphurdoxine 
Peramitamin) and people were dying and the media came in [...] erm a lot of education 
was done to increase awareness, you remember SP? [...]” Pharmacist 1 
 
4.4.3 Stakeholder Contribution 
 
Major stakeholders, such as the FDA, pharmaceutical companies and the MOH, were often 
cited as not doing enough even though some interventions have been put in place. 
 
4.4.4 Food and Drugs Agency 
 
The FDA is the central agency responsible for drug regulation and safety of medication. Some 
interventions were in place to increase reporting, but most healthcare professionals were not 
aware of them. HCPs who had a positive feedback experience were personally motivated to 
send more reports, while those with negative experiences felt reluctant. Change of leadership 
within the FDA administration also affected ADR reporting. Participants commended the 
efforts of the current FDA leadership: 
 
“…am glad to say that the current boss (FDA) that came, he has taken it upon himself 
to do a lot of sensitisation, training and letting people be aware that any time they see 
an ADR they should report. But formally there was no trainings like that but since this 
guy (FDA director) came, he has been doing well [...]” Pharmacist 2 
 
It was observed that the motivation for renewed efforts from the FDA administration stemmed 
from the background of the head of administration as a pharmacist, unlike his predecessor who 
was a food microbiologist. The director noted that the FDA had several indicators to fulfil and 
ADR reporting was just one of them. Generation of reports and awareness creation therefore 
depended on the direction or focus of the FDA administration at any point in time. 
 
4.4.5 Ministry of Health/Ghana Health Services (MOH/GHS) 
 
There were no specific policies, by-laws or protocols for reporting ADRs at the health facilities 
investigated. This affected HCP attitudes because they were inclined to pay more attention to 
memos from MOH/GHS-driven policies than to those from other stakeholders. Also, MOH 
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nursing schools did not have pharmacology as a core or examinable subject, so nurses therefore 
did not attach importance to that aspect of their practice.  
 
“…I don’t know of any policy at the hospital level where there is a framework for 
reporting. Even if it’s in the books it is not made known to us. I don’t remember it being 
mentioned when I was employed and oriented…” Pharmacist 7 
 
“…all these things about pharmacovigilance the Ministry of Health itself haven’t done 
anything about this thing (ADR reporting). They are not so much interested whenever 
you see the brochure is coming from FDA or coming from pharmaceutical company. But 
the Ministries side is indifferent. So, if you are indifferent about it why should the nurse 
be so interested. Even I believe that in the training of these people pharmacovigilance 
should become a core subject. Because we use medicines almost every day it should be a 
core subject people should take it and understand why monitoring is important…” 
Pharmacist 4 
 
MOH/GHS had no medication safety and monitoring unit at the regional level. The regional 
pharmacy unit had oversight responsibility over all medication safety issues, but no dedicated 
unit was available. 
 
4.4.6 Pharmaceutical Companies 
 
Pharmaceutical companies were less involved in pharmacovigilance and medication safety at 
the health facility level. The only interaction HCPs had with pharmaceutical companies was 
during clinical meetings or in consulting rooms when they came to market their products. 
Marketing executives were more concerned with promoting their products than discussing the 
ADR-related issues.  The following is the reaction of a pharmacist when asked about the 
contributing role of pharmaceutical companies in reporting ADRs: 
 
“[…] they (pharmaceutical companies) come, they just talk about the few side effects 
associated with the products. Sometimes they are too silent unless question time when 
people ask what the side effects of this product is and all that. They are always gentle 
(quiet) about it but as I said they put into their leaflet that if you have any ADR or side 




Some pharmacists indicated that they were not aware of any pharmaceutical company actively 
engaging HCPs in ensuring that their medicines were safely used, and ADR reported.  
 
“[...] never!! I have never seen that […] seriously the only relationship or the only 
people that you see around are reps, reps would not even want to dive into that area 
(ADR reporting) [laughing] (INVESTIGATOR: because they are marketing?) [...] 
exactly!!…theirs is to come and market their product, package it nicely and make sure 
they push it. For them whatever comes […] that is not their business they will not even 
want to talk about it […]” Pharmacist 8 
 
There was a perception among some HCPs that reporting ADR may affect the marketing and 
sales of a pharmaceutical product. HCPs therefore feared the risk of being targeted by 
pharmaceutical companies for reporting the negative consequences of a drug. HCPs were 
confident to report if they felt protected by authorities. 
 
“…sometimes too intimidation…from pharmaceutical companies and then drug 
producers. Somebody (a company) produces a drug, it is prescribed… then the patient 
takes the drug and does not do well (reacts), if you come out to say this drug did not do 
well (reacted) with the patient, then it becomes like you are against a company or you 
are sabotaging the product. You know and then… they may be legally fighting you or 
seeking to cause you harm. Yeah uhuh so and then also erm maybe the ability of the 
authority to protect people who will report on these reactions …uhuh. So, I think these 
are some of the key issues…” Nurse 10. 
 
Coupled with the fear of being negatively targeted by powerful pharmaceutical companies, 
incentives and rewards from pharmaceutical companies served as a motivation to prescribe 
particular drugs. Some HCPs were of the view that doctors were under pressure from 
pharmaceutical companies to impose brands on patients. Receiving souvenirs and incentives 








The central and most important factor was knowledge of HCPs about ADR reporting. 
Knowledge affected their attitude, practice, and willingness to report. Even though system 
factors affected ADR reporting, human factors were central to improving the overall reporting 
system. Human factors referred to how HCPs’ and patients’ actions were variously perceived 
by participants to influence ADR reporting.  
 
4.5 Personal HCP Factors 
 
Interviews revealed three HCP-related factors, relating to knowledge, attitude and practice: 
knowledge related to HCP awareness about pharmacovigilance and ADR reporting issues 
learned over time and also the importance of reporting; attitudinal factors related to the views 
and opinions held by the different HCPs about ADR reporting and finally, practice factors 
identified in the interviews related to the application of knowledge and attitudes to the routine 
daily practice of HCPs. ADR reporting was often affected by a combination of these factors 
and was also related to key issues such as medication quality, inter-personal relationships, 




Knowledge was explored based on responses to questions about pharmacovigilance, its 
importance, ADRs and the reporting process. HCP knowledge about what and where to report 
ADR affected the whole reporting process. HCPs were firstly asked if they were aware of the 
term pharmacovigilance and were then asked to describe their understanding of the term. 
Pharmacy staff and medical staff seemed more knowledgeable than nurses did; they offered 
more detailed descriptions and appeared to have a better understanding of the importance of 
pharmacovigilance and the ADR reporting process in their hospital. The following doctor was 
asked about their knowledge on pharmacovigilance and ADRs: 
 
“[…] every drug after manufacturing is tested before approval is given, however where 
it was tested is just a small fraction of the whole population. So there is anticipation 
that using this medication anybody may react to it differently, […] so there are some 
(reactions) that are noted already by the manufacturer. There are some that are not 
captured. They are expected by the manufacturer himself, so when these things happen 
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and we report it [...] it informs us and the manufacturer to modify or if possible, do 
something about it. This is how we keep the entire health delivery system in terms of 
medications safe for the general population…” Doctor 3 
 
In contrast, nurses appeared less sure of terms such as pharmacovigilance and overall ADR 
reporting. Some admitted to having never heard the term pharmacovigilance for example.  
Some made informed guesses about terms such as pharmacovigilance, by separately describing 
the words ‘pharmaco’ and ‘vigilance’ and, for example, using the term ‘cautious’ in relation to 
the latter. Some were able to describe this as relating to medicines and being watchful for side 
effects of drugs (Nurse 3). Most nurses were also not well-informed about the formal reporting 
process. The following quotations reflect the responses of some nurses about 
pharmacovigilance and ADR reporting in focus group discussion: 
 
“… about pharmacovigilance, it’s more or less like English [...] to be vigilant, trying 
to be very cautious about drugs, trying to be very careful with the way and manner of 
issuing prescribed drugs, when we give drugs to patients, if I want to put it…” Nurse 
2(FGD) 
 
“…yeah… I have head of it, though it’s not a very [...] erm if you like…it’s not a 
very…[...]popular term which is of much concern to us, it’s something I have heard of 
it’s more about being vigilant on… you know… erm the issues of drugs and the side 
effects of the drugs…” Nurse 3 (FGD) 
 
Nurses who were senior-level staff were more likely to have had experience and training on 
pharmacovigilance, which appeared to give them a better understanding of pharmacovigilance 
as shown in the following quote:  
 
“[...]Pharmacovigilance I think we even had a workshop about it. We even had about 
two workshops on it. Umm let’s even take just the word vigilant, you need to be very 
cautious of the drugs that you give to people and their side effects; we have normal 
ones and we have the adverse[...]the adverse drug reaction, they are reactions 
sometimes we don’t anticipate but it occurs and as we are giving the drug we should 
also monitor to see the reaction or the outcome of that; either it will be within the 




Of note in the above quote was that the nurse manager explicitly referred to the distinction 
between side effects and adverse drug reactions, which was unlike most nurses, who referred 




Perceived patient ignorance was influenced by other interrelated factors such as forgetfulness, 
low socioeconomic background of patients, and misunderstanding about reactions. Patients 
often could not remember the medications and misunderstood ADR as normal and an indication 
that the drug is working. For example, “[…] some patients when they see ADRs they say yes!! 
the drug is potent and working […]” Pharmacist. HCPs were of the opinion that patient 
misconceptions about their medications and forgetfulness often led to them not reporting 
important ADRs experienced as reported in the following quotation; 
 
“[…] I have seen one [ADR] from the ward level at the accident and emergency unit 
where a patient according to her took some drugs she had a reaction could not recall 
the drugs[...]” Pharmacist 1 
 
Some patients and relatives were perceived not to be knowledgeable enough to identify ADRs 
and take prompt action to report them. They were only able to report if they could attribute the 
reaction to the medicines they received from their HCP’s and this was often felt to not be the 
case. Low literacy and educational attainment were also perceived to affect patient 
understanding of medication instructions. This made it difficult for HCPs to obtain information 
about consumed medications from clients who often mixed their medications or consumed 
them incorrectly. A doctor relates the following scenario: 
 
“[...] here are others that go home and don’t know, and they go, and they mix up the 
drugs. They pick this, and after they don’t know which package for which is. That’s in 
the case of polypharmacy then afterwards they mix. And next time they are taking they 
take this one more and this one less. And when you ask them (patients) and they tell you 
how they took it you know they didn’t take it right. So those ones sometimes you don’t 
know whether to report those cases as ADR or you should just take them as side effects 
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due to an overdose. So that is usually the thing. The knowledge on these issues is a 
problem really[...]” Doctor 5 
 
Lack of knowledge about indications and contraindication of medications was also identified 
as a challenge for patients receiving treatment. HCPs were of the view that reactions 
experienced by some patients were seen as a normal indication of the drug and thus not 
reported: 
 
“… they expect to feel a certain way when they are taking medication for them to feel 
that it is working so when they start experiencing some of those things some of them 
think it is a normal thing… some of them feel that it is a normal part of taking the 
medication and if they take the medication and for instance they are sweating which is 
not normal with the drug, they will not report it, they will say ‘ooh this thing is due to 
the medication’ and they will not report it…” Pharmacist 8 
 
4.5.3 Recognising the ADR 
 
HCPs seem to lack knowledge about how to identify an ADR and what to report. For some 
HCPs, there was a belief that authorised medicines and ADRs were considered uncommon and 
therefore infrequently observed. Even though some HCPs had practised for longer periods in 
health facilities, they indicated that they had never encountered an ADR and that they were a 
rare occurrence. 
 
“[…] in fact, all the drugs on the essential medicine list, experts meet to decide that 
in Ghana we are using this. So as much as possible we procure within that list. And all 
those drugs are drugs that have been used in Ghana before and we know most of the 
basic side effects; though some people react to them it’s not much…” Pharmacist 11 
 
“[…] like I said they don’t come significantly enough for us to be reporting. So if they 
are not [...] erm if the reactions are not much… I mean we will not, we will not report 
[…]” Nurse 6 
 
 “…umm yeah but in practice I think it is rather uncommon. I think in all my practice, 
the only two cases I can think of were in 37 military hospital, but that was way back in 
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the 90s, late 90s, where they were cases of umm two cases of Stevens-Johnson 
syndrome. Since then I don’t think I have actually seen any…” Doctor 5 
 
“[…] to be honest I wouldn’t know. But if I make any guess, it’s just that either we 
don’t see it, therefore we are not sensitised enough to report to anybody because we 
don’t see it. Because if I don’t see the drug reaction, what am I going to tell the 
pharmacist? But if I see it definitely, I will let him know. So, for the whole two years or 





Overall HCPs considered reporting as important and thought of reporting as beneficial, but 
other negative behaviours were identified to influence HCPs’ ADR reporting behaviour: 
reluctance to report, uncertainty, fear of reporting, and product misconception. 
 
4.5.4 Reluctance to Report  
 
Some HCPs felt reluctant in reporting an ADR and for some, it was considered a waste of time. 
They paid less attention to ADR issues and were sometimes forgetful about reporting, blaming 
high workload. Doubts about symptoms related to the drug, reporting not deemed important, 
and possible forgetfulness affected reporting. An interaction between these factors triggered 
passivity among HCPs, as expressed by the following doctor who said clinicians do identify 
ADR but are too lazy to report it: 
 
“…what I believe, as I said [...] it’s not that we are not getting the reactions, but we 
are not documenting it …yes that is the major problem. I mean it is not also lack of 
training because we have had [...] FDA has done several trainings on these things. I 
just think as I said it’s laziness on the part of, we the clinician…” Doctor 1 
 
Some HCPs attributed their reluctance to report as lapses caused by high patient numbers and 
reactions not being serious enough to be reported. This coupled with the technical challenges 




“…the workload is so much with health insurance and the number of patients that come 
into the hospital. So sometimes, it can be an oversight. Once you handle it and it’s gone, 
it might not occur to you to report…” Physician Assistant 9 
 
The main reason, however, for the reluctance of HCPs to report ADRs was the lack of 
knowledge, which translated into poor reporting attitudes. The following quotations highlight 
the above concerns when HCPs were asked why ADR reporting in their hospital is among the 
lowest in the country: 
 
“…yes, this is an issue. In fact, the FDA pharmacist once told us this ‘that in Northern 
Region our reporting system is very bad’. It isn’t that we don’t get cases, the cases are 
there, but it looks as if the people are feeling reluctant or they don’t know in 
fact[...]…the HCPs[...]. So those who work with the patients you understand that…they 
feel reluctant and I believe it’s not umm as if they are reluctant, but they don’t know 
that[...] this thing they are seeing they are supposed to report. If not, we have been 
getting a lot of them we do…” Pharmacist 6 
 
“…you see I have come to realise that majority of us really have certain tendencies. 
The youth of today[...]the average Ghanaian worker, you know in terms of diligence 
[...]the attention of making sure that the right thing is done. Dealing with people with 
that right attitude…there are some people [diligent HCPs] …But the majority don’t 
take things so seriously, they don’t take things serious…” Pharmacist 10 
 
4.5.5 Severity of Incidence 
 
A further influence on ADR reporting was the perceived severity of the ADR. It was apparent 
that HCPs were not keen on minor medication incidents and thus were less likely to consider 
reporting them. This was the case for all HCPs, including pharmacy staff who were viewed to 
be well informed on matters relating to ADR reporting. They equally appeared to be concerned 
with only serious reports and were unsure about reporting minor events. 
 
“…If there is anything and there is a serious reaction, then they will come and tell us   
(pharmacist) but I don’t know about whether those minor or less serious reactions that 
come up and they don’t let us know… Recently we had some cases about anti snake 
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venom. That some of the patients were reacting to it. That one there was a report and 
they took it to the FDA. Yes, they took samples and they also came and looked at it. 
They filled the forms and took it to them. They brought in people…” Pharmacist 8 
 
However, HCPs completed ADR forms if they considered the case serious or life-threatening 
enough to report. The quote that follows is in response to a follow-up question asking a 
physician assistant if she remembered the last time she reported an ADR; cases which were 
considered not severe were often managed and discharged, as the quote below suggests: 
 
“… well it depends on the severity of the reaction. But I can’t remember the last time 
we even filled a form and reporting it officially. We just manage it when they come. 
Either you stop the medication or you give something to contract (stop) the reaction. 
But this hospital[...]no we do not report[...]” Physician Assistant 8 
 
Severe incidences of ADR, however, influence HCPs to complete an ADR form, as suggested 
by the nurse in the following quote:  
 
“…well one was about a child, but I don’t remember the particular drug, but it was an 
antibiotic suspension or so and she had swollen face as a result. Yes, so she reported 
back and we had to fill the form…” Nurse 2 
 
In situations where HCPs were uncertain about severity and if an ADR needed to be reported, 
nurses who were often perceived to be of the lowest ranking, exercised restraint and wanted a 
confirmation from a senior colleague, doctor or pharmacist before reporting. 
 
“… the nurse will see it and say… ‘this one I don’t think it is so serious’ and maybe 
will write it in their notebook that ‘oo this has happened’. Then they will alert the 
pharmacist or the any other person around to come and report [...]” Nurse 10 
 
4.5.6 Uncertainty between ADR and ME 
 
There were also misunderstandings emanating from HCPs’ confusion between ADR and 
medication errors (ME). The FDA encourages HCPs to report ADRs even when they are not 
sure it resulted from a medication administered. HCPs, especially nurses, feared that reactions 
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from wrong administration of a medication could cause them to be questioned and to have 
undesirable professional consequences. The following discussion in one of the focus group 
elaborates on this attitude. A nurse describes an incident that was encountered in the paediatric 
unit in the FGD as follows: 
 
“…somebody was to give IM [intramuscular] quinine he went and gave IV 
[intravenous][...]instead of diluting it[...] if the patient is reacting how do you report” 
Nurse 3 (FGD) 
 
HCPs therefore feared that incorrect administration of a drug and reporting reactions may have 
negative repercussions on the individual. The competence of the HCP may be brought into 
question because they may be exposing themselves. 
 
“…so my question is[...]how did you administer and you tell the person that he 
chewed…now it’s like you didn’t do your work well. So that fear will be there[...]in 
reporting… yes and knowing everything about the drug before you administer…in 
filling the form aren’t you exposing your ignorance? When a doctor writes and you 
know it’s not good you shouldn’t give. Now you have to fill a form. So it comes with 
legal issues…” Nurse 5 (FGD) 
 
4.5.7 Fear of ADR Reporting and Consequences 
 
A number of issues arose in relation to concerns about the ADR reporting process, and more 
specifically whether ADR reporting posed any consequences to staff. A number of emotional 
aspects were linked to this, including the fear of being blamed and guilt of being involved in 
unprofessional conduct. The fear of blame from either a supervisor or a colleague made HCPs, 
especially junior ranking officers, reluctant to report ADRs. They feared that an action could 
also be taken against a fellow colleague and they could not bear the emotional guilt of being 
responsible for it. HCPs implied that junior staff generally feared such criticism and therefore 
concealed ADRs observed at the ward level. This was linked to hierarchy and rank as factors, 
which stimulated fear among HCPs. 
 
“… sometimes the patient is genuinely reacting to a drug but because of lack of trust 
among colleagues… I[nurse] observe and report to a superior who doesn’t take time 
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to actually look at the things and start to criticise that, if you had done this or if you 
had done that…because of such criticisms, sometimes they would rather not tell 
especially if the superior is not there to see it right there they conceal it and it ends 
there… they manage their thing and they keep it there they don’t want it to go out and 
they will say ‘oo you should have done this, if you had done this you could have 
prevented that’. So I believe that is a factor that the junior staff would rather conceal 
it than report so that somebody would criticise them…” Nurse 8 
 
HCPs also felt that reporting an ADR may implicate or challenge the competency of a colleague 
in relation to their work. To avoid embarrassment of a colleague, many HCPs ignored ADR 
reporting. 
 
“…because our system is like…it is some way as if we are trying to report somebody 
or you as trying to undermine the capability of another person…that he doesn’t know 
what she or he is doing, that’s why the person is getting the drug reaction[...]. You 
know these things[...]”  Nurse 2 
  
4.5.8 Product Misconception 
 
Some HCPs, especially pharmacy staff, were of the view that pharmaceutical products which 
were more expensive and from recognised pharmaceutical companies were less likely to cause 
ADRs. They believed that patients taking medications from renowned pharmaceutical 
companies were likely to get a better therapeutic effect and fewer side effects compared to 
patients who bought other less expensive generic products or bought from unregistered local 
shops. 
 
“[…] see this drug it’s expensive [showing medicine packages with recognised brand 
names] compared to this other one (a cheaper generic) … So you see the differences? 
There is no way you will give this drug (expensive brand name) to a patient and he will 
react …It’s of high quality. Are you getting me? So, the drug is a contributing factor. 
The source of the drug, the company that is manufacturing. For example, Sanofi 
producing a drug when you give it to a patient, you will get the yielded result that you 




Product misconception was therefore seen as a notion whereby HCPs overly trusted a product 
because of its brand name or cost, which could impact their judgement and perceptions of what 




The study identified several real-world issues affecting ADR reporting practices among HCPs. 
Key among them were sub-district experience, responsibility of reporting, lack of technical 
expertise, inter-personal relations, and teamwork. 
 
4.5.9 Sub-district Experience 
 
Decentralised sub-district community health centres are managed by the GHS. These sub-
districts are usually supervised by trained nurses or a small team of specialised HCPs (between 
two to five). Working at the sub-district level appeared to have exposed them to more ADR 
issues than working in a larger hospital facility.  
 
“…in this facility it is really rare. It was only when I was in the sub-district in Bole, that 
in fact it was very common especially when we were giving elephantiasis disease drugs. 
And sometimes people taking procaine and sometimes quinine injection[...]. They 
sometime get these reactions but here it is very rare…” Physician Assistant 8 
 
HCPs who worked at a sub-district level before were more likely to have sent some reports or 
attended training compared to when they moved to a secondary or tertiary care facility. 
 
“… like I told you when I was in the sub-district…you know as a nurse but same time you 
were more or less like a doctor where we were not having a lab system as practised but 
we do almost everything…anytime they sort of um[...]um [...][...]workshop for those 
things for pharmacovigilance at the region we do organise at the district and go… yeah 
you know like I told you in the village, you prescribe[...]” Nurse 1 
 
“…yeah at the district level or sub-district level you know because I was once 
responsible for the whole issue (pharmacovigilance) so that at any time there is that 
kind of adverse drug reaction you have to contact me. So as for the district level I have 




4.5.10 Responsibility for Reporting 
 
Clear views about the responsibility of reporting ADRs emerged and for doctors and nurses, it 
was not considered by them to be their responsibility. Instead, they felt it was the duty of a 
pharmacist rather than theirs: 
 
“[…] the pharmacist should be the one. Personally, I will hold the pharmacist 
responsible because he is the link person and he should be doing the reporting. 
Unfortunately, this facility I have issues with him because he is not reporting as he 
should report…” Doctor 3 
 
Nurses considered their role to be one of reporting their observations to the pharmacist only, 
and this was often verbal and required contacting the pharmacist about any events observed. 
 
“…I think as nurses, ours is to report to them … because in the facility, it is the 
pharmacist… our duty is to report to them, and it is their duty to also forward to 
whoever[...]” Nurse 8 
 
Nurses assumed this perception because they considered the pharmacist as more 
knowledgeable on drug-related cases and were likely to be more knowledgeable about the 
reporting process. 
 
“…I believe maybe the pharmacist should have been doing that because they have the 
knowledge[...]it will be easier them to identify some of these things because they are 
more technical with drugs, more than we the nurses. It’s not all the categories of nurse 
that have much knowledge on drugs so if they do that it would be much better…” Nurse 
7 
 
In contrast, pharmacy staff felt that ADR reporting should be a collective responsibility 
requiring other HCPs to give them the necessary information or draw their attention to 
incidences of ADRs. Other HCPs however (i.e. nursing and medical staff), felt it was the 





“… it becomes a bit difficult, the pharmacist is not in the ward often[...]goes to the 
ward few hours in a day and you are not there so if information doesn’t come from the 
people who are with the patient most of the time it becomes difficult. So we keep thinking 
that someone has to do it. This person thinks this person has to do it[...]and so nobody 
ends up doing it…” Pharmacist 9 
 
Pharmacy staff were aware of the assumptions made by other HCPs about their role and the 
perceived responsibility for ADR reporting: 
 
“[...] generally I think there’s that perception ‘Oh it’s not my work is not my work’ 
that is bottom…healthcare workers[...]. I think healthcare workers we keep shifting the 
posts…mostly people think it is the duty of the pharmacist to do this if the patient has 
an adverse drug reaction in the ward[...]” Pharmacist 7 
 
4.5.11 Perceived Workload and Burnout 
 
There was a perception of workload as a hindrance to reporting among HCPs. Reporting was 
considered a waste of time. They were therefore concerned with treating patients and solving 
their reaction problems rather than reporting. 
 
“…we are overworked. We are always overwhelmed so they would rather, like I said 
earlier, on concentrate on solving the problem than reporting…you go to the ward and 
one nurse is taking care of about ten people…” Nurse 10 
 
Perceived workload led to HCPs passively reporting ADR verbally and mainly leaving the 
documentation process as the sole responsibility of the pharmacist. Participants were asked 
about the ADR reporting process in their hospital, and the quotes that follow report a common 
description by most HCPs: 
  
“[…] the pharmacist on duty is on the ward, so we have a pharmacy in our ward so if 
something happens you just move, and you tell them. You just tell them you have given 




“…because they think the workload already is too much and based on these things, they 
[HCPs] think it is an added-on responsibility. I think at times we all feel [...]…we are 
a part of that, we all feel like that. So, at times we are under pressure and then you need 
to take other time off to attend to these things. It’s only maybe when you are less under 
pressure that is the time you can comfortably interact with the patient who comes with 
this…” Pharmacist 11 
 
4.5.12 Lack of Technical Expertise 
 
Pharmacy staff are often the technical experts on medication-related issues. HCPs regularly 
required some level of support from a clinical pharmacist in identification and reporting of 
ADRs. HCPs reported that a major drawback affecting reporting, however, was the availability 
of a clinical pharmacist. Discussions with the director of pharmacy showed that there was a 
critical staff shortage among the pharmacy staff category in the study area, with the few 
available staff concentrated in regional hospitals.  
  
Nurses expressed dissatisfaction that the lack of clinical pharmacists to augment a 
comprehensive health delivery was a challenge. It was perceived that the presence of a clinical 
pharmacist could help identify medication safety issues in patients and spot ADRs more 
accurately: 
 
“…the pharmacist will be with you and some of the things… like the complaints the 
patient will be giving, the clinical pharmacist will draw your attention, that could be 
an adverse effect then they pick it on from there…but you go on rounds there is no 
clinical pharmacist the patients will be giving the complaints you will think…it’s 
another symptom yes.” Nurse 4 
 
4.5.13 Inter-personal Relations and Teamwork 
 
The level of interaction, communication and association with fellow healthcare professionals 
was considered to affect the reporting. From observation and personal reflection, some HCPs 
reported that teams did not have congenial relationships, which affected their practice and 
performance. The following quote highlights a poor working relationship with the hospital 
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pharmacists, which makes nurses feel too uncomfortable to approach them with medication-
related issues. 
 
“[...] having a chat with him [pharmacist] like maybe a client will come, the 
medications you discuss with him [pharmacist] maybe you tell the patient to come after 
maybe seeing maybe some adverse effects and all that, to report back to you […] I have 
realised that that thing (congenial relationship) is no more […] I have realised that that 
is not there and that is something I complain every time. But you know when you are 
like the only person complaining, your other colleagues don’t see it that way, it will be 
like [...]why are you alone complaining? [...]” Nurse 5 
 
Linked to the previous point, improper change management within the healthcare facilities was 
reported to affect inter-personal relationships. Medical and pharmacy staff were frequently 
transferred due to staff shortages. This high turnover affected rapport and often required the 
staff to adjust to potentially different personalities and approaches of new pharmacists and 
doctors. Furthermore, it was perceived that this situation often resulted in communication 
barriers and inter-personal/professional conflicts as expressed in the following statement: 
 
“[…] with the new pharmacist I cannot have any discussion with him. I cannot have 
any discussion with him because he is always acting defensive [...] I believe that you 
[the pharmacist] have gone to specialise in pharmacy, I have not, I have not done 
pharmacology […] I have to call a pharmacist outside to have a discussion with and 
what is my pharmacist doing?[...]” Nurse 6 
 
Inter-professional conflict as a result of a poor inter-personal relationship was considered to  
cause two further problems: firstly, it impacted negatively on the role of the pharmacist in 
ensuring that updates or new information on ADR or medication safety-related issues were 
circulated; secondly, other HCPs felt less comfortable in approaching the pharmacist on 
medication safety issues such as ADRs.  
 
Creation of a congenial work atmosphere in which HCPs could easily interact and discuss 
issues was observed as a determining factor for reporting ADRs. Some HCPs would only 
approach their fellow staff if they felt comfortable and welcomed. The demeanour of fellow 
HCPs therefore determined the level of interaction and possibly the amount of information that 
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could be retrieved in relation to ADR or other patient safety issues. Pharmacy staff explain the 
situation in the following quote: 
 
“[...] it looks like there is that kind of segregation among even the same professionals 
[...] so if that team thing is there and somebody feels comfortable that ‘oo I can easily 
walk to this professional to inquire about this’ [...] ‘this is what this patient is 
experiencing what do you think?’ It looks like people all think that they should be in 
their corner and they shouldn’t even let somebody know that, they even require an 
explanation about something[...]” Pharmacist 7  
 
Poor interaction between HCPs therefore affected teamwork. Staff who therefore needed 
education or explanation of a procedure from a colleague often lost that opportunity due to 
poor inter-personal relationships. Communication barriers among inter/intra-professional 
categories was a limiting factor in reporting. Pharmacy staff were of the view that approaching 
fellow HCPs in a friendly way, having a contact person in charge of ADR, and continuous 
learning about ADR could develop a positive reporting culture.  
 
4.5.14 Patient-related Factors 
 
So far in this chapter, individual factors relating to the reporting of ADRs have been presented 
from the perspective of the different HCPs and key differences in terms of their knowledge, 
attitudes and practices in relation to ADR reporting. However, analysis further revealed a group 
of individuals of relevance to ADR reporting were patients. HCPs attributed the low reporting 
of ADRs to patients not volunteering reports to them, which was related to several key factors. 
A predominant feature recounted was a perception among HCPs that patients lacked 
understanding and awareness about what they experienced as a possible ADR. Linked to this 
was patients’ perceived inability to remember sufficient details to be reported. This made it 
difficult to capture patient experiences in patient folders or ADR reports. Patients were also 
considered to be apprehensive about reporting ADR issues to HCPs. They were also often 
involved in self-medication and visited different hospitals refered to as “hospital shopping” 
(hospital hopping) for the same medical condition because dissatisfactory experience with one 
healthcare service. These factors were observed to be inter-related and dependent on each other. 
For example, apprehensive clients usually had low levels of knowledge and were likely to go 
hospital “shopping” because they were dissatisfied with the service received. The over-riding 
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concern was that unless an ADR was identified and reported at the bedside of a patient, patients 
themselves would typically not volunteer information to the HCP about a possible ADR: 
 
“[…] unless the thing is happening in the hospital, in the ward, under the watch of the 
healthcare professional[...]that is the only time we report but we do advise the patients 
too[...] but hardly will a patient come and report any ADR…and it is only the one the 
healthcare providers see with their eyes[...]that is the one[in-patient] [...] but what 
they[patients] feel they will never say it ...” Pharmacist 6 
 
Some participants went further and argued that responsibility actually lay primarily with the 
patient, and that it was for them to report the ADR:  
 
“[…] I think if there will be a problem then…it should come from the patient first and 
foremost. It is the person who was taken the drug who is going to feel something…and 
if he attributes it to the drug, he will come and tell you the doctor that I took this drug 
and something happened. But if the patient feels those things are not attributed to the 
drug, he will not come to you; so far as you are concerned there’s no drug reaction[...]” 
Doctor 2  
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4.5.15 Apprehensive Patients and Relatives 
 
Patients and relatives were considered apprehensive about reporting in both Out-Patient 
Departments (OPDs) and In-Patient Departments (IPDs). They were hesitant about forwarding 
medication safety-related complaints, including ADRs, to be assessed and reported by HCPs. 
Reasons were found to be related to patients’ inability to communicate their concerns, fears, 
long waiting times, poor inter-personal relationships and previous experience. 
 
The official language for clerking patients was English and may require interpretation if clients 
did not understand, which was often the case according to the participants. This created a 
communication barrier, making patients uneasy and less confident. Patients’ inability to 
communicate in English was as a result of poor educational outcomes, which affected their 
ability to communicate with the HCPs, resulting in apprehension.  HCPs were also of the view 
that uneducated clients found difficulty in reading and understanding drug information sheets, 
and thus lacked knowledge of what to be cautious about. 
 
“… the majority of our people [patients and relatives] are not educated so things 
happen to them and they don’t know what to do. But if it is in the local language that, 
if you have any issues you should report back to the pharmacist who gave you the 
medication or if it is a pharmaceutical shop [community pharmacy] in the local dialect 
so that they understand…” Pharmacist 7 
 
Submitting ADR reports through the HCP was recognised as being a significant challenge for 
patients. Some patients ended up not reporting because they were either hesitant to talk to an 
HCP or were unaware of how to directly report to the FDA. Only educated patients were 
confident and aware of how to contact the FDA directly. 
 
“[...] you know usually if the information comes to the pharmacist first before it goes, 
sometimes there can be under-reporting but if there is a line that patients can report 
directly. And I think patients do, especially the educated ones, those that are not really 
educated they hardly do but the educated ones when they take medications and they 




Patients were also more assertive if they could read or understand their medication information. 
HCPs, however, suggested that patients may be afraid of reporting ADRs for fear of exposing 
the harm of pharmaceutical companies, which might put them at risk. 
 
“…what I mean is that like you have gone to buy something [medication] and it is now 
giving him/her problems. She thinks that reporting it will have a negative effect from 
the source [pharmaceutical company]. As if he is going to do harm to the source 
[pharmaceutical company] …”  (Investigator: “…so they are protecting?”) …yes they 
think that they will be endangering[...]the source [pharmaceutical company] …” 
Pharmacist 3 
 
As noted above, low socioeconomic and educational attainment were felt by participants to 
affect their communication with HCPs and their ability to be assertive. Coupled with unfriendly 
HCP attitude, patients and relatives rarely discussed ADR issues with HCPs, especially 
prescribers. A pharmacist describes the situation in the following quote: 
 
 “[...] at times it’s difficult for them [patients] to approach some health professionals. 
So, they might even come, you ask them a question, something that they should have 
even told the prescriber, they couldn’t. It is something that has been happening. You 
ask them and it looks like they fear talking to them [prescribers] so maybe at times they 
will just sit, get their prescriptions written for them, then they bring the folder to you 
[pharmacist] at the pharmacy…” Pharmacist 1 
 
Patients only opened up to HCPs with whom they felt comfortable discussing their conditions. 
Pharmacists who were able to develop an inter-personal relationship with patients also took 
time to analyse their prescriptions and gave them more attention, making sure their 
prescriptions were not giving them any problems. According to HCPs, patients open up when 
they are approached in a friendly manner without feeling rushed.  
 
One scenario in which participants felt that patients and relatives were assertive or inclined to 
report medication-related issues was if they had previous experience of a different healthcare 
system where they reported, and action was taken. It was also challenging to retrieve 
information from patients’ relatives where the actual patient was incapacitated and therefore 
unable to talk or describe their own condition.  This was understandably more common in 
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paediatrics where mothers often had to describe reactions experienced by children to clinicians. 
Inability to communicate these events clearly often made carers apprehensive. 
 
4.5.16 Surrogate/Carer Reporters 
 
HCPs highlighted the challenging nature of reporting ADR from children, older adults and 
emergency cases. This group of patients may not be able to give information about their 
reaction other than through their carer. Furthermore, emergency situations often required 
information about any reactions to be requested from the carers, and these were often 
incomplete or lost. Some patients were also sometimes uncomfortable discussing their 
reactions in the presence of their carer. 
 
“…when we get reactions…the majority of them (patients) when they come they are not 
the people talking […] it is their relatives who bring them so if you don’t ask the relative 
to go out you want to talk to the clients yourself, some of these things (ADR) you’re not 
be able to pick them up if they don’t say…So I need time, we will prefer talking to the 
patient [...] if the person cannot communicate then it’s understandable…” Nurse 5 
 
Nurses expected mothers and carers to be able to identify ADRs and report to them. ADR 
information, however, was often lost due to the carer’s inability to recognise that the cry of a 
child may be due to an ADR. 
 
“[…] like quinine reactions and all that [...] for that one it takes time before you get to 
know if the mother doesn’t tell you… because if they don’t sleep overnight it’s the 
mother who will be able to let you know…and you know some mothers, they are not 
very observant, they child may be doing that and the person will think that the child is 
just crying. so, they will not be able to tell they are due to drug reactions…” Nurse 6 
 
Potential reports from carers were therefore often lost due to lack of vigilance and their inability 




4.5.17 Hospital Hopping and Self-medication 
 
Patient apprehension was also cited as being likely to contribute to what was termed ‘hospital 
shopping’, which also influenced ADR reporting negatively according to participants. Hospital 
shopping was described as the tendency for patients to move from one hospital to another in 
search of better medical care. Access to free healthcare through the national health insurance 
also facilitated hospital hopping and self-medication, because clients were able to get access to 
extra medicines by subverting the healthcare system. Poor healthcare system infrastructure 
made it challenging to identify patients who were receiving care or medicines from multiple 
facilities for the same condition at the same time. The following quotation capture why it is 
challenging to report ADRs from patients; 
 
“Here actually because of the health insurance we have a lot of hospital shopping [...] 
patients move from hospital to hospital. So, you may take a drug here get a reaction 
but will not go back to that same hospital for them to activate the process. They feel the 
doctor didn’t treat him or her well, so they move to a different hospital. And they may 
see it as part of the disease. So that could be another reason.” Doctor 2 
 
This behaviour also involved the use of herbal medicines at local pharmacy shops. HCPs cited 
this patient behaviour as an important barrier affecting ADR reporting, as it created 
uncertainties about how and what to report.  
 
“[…] if you look at the way our clients take medications, apart from what we prescribe 
most of them have taken other drugs and others have taken local concoctions (herbal 
medicines), before they get here. So how sure are you that what you have given is what 
is causing the reaction and not the interaction between the two medications […]” 
Doctor 2  
 
Exacerbation of the issues was caused by lack of electronic records which made tracing patient 
details difficult as well. Self-medication was also recognised as a common practice among the 
general population, including in patients during a hospital admission. On admission, patients 
often brought along their medication without disclosing it to the HCPs. For fear of being told 
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off, patients also concealed all extra unprescribed medications from HCPs. Nurses blamed this 
practice on patients taking medical advice from family and friends. 
 
“[...] Even sometimes as we are talking about those things [ADRs] it will even be 
surprising you see some patients they will come and lay on their bed and have their 
own medications[…] but because we have no right to search the fellow’s bag, the fellow 
takes the drug while myself and my sister (colleague nurse) here we are running round, 
he or she (patient) will take the medicine again and take [self-medicate][…]yes the last 
time such things happened, we went round only for us to come back and the fellow is 
unstable. Not knowing that day she was having a particular drug […]” Nurse 5 
 
In summary, HCP participants identified issues that could be related to them as individuals as 
well as to their other healthcare colleagues and also to patients. Many of these represented 
negatives and were viewed as factors that were present that tended to make ADR reporting less 
likely. In the next section, the focus shifts away from aspects of the individual, whether HCP 
or patient, and to more system- and process-related aspects.  
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This section summarises a further key theme related to the suggested ways HCPs thought ADR 
reporting could be improved. Key aspects related to HCPs views about proposed reforms in 
governance and policy, and motivation from stakeholders for improving reporting. With 
reference to motivation, internal and external strategies were identified, including educational 
training for both HCPs and patients, which was seen as key. Further analysis from FGD and 
IDI highlighted important aspects of these findings, where it was widely held that education 
and empowering the pharmacy staff to report or monitor ADRs could improve reporting. 
Several subthemes emerged as a result of the analysis, of which the key findings will be 
expounded on here. 
 
4.6.1 Education and Training Governance 
 
Governance and policy on training involving major stakeholders was suggested by HCPs as 
strategic to improving HCPs. It was also proposed that pharmacovigilance and drug related 
issues should feature in annual reviews at the district, regional and national levels. Furthermore, 
the idea of engaging professional bodies such as the Nursing and Midwifery Council or 
Medical and Dental Council, to develop policies, which accept continuous professional 
development points (CDP) from attendance at medication safety workshops, could improve 
reporting. One doctor used the analogy of compulsory ethics training required of doctors each 
year to argue that a similar training on pharmacovigilance and ADR reporting should be 
instituted: 
 
“[..] So the FDA can collaborate with other regulatory agencies like the Nursing and 
Midwifery Council or Medical and Dental Council to make it a compulsory training 
need, so that every year healthcare professionals will be required to update their 
knowledge in this area. If they do it more it will encourage people to report […]” 
Doctor 4 
 
As noted earlier in the chapter, ADR reports were often lost to undocumented incidents. To 
improve the reporting and documentation, it was proposed that verbal reporting by hospitals 
be encouraged in addition to written reports. As one participant notes, this also needed to be 
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embedded in practice and there was a suggestion to “make ADR reporting part of the nursing 
care plan” Nurse 11. Furthermore, another nurse noted that this would be analogous to the 
already existing verbal reporting for communicable diseases: 
 
 “…..Ok so I think if we institute oral reporting or verbal reporting….so that the one 
you are reporting to just like how we do disease [...]Communicable disease 
reporting….you just call the disease control officer and say I think I have a case….so 
the person comes to do the assessment and do his or her documentation….so you are 
the one reporting but normally you don't document anything….so it increases their 
reporting rates….” Nurse 12 
 
Unavailability of forms at the ward level was classified as a governance issue because of the 
external power play in ensuring that the forms were constantly available. The pharmacy units 
were the most likely places to find ADR forms. They could also be found sometimes in doctors’ 
and prescribers’ consulting rooms. It was observed that some HCPs, when asked to show a 
sample of the reporting form, often took a considerable amount to time to find one in the above 
places. Some nurses therefore advocated that management should make forms available, or to 
make it part of the patient folder system. For example, “[…] there should be forms attached to 
the patient’s folder.” Nurse 1 (FGD). These suggestions however required a change in policy 
and governance from either external agencies or internal hospital structures.  Suggestions such 
as the following would be easier to implement internally by modifying hospital governance 
and protocols. 
 
 “[…] they should be in the ward; the wards too should have them. The forms should 
be common just like anytime you want it you can find it [...] so if they give the forms to 
the hospitals actually, they will share it to the wards. So that should in case of anything 
you just report […]” Nurse 5 (FGD). 
 
Attaching forms to patient folders, training, and accepting CPD points however would require 






At the time of the research, no hospital had an ADR or incidence committee in place for 
monitoring and investigation of medication safety related cases. The majority of healthcare 
facilities also lacked a designated or contact person for ADR reporting. Only one facility had 
a drug safety unit and a contact person. All other facilities relied on the pharmacist as a default 
contact person for monitoring ADR. Monitoring was however low due to lack of interest, the 
absence of a clinical pharmacist, or lack of contact persons at localised units and departments. 
Some nurses were of the opinion that regular monitoring of prescriptions at the department and 
wards level by a pharmacist could be of benefit in improving reporting. 
 
 “[…] you know umm pertaining to my facility (hospital), we especially lack a clinical 
pharmacist […] yeah I think erm we mostly have interactions (ADR) with drugs mostly 
from the in-patients […] I think some time ago they started something (monitoring), 
they used to come around and check on medications and even dosages…because 
sometimes if you overdose that’s when all these things come to play. So, I think if they 




Unmet expectation of reward to an HCP as a result of reporting an ADR influenced their action 
negatively. Compensation from stakeholders was proposed as a way of improving reporting. 
Open-ended analysis showed HCPs were in favour of general motivation, reward and 
compensations. The enthusiasm with which HCPs approached ADR reporting and related 








At the internal level, individual HCPs were self-motivated by their love of patient safety and 
were happy to report for non-monetary or financial gains. For example, the following 
pharmacist thinks it is the duty of HCPs to ensure patient safety. 
 
 “[…] so for me I think that once you are a healthcare professional, you should help 
the system to ensure that there is quality….so the motivation should be that you are 
helping the system to ensure that there is quality of care as a caregiver ‘cause your 
duty is to ensure that the patient is safe,  so the motivation is for you to push and ensure 
that systems are better […]” Pharmacist 4 
 
Some self-motivated HCPs felt it was unprofessional to take any money for reporting an ADR. 
They felt it was their duty to report if the necessary resources were made available, as captured 
in the following: 
 
“[…] like they're saying here I don't need to be paid….at the end of the day if they say 
that okay this is the money for reporting adverse drug reaction then I shouldn't have 
administered drug as well….so if things are available, I don't think the nurses are lazy. 
they will definitely do the work.….” Nurse6 (FGD) 
 
Some participants were self-motivated because they saw reporting as a learning process, and 
they participated in reporting because they felt they could learn from feedback as expressed by 
a pharmacist:  
 
 “…so, when you do it in fact it’s even [...]you learn more. Because there may be 
something new that you do not know. It's something that one should all the time do. Not 
for reward or anything. Yeah… we should even do it the more you do it the more you 
know. You understand you learn new things….so don't sit down and say ‘oo if they don't 





4.6.5 Financial Motivation 
 
It was common for participants to be motivated by non-monetary gains. Among the few who 
wanted financial rewards for reporting ADR, it was noted that most of them were nurses. 
Excerpts from FGD of nurses articulates a nurse’s view as follows: 
 
 “…listen to this one [...]that she wants motivation (teasing)(Investigator: What kind of 
motivation?), [...] if possible financial….they should give you an envelope (money) 
after you have reported something and maybe congratulate you maybe a plaque….” 
Nurse 3 
 
The choice of financial motivation was re-emphasised by a few nurses, as for example in the 
following extract: 
 
“…So if it is agreed that the number of forms you fill per the month or year, maybe 
something should be done, some small allowance [monetary] should be given to such 
group of people, people[HCPs] they will get interested in and report ADRs[...] Nurse 
1 
 
When probed further to enquire how much they would expect as financial compensation for 
ADR reports submitted, another nurse commented that; 
 
“…as a token for whether you have reported one or three you should be given at least 
50 cedi [£8] maybe first quarter, this number of people were able to report on ADR, it 
will be in me [motivated] that I want to track drug reactions….” Nurse 3 (FGD) 
 
4.6.6 External Motivation 
 
Healthcare professionals were also motivated to report if they had a supportive external 
working environment which encouraged reporting. Some nurses were of the view that 
presentation to a reporter by FDA or MOH with a recognition plaque was a good incentive to 
keep HCPs reporting. This view was as a result of a similar gesture by the FDA, as quoted in 




 “[…] like how they (FDA) did …. that guy (HCP) was going around the wards with 
his this thing [referring to a nurse who was acknowledged by FDA for reporting] you 
understand …the motivation is there […]” Nurse 2 
 
At the external level, motivation was derived from workshops organised by stakeholders such 
as the FDA and MOH which train HCPs and acknowledge them for reporting. This resulted in 
a positive attitude, as captured in the concluding remarks of this interview: 
 
  “…At least opportunities to attend workshops is something we need. It can motivate 
us for example if you want an upgrade or further study, some of these little things when 
you add them to your CV makes it rich. At least they should have certain things like that 
to make us happy….” Nurse 2 
 
This was confirmed by other pharmacy staff and medical staff, and the following doctor 
suggested the need for citations; 
 
“… I think it's good, if they can even add a citation to the person and something for the 
facility it's good….” Doctor 7 
 
Overall, even though HCPs were generally self-motivated, some nurses were in favour of the 
introduction of financial or monetary incentives as a source of motivation.  
 
4.6.7 Reminders and Feedback 
 
Correspondences with the FDA after submitting ADR reports, served as reminders and 
motivation for HCPs to report more. Feedback from FDA or pharmaceutical companies to 





Previous experience of the absence of feedback after sending reports affected HCP attitude. An 
effective feedback system was therefore seen as necessary for improving ADR reporting. Some 
participants had positive feedback from the FDA coupled with favourable internal 
organisational elements and this led to submission of reports. 
 
 “…I think it is the time. The time in which you get feedback from my experience is 
motivational. I got into it because of just that. I have ever reported a case and the way 
they (FDA) called me and when they called, they told me they were in the process of 
investigating and gave me feedback when they finished…. I think that was just enough 
motivation for me to want to do it, but forms were always running out and I was out of 
town  (remote healthcare facility) so once a while they will send it or I come to town 
for them. Yeah so lack of feedback can be an issue[...]I don't know now but it used to 
be very prompt….” Doctor 5 
 
Feedback from the FDA was used to educate HCPs, using an experiential or problem-based 
learning approach where incidence of safety was used as feedback to train HCPs. 
 
“…Yes, what he is saying is actually true, because when they (FDA) came for the 
training the kind of feedback that they brought. They brought the feedback from 
different facilities. They brought the feedback to us, so they told us that Lisinopril was 
given to somebody and a person appeared like a person who had burns. So that is what 
they were telling us. So, they were telling us that if you couldn’t report by filling the 
form, and submitting it to them they will also report to a different facility. Though they 






Poor feedback experience however deterred some HCPs from reporting ADRs to relevant 
authorities. 
 
“…. I think lack of feedback will be this thing[...] because I never had any feedback. 
and the responsibility factor…. at least if I should report and you tell me that ‘oooo you 
are doing well’ [...]are you getting me? [...]. Keep on bringing them. I will be happy but 
when I report [...] but after reporting, that ends it. Yeah I know I am working for it, I 
am earning my salary but at least just that[...] pat my back and ‘say ooo you are doing 
well oo’ so next time I will, I will do it more, so motivation [...]. Lack of feedback is 
important and lack of motivation yes but that is what I said motivation is just about[...]. 
It’s not necessarily financial motivation (Investigator: the feedback will[...]) the 
feedback will do. ‘We have taken note of your report and we will act on it’ [….]” Nurse 
9 
 
HCP therefore suggested that general motivation and feedback had the potential to improve 
ADR reporting considerably. 
 
4.6.8 Education and Training 
 
The FDA was the main provider of education and training for HCPs. The FDA however 
tailored most of their training to pharmacists. In-service training which was cross-disciplinary 
often invited senior staffs and administrators to the neglect of junior staff who were most likely 
to encounter ADRs. HCPs therefore requested more training for all staff to increase their 
knowledge. 
 
“[…]so if they are properly trained or educated on ….that look it's not only  for 
pharmacist that can report on this then they will build on lack of knowledge…I always 
keep on saying if you really want the people (other HCPs) to do the job, then they need 
to know because if they say report on this, how do I report on it if I don't know it. So 
everything it's about [...] let the people know what it is the importance of adverse drug 




HCPs were also of the view that the FDA was seen as an external organisation and their training 
should be integrated with existing MOH/GHS training. 
 
“…so if there should be a proper education erm I would recommend that if truly the 
Ministry of Health or Ghana Health Service is really serious about this thing there 
should be proper training on this particular thing in this hospital. I think we have to do 
it every month. If we do it every month... awareness, we should create the awareness 
about ADR…” Pharmacist 3 
 
4.6.9 Patient Education 
 
Even though the FDA was campaigning in healthcare facilities for patients to report ADR, 
especially via text messaging, uptake was very low. Education of the public on the importance 
of reporting especially in local dialect was therefore suggested by some HCPs.  
 
 “…I think FDA should continue to do the sensitization, especially adverts in local 
dialect…. that one is very necessary. But they will tell you they don’t have money ‘cause 
when they do the adverts, they have to pay…. so, the sensitization should be there to 
patients and caregivers; that if you take any medications and you have any issues report 
to FDA…. so, there should be a constant reminder, because that is key for the success 
of pharmacovigilance in our healthcare system…” Pharmacist 2 
 
The low education levels and poor socioeconomic status affected patient reading and writing 
skills. Radio broadcasts in the local language was therefore suggested as an important way of 
improving reporting. 
 
[…] In fact there should be umm like radio broadcast, programmes they will be 
educating the people small small […] I think continuously sensitising the public will 
help. Because if it doesn't help the patient himself or herself, it's going to help the 
public. because we will finally get to know either this drug is dangerous or it's not 






4.6.10 Summary of Qualitative Findings  
 
Overall, these findings showed that HCPs recognised ADR reporting as an important activity 
for patient safety in clinical practice. There were significant variations in experiences and 
beliefs about ADR and associated reporting based on professional roles with varying 
knowledge, power and responsibility aspects emerging. The role of the pharmacist was viewed 
as significant in the ADR reporting process, but current practice and beliefs appeared to limit 
the degree to which these could comprehensively enhance ADR reporting. Negative attitudes 
to reporting as a result of multiple threats from internal, external, patient and HCP related 
factors appeared to strongly affect reporting. HCPs suggested three key areas to improve 
reporting through changes in governance and policy, monitoring and motivation. Interventions 
targeted at improving reporting may be required for each of the cardinal factors identified that 
influence reporting. 
In terms of strategies for improving reporting, the concluding section of the chapter shows what 
HCPs considered imperative ways to improve ADR reporting. Motivation was a key 
determinant for improving reporting, and HCPs were either self-motivated or depended on 
external initiatives such has financial rewards, reminders, education and training. HCPs also 
suggested improvements in governance, policy, reminders, and regulations on education. The 
next chapter (quantitative) will explore further suggestions for improving reporting, alongside 










This second chapter of findings reports the emerging data based on analysis of the surveys of 
HCPs at four hospital sites. The first sections report descriptively the survey responses based 
on the background characteristics of the sampled population. Frequencies and percentages are 
used to summarise the characteristics of the sample in tables. The subsequent sections of this 
chapter will firstly focus on responses relating to factors affecting ADR reporting, such as 
knowledge, reporting practices and attitudes. Finally, suggested opinions for improving ADR 
reporting will be reported on. Pearson Chi Square tests were run to test difference between 
categorical variables to show how likely the results were due to chance. Some variable cells 
were aggregated in order not to invalidate the Chi Square test because of low cell counts. Cells 
which were invalidated by low sample size were excluded from Chi Square analysis. The main 
research questions explored were: 
 
1) What self-reported factors are related to ADR reporting among Ghanaian HCPs?  
● Are HCPs aware and knowledgeable about reporting ADRs? 
● What are the attitudes of HCPs towards reporting? 
● What are the practices and perception of HCPs’ role in reporting ADR? 
 
2) What is the association between the factors affecting ADR reporting and HCPs?  
● Were their knowledge, attitudes and practices influenced by any background 
characteristics, such as training, internet access, department, hospital, HCP category, 
number of patients seen per day, level of experience or education? 
 
3) What methods can be suggested to improve ADR reporting? 
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5.1 Sociodemographic Characteristics 
 
Out of 450 survey questionnaires distributed, 386 were completed, representing a response rate 
of 86%. Of these, 70% (n=295) were nursing staff, 13% (n=48) were medical staff and 9% 
(n=34) pharmacy staff (Table 13). Even though pharmacy staff made up the smallest number 
of staff in the sample, they represented more than half of the pharmacy staff population in the 
selected hospitals. For example, out of the population of 62 pharmacy staff in the four study 
hospitals, the response received represents half (55%, n=34) of the overall sample of pharmacy 
staff compared to the total representation of doctors (21%, n=286) and nurses (17%, n=1,716). 
Just over half were aged between 20 to 30 years and fewer than half (48%) were female. The 
majority (43%, n=164) of participants had a diploma level qualification and at least (62%, 
n=235) five years’ experience. Also, 63% (n=232) of HCPs reported attending to no more than 
20 patients a day, and the most commonly reported department was surgery with 24% (n=89), 
followed by general medicine (15%, n=59), and obstetrics and gynaecology (13%, n=48). In 
terms of the hospital facilities investigated, Tamale Teaching Hospital (TTH) was the largest 
representation (61%, n=236) and Seventh Day Adventist Hospital (SDA) the smallest (8%, 
n=29). Tamale Central Hospital (TCH) and Tamale West Hospital (TWH) had similar 
proportions, representing 15.9% and 14.3% of HCPs respectively. Comparative representation 
of nurses within each healthcare facility showed more nurses in the SDA sample (88%) and 
the least from TTH (73%). There was, however, more representation of medical and pharmacy 





Table 13: Sociodemographic characteristics of the sample (n=386) 
 
Main group Category n (%) Total   
Age (years) 20-30 201 (53) 381   
31-40 148 (39) 
41+ 32 (8) 
Gender Male 199 (52) 386   
Female 187 (48) 
Healthcare professional 
category 
Nursing staff 295 (78) 377   
Medical staff 48 (13) 
Pharmacy staff 34 (9) 
Level of education Postgraduate 22 (6) 385   
Bachelors 120 (31) 
Diploma 164 (43) 
Certificate 44 (11) 
MBChB 35 (9) 
Years of experience ≤5years 235 (62) 370    
6-10 years 100 (26) 
≥11years 44 (12) 
Patients per day ≤20 232 (63) 367    
 
21-40 102 (28) 
≥41 33 (9) 
Hospital Tamale Central 
Hospital (TCH) 












Department Psychiatry 11 (3) 370    
General medicine 59 (16) 











Public health 14 (4) 
Pharmacy 31 (8) 




5.2 Knowledge of ADR Reporting 
 
Knowledge of HCPs was assessed based on five questions, which were designed to determine 
the level of knowledge and awareness about the ADR reporting process in their healthcare 
system. Firstly, their general awareness was ascertained, followed by specific knowledge-
based questions to support their first response. Participants were required to select the correct 
or expected response from a multiple-choice question on ADR.  
 
The results show that HCP knowledge was generally low across all the five questions asked, 
with an average awareness of 19% slightly skewed in favour of pharmacy staff (35.4%) who 
showed better knowledge compared to nursing (16%) and medical staff (21%). Facts about 
reporting showed that more than a quarter (32%) of HCPs’ responses showed they were aware 
of the national PV centre. Comparative levels of knowledge showed that a majority of 74% of 
pharmacy staff were more likely to be aware of the national PV system than medical (48%, 
n=23) and nursing staff (24%, n=71) categories (P<0.05) (Table 14). PV awareness was 
statistically significant for HCPs between 31–40 years of age (Χ2=18.332, P=0.000), males 
(Χ2=4.691, P=0.030) and HCPs who saw at least 20 patients per day (Χ2=26.395, P=0.000) 
(Appendix S). 
 
Only 5% percent reported they knew the short code (4015) to send an ADR report via a mobile 
phone Short Messaging System (SMS) to the FDA when they were asked about this. Most 
correct responses about this were from pharmacy staff (26.5%, n=9), compared to medical (4%, 
n=2) and nursing staff (2.7%, n=8) categories (Χ2=35.554, P=0.000). This was a statistically 
significant difference for HCPs who saw at least 20 patients per day (Χ2=8.722, P=0.013) 






Table 14: Comparative level of knowledge among HCPs on selected ADR topics 
 
 
Thirty-five per cent (n=126) of respondents demonstrated good knowledge on what basic 
information was required on the ADR form (i.e. patient details, suspected drug, suspected 
reaction and reporter details) by selecting the right response from three others.  Nearly two 
thirds (65%, n=22) of pharmacy staff demonstrated correct responses compared to responses 
from medical staff (38%, n=18) and nursing staff (31%, n=86) (Χ2=15.833, P=0.000). Basic 
demographics showed statistical significance difference for years of practice, where more than 
half of those who correctly responded that had practised for at least five years (Χ2=10.224, 
P=0.037) (Appendix Q). 
The knowledge domain that HCPs were least aware of was the recommended 28 working days 
to report any type of ADR observed to authorities, as required by the FDA.  Additionally, the 
regulation on submitting a serious ADR report within seven working days following an 










Chi  χ2 
 
Aware of national 
PV centre? 






222 (59) 25 (7) 9 (2) 256 (68) 









284 (76) 45 (12) 25 (7) 354 (95) 
What basic info is 









195 (24) 29 (8.0) 12 (3) 236 (65) 
All ADRs should 
be reported within 
how many days? 
Correct 
response 




286 (78) 48 (13) 33 (9) 367 (99) 
Serious ADRs 
should be reported 









239 (65) 35 (10) 22 (6) 296 (80) 
Average correct responses 
within professional category 
(%) 
217 (16) 56 (21) 67 (35) 340 (19)  
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encounter was known by only 20% of HCPs (P<0.05). Within professional staff categories, 
only 13.5% (n=50) of nurses indicated correct responses compared to pharmacy (33%, n=11) 
and medical staff (27%, n=13), and the difference was statistically significant. There was a 
statistical significance when comparing demographic variables such as age, patients seen per 
day and years of practice. This was statistically significant for HCPs between 31–40 years 
(Χ2=14.732, P=0.001), seeing between 21 to 40 patients per day (Χ2=15.320, P=0.000) and who 
had practised for at least five years (Χ2=24.181, P=0.000) (Appendix S). 
In summary, levels of awareness on key aspects of ADR reporting were low and varied from 
an almost complete lack of knowledge (of the time limit to report an ADR) to just over one 
third knowing the basic information to report and also being aware of a national PV centre. 
Pharmacy staff were more likely to be aware than the other two HCP groups, and nurses were 
less likely to be knowledgeable about ADR reporting.  
 
 
5.3 ADR Reporting Practices 
 
As well as exploring knowledge of ADR reporting, a key aim was to understand the scale of 
ADRs observed and associated reporting, as reported by HCPs in their clinical practice.  Three 
key aspects were explored in the survey: self-reported frequency of observing an ADR, 
frequency of subsequently reporting an ADR, and the frequency of using an ADR reporting 
form. These are now considered in turn and are summarised in Figure 18, and, as will be shown, 
revealed wide variation in the self-reported incidence overall and also between HCPs. 
 
5.4 Observing ADRs 
 
It was common that HCPs had not witnessed an ADR in practice. Overall, aggregated data 
showed that fewer than half (43%, n=158) of participants had observed an ADR at least once. 
Nineteen per cent indicated that they had never observed an ADR, and 38% could not recall 
observing one (Table 15). There was a statistically significant difference comparing HCPs who 
observed ADRs and worked in a general medicine department (P<0.05) and those who saw at 
most 20 patients per day (P<0.05). HCPs who reported having observed an ADR indicated they 
reported it once a year (13.2%, n=49), which was the most frequently reported period (Table 
15). Daily observations (10%, n=38) and weekly (2%, n=9) observations were infrequent, 
especially among medical and pharmacy staff. Aggregating the data, HCPs were more likely 
to have observed an ADR at least monthly (19%, n=70), compared to those who witnessed an 
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ADR at least every six months (11%, n=39) or once a year (13%). Fifty-four HCPs (14%) who 
observed ADRs indicated that they had also reported an ADR, and 34 (9%) of them completed 
an ADR form. Only 5% (18) of HCPs stated that they had observed, reported and completed a 
form at the same time. 
 
There were more pharmacy staff (56%) observing ADRs than nursing (41%) and medical 
(43%) staff. Within professional categories, the majority of medical (15%) and nursing (14%) 
staff were more likely to observe an ADR once a year than during any other time period. The 
most frequent period ADRs were observed by pharmacy staff was every three months (18%). 
There were more pharmacy staff who observed ADRs every three months than nursing (5%) 
and medical (11%) staff. Furthermore, nursing (11.7%) and pharmacy (12%) staff were more 
inclined to observe ADRs daily compared to medical staff (0%). Further aggregation showed 
a greater percentage of pharmacy staff (n=9, 27%) had observed ADRs within a three- to six-
month period compared to medical (n=6, 13%) and nursing staff (n=24, 8%).  
 
Table 15: Observation of ADRs among HCPs 
 
 
5.5 Reporting and Documentation 
 
Even though 43% (162/379) of participants indicated to have observed an ADR, only a quarter 
(24.6%) of HCPs reported (61/250), and only 14% (38/265) completed a form for it (Figure 
18). In practice, among HCPs who indicated to have ever reported, medical staff were least 
(9%) likely to have ever reported an ADR, compared to nursing (24%, n=47) and pharmacy 
staff (52%, n=11) (Χ2=14.090, P=0.000). The most common frequency with which HCPs sent 
Paraphrased Questions (See 
Appendix N for full version) 
Number of respondents TOTAL 
Nursing 
staff  
N  (%) 
Medical 
staff N  
(%) 
Pharmacy 
staff N  
(%) 
Total within HCP 
N  (%) 
Ever observed an 
ADR? 
Yes 119 (41) 20 (43) 19(56) 158(43) 
No 51 (18) 15 (32) 6 (18) 72 (19) 
Not sure 120 (41) 12 (26) 9 (27) 141 (38) 
How often do you 
observe ADR? 
 
Daily 34(12) 0(0) 4(12) 38 (10) 
Weekly 8(3) 1(2) 0(0) 9(2) 
Monthly 13(5) 6(13) 4(12) 23(6) 
Every 3 months  15(5) 5(11) 6(18) 26 (7) 
Every 6 months 9(3) 1(2) 3(4) 13(4) 
once a year 40(14) 7(15) 2(6) 49(13) 
Never 51(18) 15(32)   6(18) 72(19) 




reports was every six months (5%). Aggregating the frequency of reporting ADRs, 38% of 
HCPs indicated that they reported ADRs at least once a year. Further analysis within HCP 
categories showed pharmacy staff reported ADRs regularly compared to other HCPs (Table 
16). A statistically significant result showed that more than half (55%) of pharmacy staff were 
more likely to report at least once a year compared to nursing (38%) and medical staff (22%) 
(p>0.005). Open-ended responses concerning to whom HCPs reported an ADR, indicated that 
the ‘in-charge’ or the supervisor (39%) on duty was the person HCPs commonly reported 
incidents to first hand, followed by medical staff (28%) and pharmacy staff (17%) (Figure 19). 
Some of the ‘in-charges’ at the departmental level were medical staff, but mostly nurses. 
 







Figure 19: Recipients of ADR reports 
 
 
5.6 Completing a Form 
 
HCPs who completed ADR forms were mainly pharmacy staff (43%, n=10), followed by 
nursing (11%, n=24) and medical staff (7%, n=2). In addition to using the required ADR 
(yellow) forms, documentation of ADR information through alternative channels, such as 
incidence books, review notes and patient folders, was common as was indicated by 64% of 





Figure 20: Where ADRs were documented 
 
 
Sixty-nine per cent of nurses and 67% of medical staff used different reporting channels 
compared to pharmacy staff (14%) (Χ2=12.921, P=0.044). Patients form an important source 
of information – approximately half (50.3%) of HCPs responded affirmatively that patients 
always reported ADRs, and more than half of medical (51.1%) and 53% of nursing staff 
responses were affirmative of this, compared to pharmacy staff (27%) (p>0.005). The majority 
of HCPs (62% n=229) specified that patient education was part of their clinical practice, but 
there was no statistically significant difference in HCP responses. 
Self-reported responses on number of ADRs reported in the year showed that 18.4% (n=45) 
recounted between one to five ADR reports, while the majority (76%) submitted no report to 
an authority. Only a small fraction of HCPs (6.1%, n=15) reported six or more ADRs, of which 
the majority were nurses (93%, n=14). Among those who reported, only 13.9% (n=36) 
completed an ADR form. It was noted that 11% of HCPs who indicated they reported did this 
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by notifying their in-charge (superior) (40%), pharmacy staff (17%) or medical staff (27%). 
Pharmacy staff were more likely to report an ADR to the FDA (46%), nursing staff were more 
likely to report to an in-charge (33%) or a member of medical staff (44%), and medical staff 
were also most likely to report to pharmacy staff. A minority group of nurses (6%) were more 
likely not to report ADRs and took no further action (p>0.005). 
 
5.7 Contact Person and Availability of Forms  
 
ADR reporting forms were generally unavailable. Only 95 (28%) HCPs indicated the forms 
were available in their departments or units. Within HCP categories, 77% of pharmacy staff 
were more likely to indicate that the forms were available, compared to medical (16%) and 
nursing staff (24%) [x2=45.415, df=4, p=0.000] (Table 17). Among the four healthcare 
facilities investigated, only one healthcare facility (TTH) had a designated department and 
contact person for PV and medication safety. At other facilities, pharmacy staff took on the 
responsibility for ADR reporting activities. The overall majority (81%, n=305) of HCPs 
indicated they were either not sure or did not have an institutional contact person at their place 
of work. Among the 19% who indicated that they had a contact person, nearly half of the 
pharmacy staff (48%) were more likely to be aware of this compared to nursing (16%) and 
medical staff (13%) [Χ2=24.612, df=4, P=0.0000]. Even though TTH had an institutional 
contact person and a department ensuring the distribution of forms and coordination of ADR-
related activities, only 37 (14%) respondents from that facility indicated they had one. Within 
HCP categories, medical staff (6%) were least likely to be aware of the presence of a contact 
person in TTH compared to nursing (10%) and pharmacy staff (Χ2=31.650, df=4, P=0.0000). 
 




Paraphrased Questions (See 
Appendix N for full version) 






N  (%) 
Medical 
staff N  
(%) 
Pharmacy 
staff N  
(%) 
Total within HCP 
N  (%) 
Do you have an 
institutional 
contact person? 





No 93 (32) 15 (31) 6 (18) 114 (30) 
Don’t know 153 (52) 27 (56) 11 (32) 191 (51) 
Are forms 
available in your 
facility? 





No 140 (52) 19 (43) 5 (17) 164 (48) 




5.8 Training and Feedback 
 
Training on PV and ADR reporting is a routine practice by the FDA and stakeholders to update 
HCPs’ knowledge base on medication safety practices. Participants were therefore questioned 
about training and feedback from stakeholders. 
Only 23% of HCPs recalled having training on PV and ADR reporting. Pharmacy staff were 
more likely (65%, n=22) to have received training compared to nursing (16%, n=47) and 
medical staff (31%, n=15) (P<0.005) (Table 18). Even though other HCPs perceived pharmacy 
staff as knowledgeable and given reporting dominance, levels of training were low. Pharmacy 
staff were, however, more likely to have had recent training, e.g. three months ago, compared 
to medical and nursing staff, who indicated they had training up to six months ago. More than 
half of participants could not remember the last training they had on PV and ADR reporting. 
Sixty-nine per cent of HCPs, however, felt they were more likely to report after the training, 
while the rest either indicated ‘no’ or were ‘not sure’. Although HCPs occasionally received 
information from the FDA, especially during training, feedback was low and only 12% (n=34) 
of HCPs received feedback from the FDA after submitting ADR reports, while 14% (n=51) 
specified they read the FDA newsletter DrugLens. Again, pharmacy staff were most likely 
(30%, n=10) to have read the FDA newsletter on medication safety compared to medical (4%, 
n=4) and nursing staff (13%) (P<0.005). Thirty four per cent of HCPs received products from 
pharmaceutical companies. Of these, medical staff (58%) were more likely to be presented with 
products more frequently (i.e. every month) compared to nursing (10%) and pharmacy staff 
(38%). Further enquiry about awareness of posters and adverts on ADR reporting in their 




Table 18: Training and feedback practices among healthcare professionals 
 
 
5.9 Reporting Methods and Responsibility 
 
HCPs preferred reporting ADR to medical staff (39%, n=138) as they considered it convenient. 
Nursing staff (45%) were more likely to report to medical staff, compared to medical staff 
themselves (25%) and pharmacy staff (6%) (P<0.005). Reporting electronically was the most 
preferred option for pharmacy staff, while doctors preferred using the paper forms. Sixty per 
cent (n=213) of HCPs in general preferred to report to either the pharmacy staff or medical 
staff (Table 19).  
  
Paraphrased Questions (See 
Appendix N for full version) 






N  (%) 
Medical 
staff N  
(%) 
Pharmacy 
staff N  
(%) 
Total within HCP 
N  (%) 
Do you receive 
feedback from 
FDA? 





 No 82 (36) 14 (41) 4 (17) 100 (35)  
 Not sure* 121 (53) 17 (50) 16 (67) 154 (54)  
Recall having PV 
training? 





 No 217 (76) 28 (64) 10 (29) 255 (70)  
 Not sure 22 (8) 1 (2) 2 (6) 25 (7)  
Do you read the 
FDA newsletter? 




 No 214 (74) 42 (88) 18 (55) 274 (74)  
 Don’t know 39 (13) 2 (4) 5 (15) 46 (12)  
Aware of ADR 
reporting adverts 
in your facility? 





 No 112  (40) 14 (30) 10 (29) 136 (38)  












Every 3 months 12 (4) 12(26) 4(12) 28 (8) 





When asked about which HCP category had the potential to send the most reports, more than 
half (57%, n=215) expressed the view that nursing staff had the potential to send the most 
reports compared to other HCP categories (P<0.005). However, whilst the majority of medical 
and nursing staff held this belief, most pharmacy staff respondents thought that all HCPs had 
the potential to send the most reports. Overall, more than half (51%, n=191) were of the opinion 
that all HCPs were ultimately responsible for reporting ADRs. Within HCP categories, the 
majority (77%, n=26) of pharmacy staff felt more strongly that reporting was a responsibility 
for all in contrast to nursing staff of which less than half (48%, n=140) (P<0.005) were of the 
same opinion. Considering what HCPs thought of themselves, 32% of nurses felt nursing staff 
had the ultimate responsibility, 17.6% of pharmacy staff felt it was their responsibility and 38% 
of medical staff felt it was their responsibility. Pharmacy staff therefore were observed to be 











Paraphrased Questions (See 
Appendix N for full version) 








staff N  
(%) 
Pharmacy 
staff N  
(%) 
Total within HCP 
N  (%) 
Do patients 
report ADR? 





No 30 (10) 3 (6) 4  (12) 37 (10) 
Sometimes 108 (37) 20 (43) 21 (62) 149 (40) 










No 13  (5) 2 (4) 2 (6) 17 (5) 
Sometimes 94 (32) 21 (45) 11 (32) 126 (34) 
Most convenient 
method for ADR 
reporting 





electronic 38 (14) 13 (27) 9 (27) 60 (17) 




124 (45) 12 (25) 2 (6) 138 (39) 
Other 5 (2) 1 (2) 0 (0) 6 (2) 
     
Who has the 
potential to send 
the most reports? 





Medical staff 6 (2) 12 (25) 2 (6) 20 (5) 
Pharmacy staff 14 (5) 2 (4) 11 (32) 27 (7) 
All 82 (28) 15 (31) 15 (44) 112 (30) 
other 3 (1) 0 (0) 0 (0) 3 (1) 











Medical staff 13 (4) 18 (38) 0 (8) 31 (8) 
Pharmacy staff 48 (16) 5 (10) 6 (18) 59 (16) 




5.10 Attitudes and Opinions on ADR Reporting 
 
Attitudinal data was acquired using a five-point Likert-type scale which sought to explore HCP 
perspectives on ADR reporting by modifying Inman’s theoretical model of the ‘deadly sins’ of 
under-reporting (Inman, 1996). Additionally, seven questions further soliciting their opinions 
on ADR reporting were explored.  In total, 14 questions were reworded as presented (Table 
20). These attitudinal questions were a combination of negative and positive statements to 
explore HCPs’ inclination towards these statements. Further assessment of the difference in 
response between HCPs was completed by recoding the five-point Likert scale to a three-point 
one, to satisfy Chi Square assumptions.  
 




Overall, the line of response of HCPs showed a positive attitude towards ADR reporting. The 
majority of HCPs agreed or strongly agreed with statements which encouraged reporting but 
disagreed or strongly disagreed with statements which discouraged reporting or were usually 
negatively worded. For example, HCPs’ response to “I don’t think I should report an ADR 
when I am not sure of the causality between the reaction and the drug” showed a 70% 
disagreement/strong disagreement with this statement, indicating a positive attitude.  
Abbreviation Full statement 
Reward/Motivation I would report more if there were monetary gain or percentage increase in salary  
Complex Forms I feel the ADR form is complex to complete  
Patient Safety I feel patient safety in my hospital can be improved  
Seriousness I feel only serious ADRs should be reported  
Cost I feel ADRs can increase healthcare cost in my facility  
Effective I feel ADR reporting in my hospital is generally effective  
Efficient I feel reporting process in my hospital is efficient  
Ignorance (Inman)  I feel there is lack of knowledge and awareness of the reporting process involved in 
submitting an ADR report  
Lethargy (Inman)  I feel there are so many patients to handle and we don’t have time, so ADRs become 
unimportant  
Diffidence (Inman) I don’t think I should report an ADR when I am not sure of the causality between the 
reaction and the drug  
Ambition (Inman) I keep the ADR reports because I can collect case series and publish to better my career.  
Guilt (Inman) I feel guilty for ADR that occurred because of a drug I administered or prescribed 
Litigation (Inman) I feel that reporting ADR can lead to investigations by the health department which can 
affect my job 
Complacency 
(Inman) 





Most HCPs were not in support of financial motivation. Seventy-six per cent of HCPs strongly 
disagreed (39%) or disagreed (37%) with reporting for monetary gain or percentage increase 
in salary. There was, however, a statistically significant difference where pharmacists (21%) 
were more likely to agree or strongly agree with this statement than medical (13%) and nursing 
staff (14%) (P<0.005) (Table 15). There were a large number of neutral responses (i.e. 39.4% 
neither agreed nor disagreed) when HCPs were asked for their opinion about the complexity 
of the ADR forms. Only 5% strongly agreed that the ADR forms were complex. The majority 
(93%) of HCPs agreed (30%) and strongly agreed (63%) that patient safety in their hospitals 
could improve through ADR reporting. There was a general disagreement (79%) about 
reporting only serious ADRs – 31% of HCPs strongly disagreed and an additional 48% 
disagreed. HCPs had a negative attitude to cost, effectiveness and efficiency of the reporting 
systems. In terms of cost, they either strongly disagreed (24%) or disagreed (43%) that ADRs 
could increase their healthcare costs. HCPs also felt that the reporting process in their facilities 
was not efficient (i.e. 24% strongly disagreed and 37% disagreed). They also doubted (i.e. 
strongly disagreed (25%) and disagreed (33%)) the effectiveness of the ADR reporting in their 
hospitals. 
In relation to Inman’s typology, only ‘ignorance’ was agreed or strongly agreed with. HCPs’ 
responses showed that the majority (79%) either strongly agreed (46%) or agreed (33%) that 
there was a lack of knowledge and awareness about reporting. HCPs either disagreed or 
strongly disagreed with the other attitudes proposed by Inman (lethargy, diffidence, ambition, 
guilt, litigation and complacency) thereby reflecting a positive attitude towards reporting. The 
majority (81%) strongly disagreed (44%) or disagreed (36%) with the statement “I feel there 
are many patients to handle and we don’t have time, so ADRs become unimportant”. More 
than half (69%) of the participants either strongly disagreed (29%) or disagreed (40%) that 
HCPs must establish causality before reporting an ADR. The ambition to keep ADRs for 
publication and career progression was a disagreeable attitude for 47% of HCPs. Fifty-nine per 
cent of HCPs felt no guilt (i.e. strongly disagreed (25%) and disagreed (34%)) for an ADR 
which occurred as a result of a drug they administered. Eighty-one per cent of HCPs strongly 
disagreed (37%) or disagreed (44%) that investigations could affect their job because of 
reporting an ADR. There was also a large (73%) disagreement that only safe drugs were 









Responses were recoded into agree, neutral or disagree to enable inferential analysis and 
comparison of attitudinal responses with key independent variables. Comparing attitudinal 
responses between the HCPs interviewed, reward/motivation, complex forms and cost were 
found to be statistically significant (P<0.005). In terms of financial reward and motivation, 
medical staff were more likely to disagree (83%) compared to nursing (79%) and pharmacy 
staff (50%). Pharmacy staff were most likely to agree to rewards and incentives for reporting 
compared to nurses and doctors (Χ2=22.296, df=4,, P=0.000).  Only 19% (n=72) of HCPs agreed 
ADRs could increase healthcare costs. Within staff categories, 79% of pharmacy staff were 
more likely to disagree with this statement than medical staff (50%) or nursing staff (69%).  
 
In terms of ambition, when HCPs were asked to assess a statement about keeping case reports 
for the purpose of compiling case series for publication to better their careers, 48% disagreed 
with this. Within HCP categories, more than half (58%) of medical staff disagreed with this 
compared to nursing staff (47%, n=139) and pharmacy staff (21%, n=7). 
 
Although not statistically significant, the majority of HCPs agreed reporting ADRs could 
improve patient safety. This was especially so for nurses, with 93% (n=275) agreeing to this 
statement. Also, a large number of respondents (81%, n=306) disagreed with the statement “I 
feel there are so many patients to handle and we don’t have time, so ADRs become 
unimportant”. Most medical staff (88%, n=42), disagreed with this statement compared to 
other HCPs. In terms of reporting an ADR, pharmacy staff were the majority (85%, n=29) who 
were most likely to disagree about litigation issues based on the statement that “I feel that 
reporting ADR can lead to investigations by the health department which can affect my job” 
























Staff  (% 
within staff) 
Medical 




staff  (% 
within staff) 
Total Pearson Chi 
χ2 





Neutral 22 (8) 2 (4) 10 (29) 34 (10) 
Agree 41 (14) 6 (13) 7 (21) 54 (15) 




Neutral 117 (40) 28 (60) 3 (9) 148 (41) 
Agree 49 (17) 5 (11) 10 (29) 64 (17) 




Neutral 6 (2) 1 (2) 0 (0) 7 (2) 
Agree 275 (93) 44 (92) 3 (91) 322 (92) 




Neutral 32 (11) 15 (31) 2 (6) 50 (13) 
Agree 58 (69.4) 9 (19) 5 (15) 72 (19) 




Neutral 11 (4) 1 (3) 1 (3) 13 (3) 
Agree 55 (19) 7 (21) 7 (21) 69 (18) 




Neutral 58 (20) 10 (21) 7 (21) 75 (20) 
Agree 58 (20) 5 (10) 6 (18) 69 (18) 




Neutral 48 (16) 9 (19) 7 (21) 64 (17) 
Agree 80 (27) 6 (13) 8 (24) 94 (25) 




Neutral 11 (4) 2 (4) 2 (6) 15 (4) 
Agree 232 (79) 42 (88) 23 (68) 297 (79) 




Neutral 21 (7) 2 (4) 1 (3) 24 (6) 
Agree 37 (13) 4 (8) 5 (15) 46 (12) 




Neutral 20 (7) 6 (13) 2 (6) 28 (7) 
Agree 74 (25) 4 (9) 8 (24) 86 (23) 




Neutral 58 (19) 15 (31) 7 (21) 80 (21) 
Agree 98 (33) 5 (10) 14 (41) 117 (31) 




Neutral 26 (9) 9 (19) 6 (18) 41 (11) 
Agree 92 (31) 9 (19) 8 (24) 109 (29) 




Neutral 27 (9) 5 (10) 2 (6) 34 (9) 
Agree 29 (10) 3 (6) 3 (9) 35 (9) 
Complacency (Inman) 
 




Neutral 16 (5) 0 (0.0) 3 (8) 19 (5) 




5.11 Attitude on Completing a Form 
 
Cross-tabulation of ADR form completion as a dependent variable against HCPs’ attitudes 
showed that reward/motivation (P<0.05) and complex forms (P<0.05) were statistically 
significant, when comparing those who completed ADR forms with those who did not and 
those who were not sure.  HCPs who felt ADR reporting in their hospital was generally 
effective, and those who were hesitant to report because they were unsure about causality, were 
statistically significant. 
Among HCPs who disagreed with reward and motivation, the majority (71%, n=140) did not 
report ADRs or were not sure (14%, n=28) if they reported. There was a statistically significant 
difference between those who agreed that the form was complicated and those who did not 
complete an ADR form (P<0.05). Of those who disagreed that the form was complicated, only 
21% (n=24) completed a form for an ADR they had observed, which may be attributed to other 
reasons associated with form completion. 
The majority of HCPs disagreed that ADR reporting in their hospitals was either effective 
(62%, n=164) or efficient (58%, n=218), although this was not significant (Χ2=2.443,  
P=0.655). There was marginal significant difference between those who disagreed (50%, n=38) 
that reporting was effective (Χ2=9.407, P=0.052) and those who reported an ADR (Table 22). 
HCPs who disagreed that it was either effective or efficient were more likely to be medical 
staff than nursing or pharmacy staff. 
The only Inman factor which was statistically significant (P<0.05) was ‘diffidence’, which 
stated that “I don’t think I should report an ADR when I am not sure of the causality between 
the reaction and the drug”. Diffidence referred to the belief that HCPs would only report an 
ADR if sure that it was related to the use of a particular drug and not based on mere suspicion. 
The majority of HCPs disagreed (65%, n=172) with the statement on diffidence. Seventy-three 
per cent (n=125) of those who disagreed either did not complete a form or were not sure (12%, 
n=20) whether they did. Only 12% (n=9) agreed they would report only if they were sure of 












COMPELETED ADR FORM  Pearso
n Chi 
χ2 










Neutral 7 (19) 14 (7) 4 (10) 25 (9) 
Agree 1 (3) 34 (18) 7 (18) 42 (16) 





Neutral 4 (11) 76 (41) 17 (44) 97 (37) 
Agree 10 (26) 32(17) 8 (21) 50 (19) 





Neutral 0 (0) 4(2) 2 (5) 6 (2) 
Agree 34 (90) 176 (94) 36 (92) 246 (93) 





Neutral 2(5) 28 (15) 5 (13) 35 (13) 
Agree 11(30) 38 (20) 9(23) 58 (22) 





Neutral 2 (5) 6 (3) 4 (10) 12 (5) 
Agree 6 (16) 36 (19) 9 (23) 51 (19) 





Neutral 10 (26) 25 (13) 11 (28) 46 (17) 
Agree 9 (24) 36 (19) 9 (23) 54 (20) 





Neutral 7 (18) 28 (15) 6 (15) 41 (16) 
Agree 12 (32) 50 (27) 14 (36) 76 (29) 
Ignorance 
(Inman) 
Disagree 8 (21) 29 (15) 11 (28) 48 (18) Χ2=3.8
44 
df=4 
Neutral 2 (5) 10 (5) 2 (5) 14 (5) 














Neutral 2 (5) 10 (5) 4 (10) 16 (6) 
Agree 6 (16) 22 (12) 9 (23) 37 (14) 
Diffidence 
(Inman) 





Neutral 2 (5) 10 (5) 8 (21) 20 (8) 
Agree 9 (24) 53 (28) 11 (28) 73 (28) 
Ambition 
(Inman) 





Neutral 8 (21) 44 (23) 10 (26) 62 (23) 
Agree 10 (26) 54 (29) 15 (39) 79 (30) 





Neutral 5 (14) 18 (10) 61 (15) 29 (11) 
Agree 8 (22) 63 (34) 11 (28) 82 (31) 
Litigation 
(Inman) 





Neutral 2 (5) 20 (11) 3 (8) 25 (9) 









Neutral 1 (3) 10 (5) 2 (5) 13 (5) 






5.12 Improving ADR Reporting 
 
Additional data was collected in the quantitative phase about improving ADR reporting to 
embellish the qualitative phase, which explore that same question. Questions about improving 
ADR reporting were posed to HCPs in 13 Likert-type questions with a five-grade response 
(strongly agree, agree, neither, disagree, strongly disagree) (Table 23) and a final open response 
qualitative question. The option most strongly agreed with was continuous medical education 
(68%, n=265). The option least strongly agreed with of the suggested ways of improving ADR 
reporting was making ADR reporting compulsory. Compulsory reporting reported the largest 
(10.4%, n=40) number of neutral opinions compared to the rest, especially continuous medical 
education where only one person was neutral. Furthermore, even though a small percentage 
(5%) disagreed with compulsory reporting, it was the opinion which HCPs disagreed with the 
most.  HCPs agreed strongly with four out of the thirteen suggestions, i.e. feedback (54%, 
n=210), increasing awareness about new drugs (54%, n=203), nominated contact person (51%, 















Organizing continuous medical education, training and refresher courses for 
staff on ADR reporting. 
Feedback 
 
Encouraging feedback among patients, prescribers and dispensers of 
medicines. 
Reminders  Regular reminder visits from a qualified person for pharmacovigilance 
(QPPV). 
Communication Increased communication among different healthcare professional cadres 




Increasing awareness about new drugs in health facilities. 
HOD nudge Encouragement from heads of departments. 
ADR network Forming an ADR reporting network 
Mobile app  Introduction of mobile phone application for online reporting. Having an ADR 
focal person in every unit/department 
Compulsory 
reporting 
Make ADR reporting a compulsory obligation for all healthcare professionals 
Accessibility of 
forms 
Making ADR forms available and accessible in every department/unit  











5.13 Comparing HCPs’ Responses to Improving ADR Reporting 
 
Overall, HCPs were positive and agreed with all the methods for improving ADR reporting, 
although there were differences in the level of agreement between HCPs. The opinion about 
making ADR a compulsory obligation was the only statistically significant variable (p=0.006). 
Eighty-three per cent agreed that making ADR reporting compulsory would improve reporting. 
The highest level of agreement was among nursing staff (85%, n=252), compared with medical 
(79%, n=38) and pharmacy staff (61.8%, n=21). 
Medical staff were in total agreement (100%) with three statements on creating awareness on 
new drugs, support from heads of departments and forming an ADR network. Similarly, 
pharmacy staff were in total agreement (100%) with six suggested ways of improving ADR: 
continuous medical education, feedback, using mobile phone applications, accessibility of 
forms, reminders and communication. Nursing staff, however, were not in total agreement 
about any of the suggested ways of improving reporting (Table 24). 
 
























Disagree 9 (3.1) 1 (2.1) 0 (0.0) 10 (2.7) 
Neutral 1 (0.3) 0 (0.0) 0 (0.0) 1 (0.3) 
Agree 285 (96.6) 47 (97.9) 34 (100) 366 (97) 
Feedback 
 
Disagree 4 (1.4) 1 (2.1) 0 (0.0) 5 (1.3) 
Neutral 2 (0.7) 0 (0.0) 0 (0.0) 2 (0.5) 
Agree 286 (97.9) 47 (97.9) 34 (100) 367 (98.1) 
Multimedia Disagree 12 (4.1) 0 (0.0) 1 (2.9) 13 (3.5) 
Neutral 13 (4.4) 2 (4.3) 1 (2.9) 16 (4.3) 
Agree 269 (91.5) 45 (95.7) 32 (94.1) 346 (92.3) 
New drug 
awareness 
Disagree 7 (2.4) 0 (0.0) 0 (0.0) 7 (1.9) 
Neutral 11 (3.8) 0 (0.0) 1 (3) 12 (3.3) 
Agree 270 (93.8) 46 (100) 33 (97.0) 349 (94.8) 
HOD 
nudging 
Disagree 6 (2.1) 0 (0.0) 0 (0.0) 6 (1.6) 
Neutral 10 (3.4) 0 (0.0) 1 (2.9) 11 (2.9) 
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Agree 276 (94.5) 48 (100) 33 (97.1) 357 (95.5) 
ADR network Disagree 6 (2.0) 0 (0.0) 1 (2.9) 7 (1.9) 
Neutral 6 (2.0) 0 (0.0) 1 (2.9) 7 (1.9) 
Agree 282 (95.9) 48 (100) 32 (94.1) 362 (96.3) 
Mobile App 
 
Disagree 24 (8.1) 1 (2.1) 0 (0.0) 25 (6.7) 
Neutral 25 (8.5) 3 (6.4) 0 (0.0) 28 (7.5) 
Agree 246 (83.4) 43 (91.5) 33 (100) 322 (85.9) 
Focal Person Disagree 7 (2.4) 1 (2.1) 0 (0.0) 8 (2.1) 
Neutral 14 (4.7) 1 (2.1) 1 (2.9) 16 (4.2) 
Agree 274 (92.9) 46 (95.8) 33 (97.1) 353 (93.6) 
Compulsory 
reporting 
Disagree 20 (6.8) 3 (6.3) 4 (11.8) 27 (7.2) 
Neutral 23 (7.8) 7 (14.6) 9 (26.5) 39 (10.3) 
Agree 252 (85.4) 38 (79.2) 21 (61.8) 311 (82.5) 
Accessibility 
to forms 
Disagree 4 (1.4) 0 (0.0) 0 (0.0) 4 (1.1) 
Neutral 1 (0.3) 1 (2.1) 0 (0.0) 2 (0.5) 
Agree 285 (98.3) 47 (97.9) 34 (100) 366 (98.4) 
Dropbox Disagree 10 (3.4) 1 (2.1) 0 (0.0) 11 (2.9) 
Neutral 13 (4.4) 1 (2.1) 1 (2.9) 15 (4) 
Agree 272 (92.2) 46 (95.8) 33 (97.1) 351 (93.1) 
Reminders 
 
Disagree 8 (2.7) 1 (2.1) 0 (0.0) 9 (2.4) 
Neutral 7 (2.4) 1 (2.1) 0 (0.0) 8 (2.1) 
Agree 279 (94.9) 46 (95.8) 34 (100) 359 (95.5) 
Communicati
on 
Disagree 6 (2.0) 1 (2.1) 0 (0.0) 7 (1.9) 
Neutral 4 (1.4) 1 (2.1) 0 (0.0) 5 (1.3) 








5.14 Summary of Quantitative Results  
 
These findings show a complex set of factors affecting PV and ADR reporting among HCPs. 
Variations in self-reported attitudes, practices and knowledge show apparent variation between 
medical, nursing and pharmacy staff.  
Firstly, HCPs showed low levels of knowledge, demonstrated by the high percentage of 
incorrect responses from questions on knowledge. Pharmacy staff, however, were 
comparatively more knowledgeable than medical and nursing staff on PV and ADR issues. On 
the other hand, nursing staff were likely to be less knowledgeable on ADR issues compared to 
pharmacy and medical staff.   
Secondly, a generally positive attitude to reporting ADR was observed among HCPs. For 
example, the majority of HCPs disagreed with statements which had unfavourably worded 
statements and agreed with optimistically worded attitudes. HCPs disagreed about financial 
motivation, complex forms, litigation, guilt, diffidence, cost implications and complacency as 
factors affecting reporting. They agreed, however, that patient safety could improve with 
reporting and that HCPs’ ignorance about the reporting system mired ADR reporting. 
Thirdly, in practice, reporting ADRs was presumed to be the responsibility of the pharmacy 
staff. Although 43% observed an ADR at least once a year, with 19% observing daily, weekly 
or monthly, it did not translate into reporting. Forms were generally unavailable, and a large 
proportion of HCPs were unsure of whom their institutional contact person for ADR was. There 
were more pharmacy staff observing ADRs than medical and nursing staff. Only a few had 
ever sent a report, and a large proportion had never completed a form. In addition, even though 
pharmacy staff were more likely to receive training, feedback from the FDA to HCPs in general 
was low. Overall, half of HCPs acknowledged that reporting ADRs was the responsibility of 
all HCPs. More than half of HCPs specified that nursing staff had the potential to send the most 
reports, as affirmed by half of the nursing staff.  
Overall, HCPs supported the suggested approaches for improving ADR reporting; although 
levels of agreement varied, continuous medical education was the most favourably considered. 
There was, however, a significant number of HCPs who were uncertain about suggestions to 
make ADR reporting compulsory. The majority, however, agreed with this, and there were 









This concluding chapter provides an in-depth discussion of the findings from both phases of 
the study and considers how these have answered the research questions set out in chapter 2. It 
begins by offering an overview of the main findings before going on to present an integrated 
discussion of findings; this offers additional context on critical aspects, as well as considering 
how the findings from this study relate to the existing literature and theory presented in chapters 
1 and 2. The study’s strengths and limitations will be considered, before moving on to consider 
various recommendations and implications of the findings; this section will describe how the 
emerging data could inform different aspects of policy and practice, particularly in the context 
of the Ghanaian healthcare system. Opportunities for further research will be suggested before 
a final reflective section on the overall doctoral research process. The chapter and thesis 
conclude with a further summary statement of the main aims and findings. 
 
6.1 Key Findings 
 
This study sought to explore the perceived factors influencing ADR reporting among Ghanaian 
HCPs, and ways of improving reporting in routine hospital practice. Specifically, the research 
aimed to understand the self-reported knowledge, attitude, perceptions and practices of ADR 
reporting from the perspective of key HCPs, primarily including doctors, nurses and 
pharmacists. Furthermore, the research sought to describe the reporting process more generally, 
together with associated contextual issues and suggestions for improving the reporting process. 
HCPs identified several underlying and sometimes inter-related factors influencing reporting 
in both phases of the study, reflecting both system and human factors.  
System factors were often perceived as distal and not in the immediate control of HCPs and 
were either internal or external. Key internal factors related to hospital administrative issues 
and a challenging reporting process, whilst key external system issues were viewed as being 




In contrast, human factors involved opinions about personal and professional aspects of HCPs 
and beliefs about how patients influenced reporting. This study suggests that knowledge of the 
ADR reporting process was low among HCPs, although pharmacy staff were more likely to be 
knowledgeable and were perceived to have a more significant role in reporting than medical 
and nursing staff. Pharmacy staff were also the main HCPs engaged in reporting, as identified 
in the survey and interviews. The data suggest that they considered reporting as part of their 
duty, and their supervisors encouraged them to report. This contributed to a greater proportion 
of pharmacy staff reporting ADR compared to other HCPs, based on self-report responses in 
the survey in particular. Pharmacy staff, however, did not perceive themselves as having the 
ultimate responsibility to report ADRs even though they played such a significant role.  Self-
reported evidence suggests that less than half of HCPs (43%) had ever observed an ADR and 
only around a quarter (25%) had ever reported an ADR, with 14% of those reported to having 
done so using a form. These results show a lower ADR observation compared to studies in 
Nigeria which stated between 70% to 93% observations. The rates of ADR reporting, however, 
were varied, ranging between 3% to 43% among HCPs. These variations may be due to 
variations in methodologies and samples (Ohaju-Obodo and Iribhogbe, 2010; Okezie and 
Olufunmilayo, 2008; Adedeji et al., 2013; Fadare et al., 2011). 
In terms of measurement of participant attitudes, in this study, HCPs were generally positive. 
The majority (92%) strongly believed that patient safety could be improved if they reported 
ADRs. Only one of Inman’s ‘seven deadly sins’ (Inman, 1996) – relating to ignorance of the 
reporting system – was viewed as influencing their ADR reporting and was considered a 
significant reason for non-reporting. All the other attitudes proposed by Inman were either 
disagreed with or strongly disagreed with by a majority of HCPs, indicating a positive attitude.  
Using concurrent triangulation design was suitable for cross-validation and confirmation of 
findings from both phases of the study into a single study. The design, however, was limited 
in that some discrepancies were difficult to explain. For example, even though HCPs disagreed 
with six of Inman’s typologies, i.e. ambition, lethargy, diffidence, guilt, litigation and 
complacency in the survey, they highlighted some of them in the qualitative interviews as 
essential factors influencing reporting, in addition to several other factors. While HCPs 
disagreed that fear of litigation affected reporting in the survey, it was raised as an external 
factor relating to engaging with pharmaceutical companies; a nurse said she would report if 
she trusted the “ability of the authority to protect people who will report on these reactions” 
because she feared the risk of litigation or harm. Protection was considered as the establishment 
of a law or policy to safeguard reporters. A sequential explanatory design would have been 
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beneficial in generating data and guided by a theoretical perspective which would have been 
easy to implement. Challenges in time and resources made it difficult to use this alternative 
approach. In the sections that follow, the findings from this study are considered in relation to 
the main research questions explored using a concurrent design and compared to existing 
research to understand the level of evidence which was considered important in this study. 
 
6.2 Factors Influencing ADR Reporting 
 
Moving on from the overall key findings, attention is now focused on what emerged 
significantly as factors influencing ADR reporting. These would be considered in light of 
existing evidence and literature, and it is argued that this research established several related 
but unique experiences of HCPs identified to influence ADR reporting in a Ghanaian context. 
Key examples relate to the human (patient or healthcare professional) and system (internal or 
external) factors where HCPs had positive attitudes and were willing to report, but poor 
knowledge, working relations, availability of reporting tools and other administrative 
bottlenecks became a challenge. 
As already noted, the findings of this study suggest that ADR reporting was low and intentions 
to report were influenced by four factors: internal systems, external systems, healthcare 
professional and patient-related factors. HCPs identified more system factors than human 
factors. A key emerging finding was that HCPs appeared to have broadly positive attitudes 
towards reporting (as observed from responses to questions and the operationalisation of 
Inman’s ‘seven deadly sins’). However, a contrast existed in relation to this positivity about 
intentions and actual self-reported incidences: poor practice affected by lack of knowledge, 
low reporting and availability of ADR reporting tools being more typical. Several of these 
issues are now considered in more detail, with particular emphasis on inadequate knowledge 
of HCPs, perceived patient attitude, positive HCP attitudes, roles and responsibilities of HCPs, 
and the reporting process. 
 
6.2.1 Inadequate Knowledge and Information 
  
One of the most important factors influencing ADR reporting was associated knowledge of 
ADRs, specifically how to report, and crucially the relative lack of such knowledge among 
HCP participants. Both phases of this study showed a general lack of knowledge among 
participants which has been reported widely in the literature. Ignorance and lack of awareness 
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about PV, poor definition of ADR, the inability to differentiate between ADR and side effects 
have been identified in the literature as examples of poor HCP knowledge on PV and ADRs, 
especially in Africa (Ezeuko et al., 2015; Lopez-Gonzalez et al., 2009a; De Angelis et al., 2016; 
Fadare et al., 2011; Daher et al., 2013; Okezie and Olufunmilayo, 2008). In this study, only an 
average of 18.5% of participants remembered key information used to assess HCPs’ knowledge 
on ADR reporting, such as awareness of the national PV centre, SMS short code to send a 
report and details needed on the reporting form. This was found in similar studies reported 
elsewhere which found generally inadequate knowledge among HCPs as well (Necho Mulatu 
and Worku, 2014; Shanko and Abdela, 2018; Kefale et al., 2017; Khoza et al., 2004; Gurmesa 
and Dedefo, 2016). The majority of participants in these studies were not familiar with the 
terms ‘PV’ or ‘ADR’, or with the reporting system in general. 
The majority of nurses had inadequate knowledge compared to medical and pharmacy staff. 
Pharmacy staff in contrast showed comparatively better understanding. For example, even 
though only 32% of staff were aware of the national PV centre, 74% of pharmacists knew about 
this. In the qualitative phase, pharmacy staff showed greater familiarity with PV and the 
significance of reporting compared to other HCPs. This may be attributable to their training as 
drug specialists or the additional workshops and training that they receive as part of their 
continuous professional development (CPD). Other studies (Hailu et al., 2014; Alraie et al., 
2016; Granas et al., 2007) have also found pharmacists to be more knowledgeable in ADR 
reporting and that their reports were of higher quality. Such a finding in this and previous 
research is arguably not unsurprising, given that pharmacists have a key role in healthcare 
systems for the safe use of medicine (Thamby and Subramani, 2014). HCPs were of the view 
that the FDA was channelling more training to pharmacists than to other HCPs, which was 
further enhancing their knowledge and capacity, and demanded a rather general approach to 
training and workshops on ADRs. Both phases of the study mutually underscored the general 
lack of knowledge and the importance of the role of the pharmacist in pharmaceutical care. A 
triangulation protocol (Table 25) (Farmer et al., 2006) shows how the mixed methods were 
used to mutually enforce the findings in terms of the level of knowledge which was assessed 





6.2.2 Positive Attitude to Reporting 
  
There was a positive attitude to reporting ADRs if HCPs had the tools and an enabling 
environment that supports reporting. HCPs agreed or strongly agreed with statements which 
were worded to suggest optimism in the reporting system. For example, “I feel patient safety 
in my hospital can be improved”. In contrast, they either disagreed or strongly disagreed with 
statements which suggested falsehood or misrepresentation of a functional reporting system. 
For example, “I feel the ADR form is complex to complete” or “I feel only serious ADRs should 
be reported” were either disagreed or strongly disagreed with, which was interpreted as a 
positive attitude. Although this study did not attempt to produce a composite score based on 
reporting attitude, comparisons can be made with other studies. Several of these estimated 
composite scores for attitude, and although results did vary somewhat, they presented a positive 
attitude among HCPs in Africa. For example, in Ghana, Ameade et al. (2014) undertook an 
assessment of nurses in the Tamale region (where the present research was undertaken) and 
found attitudes to reporting to be generally positive (59%). Similarly, a regional study of the 
Volta region of Ghana found a much higher attitudinal score of 74%, with pharmacists being 
more likely to have a higher (84%) attitudinal score than doctors and nurses, even though they 
scored the lowest attitude scores for the assertion that reporting was their professional 
obligation (Amedome and Dadson et al., 2017).  
A further sign of a positive attitude was HCPs saying that reporting increased patient safety. 
Other studies in Africa have shown positive attitudes as well, for example in Uganda, HCPs 
disagreeing (73%) that reporting took up their time or put their careers at risk (76%), which 
showed a positive attitude towards reporting (Kiguba et al., 2014). Other studies from Nigeria, 
Sudan and Ethiopia (Oshikoya and Awobusuyi, 2009; Angamo et al., 2012; Awodele et al., 2011) 
have used different questions and methods in the assessment of attitudes. These studies 
reported that most HCPs, however, perceived reporting and monitoring to be important and 
part of their professional obligation, which was interpreted as a positive attitude similar to this 
study. This positive attitude is reassuring, although as noted previously it was not matched by 
similar self-reported behaviours in relation to ADR reporting. Nonetheless, such positivity 
could be capitalised on, and shows that HCPs may be receptive to interventions aimed at 
improving reporting because of their recognition of the importance of reporting. Of note, again, 
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is that these themes were clear in both phases of the study and underscore the difference in 
levels of attitude and positivity among HCPs.  
 
6.2.3 Negative Patient Influences 
 
Compared to other studies on ADRs, HCPs had a different perception of factors affecting their 
reporting behaviour, which was linked to patient attitudes, which has not been previously 
explored. They identified several patient attributes, and particularly behaviours, which made it 
difficult to retrieve information on ADRs from patients and exerted a negative influence on 
whether an ADR was reported. This study is unique in identifying HCP perceptions about 
patients in relation to ADR reporting. HCPs seem to suggest that, in this study, patients were 
apprehensive, involved in hospital hopping, self-medication of serious illness and poor 
awareness about reporting. These patient attitudes may have influenced HCP reporting 
negatively. As noted in chapter 2, Obonyo (2014) briefly described the role of patients in 
‘healthcare provider factors’ that influence ADR reporting and recognised the importance of 
this relationship. However, the majority of previous studies have tended to focus more 
exclusively on patient reporting, of which some have reported on patients’ perceptions of HCPs 
as being unfriendly and uncommunicative about ADR reporting.  
Similar reasons for non-reporting of ADRs among HCPs identified in this study have been 
reported among patients as well, such as lack of feedback, poor awareness and not being sure 
who to report to (Dweik et al., 2017; Dweik et al., 2016). Even though this study did not receive 
any direct patient responses, other patient studies in Ghana have reported specific factors, such 
as unfriendly HCP attitude and inadequate patient education on medication effects as factors 
affecting patient reporting (Chatio et al., 2016). Patients’ attitudes to reporting can be 
influenced by the consequences of reporting and HCP assertiveness (Jacobs et al., 2018; 
Sabblah et al., 2019), where positive patient reporting attitudes could be as a result of positive 
HCP attitude and vice versa. There is evidence to suggest that knowledge about health 
information can influence attitudes and subsequently could result in positive health practices 
(Abubakar et al., 2014a). In the theory of the acquisition of habits in health sciences (Hong et 
al., 1995), elements of the theory of KAP were identified as predictors to behavioural change 
and could explain the factors influencing HCPs’ reporting behaviour. 
HCP factors for non-reporting were closely linked and inter-related with patient factors in this 
study and are worth mentioning even though this is not a patient-centred study. When asked if 
HCPs educated patients about ADRs, 62% of survey respondents answered in the affirmative 
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and 50% suggested patients reported their ADRs directly to them. This corresponds with other 
patient-centred studies where 67% of patients also indicated they reported the ADRs they 
experienced (Jacobs et al., 2018). In this study, however, HCPs felt some patients were 
apprehensive and did not report to them because they were engaged in unapproved practices 
such as hospital hopping and self-medication of serious illnesses. For fear of being 
admonished, patients who were perceived to be involved in these practices often did not feel 
confident in reporting any ADRs experienced.  
Also, weak healthcare system infrastructure made it more challenging to identify if a patient 
had received care from a different healthcare facility due to lack of electronic patient records 
and a robust health informatics system. Additionally, this attitude of patients could be 
associated with the unfriendly nature of HCPs as identified by Chatio (2016). Most patients 
were seen as passive receivers of care. HCPs noted that patients were more open to discuss 
their ADR and health issues if they felt confident the HCP would be friendly to them, but high 
in-patient numbers and busy schedules often made HCPs come across as unfriendly. The only 
way ADR reports could be increased is if HCPs encourage patients to report. The relationship 
between HCP and patient remains a key one however, and it has been argued that there are 
competing responsibilities for both patients and HCPs: 
Spontaneous reporting of ADRs […] involves three key players: the patient who 
consumes the drug, experiences the adverse drug reaction and notifies the health 
worker; the health worker who is responsible for identifying the ADR and filling in the 
report, and the  PPB (Pharmacy and Poisons Board) which is responsible for collecting 
and analyzing the reports as well as providing reporting tools and supporting 
resources. The health worker is an important component of ADR reporting because he 
[sic] is the link between the patient and the PPB. The health worker is responsible for 
educating the patient on the possible adverse effects that he could experience and is 
supposed to encourage the patient to report the ADR. If the patient experiences the 
ADR and reports it to the health worker, the health worker is responsible for identifying 
the potential adverse drug reaction and reporting it to the PPB” (Obonya, 2014, p.42). 
A further challenge relates to surrogate reporting, which made it even more problematic for 
HCPs to retrieve and document ADR information from children or critically ill patients who 
could not communicate or explain their conditions. Even though patient reporting confers 
advantages on the reporting of novel information and ADR experiences by providing detailed 
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descriptions of events (Inácio et al., 2017), surrogate reporting made this more challenging. In 
paediatric units, children often reported ADRs through their parent or guardian, and it took 
extra vigilance by parents to identify and report them to HCPs, which often resulted in 
incomplete patient data. This was often challenging, even with serious ADRs, and those which 
HCPs would usually report often went unreported. HCPs believed that these patient attitudes 
were because of lack of awareness of reporting procedure and of what is expected of them. 
 
6.2.4 Defined ADR Reporting Roles and Responsibilities 
  
It was observed that clear roles and responsibilities about what and how to report, and 
understanding of the obligations, was lacking. The majority of HCPs were of the view that it 
was the pharmacists’ responsibility to report ADRs. Lack of clear roles and responsibilities has 
been observed as an important and common reason for under-reporting in many studies (Nde 
et al., 2015; Gurmesa and Dedefo, 2016; Kiguba et al., 2014; De Angelis et al., 2016). Even 
though pharmacy staff had positive attitudes and acknowledged reporting as important for 
patient safety, they felt reporting ADRs was not their sole responsibility. Over-reliance on the 
pharmacists for ADR reporting initiatives may explain the general low reporting among HCPs. 
The quantitative phase showed that half (191/377) of the respondents perceived reporting as 
the responsibility of all, while only 29.7% (112/377) felt all HCPs had the potential to send the 
most reports. Uncertainty about roles and responsibilities led to HCPs thinking that ADR 
reporting was the responsibility of the pharmacist, which was very apparent in the qualitative 
interviews. This was seen in the pre-data-collection stage, where most nursing and medical 
staff, upon hearing about the study, suggested it was the type of study for pharmacists and not 
them. Pharmacy staff only partly accepted this view. The majority of them accepted reporting 
as part of their routine work but felt that other HCPs were also responsible, and that ADR 
reporting was a collective responsibility for all HCPs. For example, when asked who had the 
potential to send the most reports and who had the ultimate responsibility for reporting ADRs, 
pharmacy staff saw nursing and medical staff as having the potential and ultimate 
responsibility. This contrasted with medical and nursing staff who saw themselves as having 
the potential and ultimate responsibility. Even though this could be linked to a positive attitude 
to reporting, it contrasted with what was being practised. Similar research has been reported in 
a Pakistani study of pharmacists (Hussain et al., 2018). Nursing and medical staff have shown 
less commitment to actual reporting responsibilities, such as filling in a form for an ADR. The 
findings are similar to the literature, which suggests burnout, workload, lethargy, blame, 
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bureaucratic procedures, lack of incentives and availability of forms as common reasons for 
non-reporting (Aljadhey et al., 2015). Most HCPs, especially nurses, resort to verbal reporting 
because they find it more convenient and less time-consuming to tell their immediate superior 
about an ADR rather than completing a form, especially when forms are not available at the 
ward level. Another plausible reason for verbal reporting, especially among nurses, was fear 
of blame and merely following organisational bureaucracies. The nurses’ traditional role of 
taking instructions made them susceptible to fear and the blame of wrongdoing or malpractice, 
thus they preferred not to be at the forefront and often needed to check with doctors before 
reporting ADRs. As part of a functional PV system it is required that a committee be set up to 
oversee and take responsibility for reporting. This, however, was lacking in all study sites, even 
though one study site had a PV centre. Pharmacy staff were solely responsible for reporting 
ADRs in other facilities. Also, based on the data, there critical staff shortages within the 
pharmacy staff category leading to few clinical pharmacists at healthcare facilities. Reporting 
ADRs therefore became an additional responsibility. It would be useful to have nominated 
persons from each HCP cohort, unit or department as contact persons and facilitators of 
reporting among HCPs. Lack of roles and responsibilities created gaps and reporting challenges 
among HCPs. Academic detailing has been argued to be relevant; this involves a form of 
educational outreach and: 
 
“[…] structured visits by trained personnel to health care practices for the purpose of 
delivering tailored training and technical assistance to health care providers to help 
them use best practices” (Soumerai and Avorn, 1990, p.24).  
 
This has been shown to improve knowledge, attitude and practice among HCPs in prescription 
behaviours and other public health interventions (Izham et al., 2018; Markey and Schattner, 
2001), which could help to improve reporting systems and support reporting responsibilities, 
especially through clinical pharmacists. 
 
6.2.5 The Reporting Process and Verbal Reporting 
  
The way in which ADRs were reported and the factors responsible for that were important in 
predicting whether a form would be completed, or a designated responsible authority would be 
contacted. Lack of awareness of the ADR reporting processes has been identified in many 
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studies as a barrier to reporting ADRs (Bhagavathula et al., 2016; Wilbur, 2013; Ezeuko et al., 
2015; Gupta and Udupa, 2011).   
The reporting processes in the study hospitals were similar. Apart from TTH, which had a PV 
unit and a designated officer-in-charge, the facilities channelled their reports through a clinical 
pharmacist. Despite the provision in TTH, 86% of staff were unaware there was an officer-in-
charge of PV, which resulted in high levels of under-reporting. Generally, identification and 
reporting of ADRs were carried out either formally or informally. Formal reporting was 
influenced by two factors, i.e. severity and availability of reporting forms. This suggests that if 
an HCP perceived an incident as serious, felt capable and forms were available, they would 
formally report it by completing a form and reporting appropriately. The system was often 
challenged by the unavailability of forms. In the quantitative phase, only 28% of HCPs 
indicated that ADR forms were available in their facility, with 64.1% of TTH staff indicating 
no availability of ADR forms. Lack of availability of forms has been a significant factor for 
under-reporting in several studies (Dweik et al., 2017; Gupta and Udupa, 2011; Aljadhey et al., 
2015; Amin et al., 2016; Amedome and Dadson, 2017).  
The unavailability of forms and reporting tools, coupled with other human factors, resulted in 
informal reporting which was often verbal.  Informal verbal reporting was common among 
HCPs where superiors were often informed about cases which were sometimes either noted in 
nurses’ notes or patients’ folders. This suggests that ADR reports were being lost through 
informal routes despite a large number of ADRs being observed. Documenting in patients’ 
folders was, however, problematic because it was unauthorised for junior staff, especially 
nurses, to write on patient folders.  
There was also inter-staff conflict where some pharmacists felt challenged by doctors for 
writing in patients’ folders. This perceived and actual medical dominance was observed 
between doctors and nurses as well as doctors and pharmacists. Medical dominance is 
described as: 
 
“the medical profession’s control over the content, terms and conditions of its own 
work (autonomy), control over other health occupations and the health division of 
labour (authority), control over clients and control over the broader context of health 
care (sovereignty)” (Freidson, 1970, p.30).  
 
This has been explored in many studies, with a recent finding showing how pharmacists felt 
frustrated and undervalued when doctors evaded scrutiny and demeaned their expertise 
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(Luetsch and Scuderi, 2019). Recent approaches to healthcare and prescription practices in 
Ghana have decentralised patient care and some medication prescriptions to medical assistants, 
nurse practitioners and pharmacists. Medical dominance has not declined as a result of the 
decentralisation but has rather created some degree of conflicting interactions between HCPs 
about who can write in patient folders and responsibilities about whom to report to. Pharmacists 
and nurses in this study felt challenged when they wanted to document in patients’ folders and 
the ability for HCPs to satisfactorily support in ADR reporting process and PV activities 
effectively was therefore compromised. This was partly linked to internal hospital hierarchy 
and power, and the need to follow bureaucratic procedures. Nurses, in particular, felt less 
confident and capable of sending reports directly without approval from a doctor, pharmacist 
or in-charge. This created disruptions and delays in reporting. Electronic reporting, which has 
been reported in many studies as a way of improving the reporting system or process, was not 
in place at the time of the study even though a new electronic reporting system has recently 
been launched for patients and HCPs to report through mobile applications. The ADR reporting 
system was challenged by technical problems, which incapacitated HCPs in their reporting 
duties. A combination of electronic patient records and recent ADR reporting applications 
could improve the reporting process and medication safety practices. Even though theoretically 
HCPs knew patient care involved teamwork, the reporting process was often challenged by 
interprofessional interactions as a result of medical dominance. Notwithstanding this, the 
patients’ folders and nurses’ notes may serve as a repository for ADR cases often not officially 
reported through the yellow form. 
  
6.2.6 External Factors 
 
This research identified negative factors influencing HCP ADR reporting, both within and 
outside the settings in which they occurred, as previous research and typologies of ADR 
reporting factors have also shown (Oboyo, 2014). In terms of external system factors, HCPs 
identified concerns with stakeholder activities, coupled with infrastructural challenges and 
inefficient use of multi-media to enhance reporting. The main external stakeholders were 
patients, the FDA, MOH, the media and pharmaceutical companies. Even though the FDA was 
advocating training and creating awareness about reporting, some HCPs were of the view that 
these pieces of training were only channelled to pharmacy staff.  This assertion may be true 
because pharmacists were seen as gatekeepers of adverse reaction reporting, and most 
interactions by the regulatory authorities were directly with them. HCPs were also concerned 
 
 215 
that the few pieces of training meant for clinicians were sometimes attended by administrators 
who returned without cascading the training to clinicians. HCPs noted this behaviour was as a 
result of financial benefits and allowances participants received by attending these workshops. 
The links between FDA/MOH and also pharmaceutical companies/healthcare professionals or 
facilities on adverse reaction and safety reporting was weak. Even though healthcare 
professionals/facilities and pharmaceutical companies had a strong link in terms of product 
marketing, aspects of ADRs and PV were non-existent. HCPs were of the view that MOH-led 
training and protocols were often taken more seriously than external organisations, such as the 
FDA or pharmaceutical companies. HCPs appeared to pay attention only to MOH directives 
rather than to other stakeholders. In the survey, 20% of HCPs, especially pharmacy and medical 
staff, indicated they had contact from pharmaceutical companies at least every month. 
According to the Ghana FDA, MAH are required to have a QPPV representing manufacturing 
companies or distributors, which was not the case. Most of the QPPV were based in the capital 
city (Accra) with no representatives at the regional and district levels. 
 
6.2.7 Administrative Issues 
 
Healthcare facilities in this study were confronted with several administrative challenges. 
Hospital management and leadership did not prioritise PV and ADR reporting. The study 
showed that these administrative lapses also led to HCPs not treating ADR reporting issues 
seriously. From the data, HCPs pointed out that the MOH rarely featured these issues in their 
annual review meetings, there seemed to be limited budget and funding, and there was over-
reliance on external donor support. It was also observed from how the reporting system 
operated that the FDA was the only stakeholder actively facilitating pieces of training and 
education on ADR reporting and PV; reporting activities were not adequately integrated into 
MOH plans. This, therefore, created a gap in vigilance, which affected HCP engagement and 
reporting rates. Even though there was necessary technical infrastructure, such as an electronic 
platform for the management of patient records (Hospital Administration and Management 
Systems Software), this was often challenged by technical glitches. Furthermore, reporting 
forms were often also unavailable, especially at the ward level, further complicating 
documentation challenges. These challenges made HCPs resort to verbal reporting, and 
pharmacy staff, who were often the gatekeepers, were challenged by incomplete patient data.  
 




Inadequate infrastructure, such as telecommunication network, poor road network and access 
to information, was a challenge, particularly for rural communities. Rural community health 
centres were challenged with transportation and communication issues (Kiguba et al., 2014). 
This made it difficult to send or receive ADR reports and other important safety reports in real 
time, especially during public health programmes, which involve mass administration of 
medicines in rural areas. Media publicity through radio has therefore been useful in 
disseminating medication safety issues to rural communities. Previous broadcasts saw an 
increase in reports, which could be explained as a facilitator, especially in rural areas. Also, 
recent introduction of mobile applications for reporting can bridge the gap between rural and 
urban centres, but a study of implementation of similar reporting systems in Kenya has raised 
concerns about the challenges of internet connectivity and other technical glitches which may 
need consideration and re-evaluation based on feedback as time goes on (Agoro et al., 2018). 
In summary, several key factors have been argued to influence HCPs’ perceptions of ADR 
reporting in the hospital setting in Ghana. Many of these reflect existing themes and evidence 
in the literature, both in Africa and elsewhere, suggesting that there are common issues within 
healthcare systems and hospitals more specifically that are of concern and could be the focus 
of improvements; these are considered more specifically in the next section. 
 
6.3 Improving Reporting 
 
This sub-section sees a shift from exploring the situation of ADR reporting from ‘what it is’ to 
‘what should be’, considering HCPs’ suggestions of improving reporting. As well as 
considering attempts to address issues identified in the previous section, this study also sought 
specific responses from the three professional groups of HCPs about how they felt ADR 
reporting could be improved. Two main themes emerged from participants’ views, relating to 
education and also motivation for HCPs. 
 
Education and training were the most important interventions HCPs found which could 
improve ADR reporting in both phases of the study (Table 21). In the quantitative phase, out 
of 12 suggestions, HCPs were mostly in favour of “organizing continuous medical education, 
training and refresher courses for staff on ADR reporting” (97%, n=374), “encouraging 
feedback between patients’ prescribers and dispensers” (98%, n=375) and “encouragement 
from heads of department” (95%, n=364). As mentioned earlier, several empirical studies have 
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shown the beneficial effect of educational interventions (Pagotto et al., 2013), awareness 
workshops (Alraie et al., 2016; Herdeiro et al., 2012), information communication technology 
(Ribeiro-Vaz et al., 2016), increasing yellow card availability (Avery et al., 2011), training on 
ADRs (Morrison-Griffiths et al., 2003) and a dropbox (Amit and Rataboli, 2008) as measures 
for improving ADR reporting. Common among these studies, however, is that only sustainable 
interventions yielded the desired effect. Organising continuous medical education would 
therefore be more beneficial than one-off activities or interventions. The evidence shows that 
active multi-faceted educational strategies appear to be more beneficial and sustainable. The 
most effective intervention used three multi-faceted strategies involving weekly educational 
outreach, reminder cards and distribution of reporting forms. In Ghana, efforts have been made 
to incorporate PV subjects in the training of HCPs, especially in nursing training. The FDA’s 
DrugLens also reported that 40 pharmacists were awarded CPD points for taking online courses 
on PV and reporting medication safety issues to the FDA in 2018. These strategies, although 
they are passive, have a positive impact on reporting, and similar arrangements for nurses and 
medical practitioners would therefore also be beneficial to reporting. 
 
Three types of motivation were identified as facilitators to improving reporting: self-
motivation, financial motivation and external motivation. HCPs were self-motivated to report 
because of personal reasons, such as patient safety and feeling that reporting is a professional 
obligation. These strategies have been reported in similar studies as facilitators of ADR 
reporting. Some HCPs, especially nurses, were of the view that financial incentives would be 
a motivational factor for reporting. External motivation such as awards, feedback, recognition 
or public acknowledgements for reporting efforts was seen as an important motivation which 
the FDA was already doing – the FDA acknowledges and gives feedback for HCP reports albeit 
not efficiently. HCPs therefore advocated improved feedback and reminders for reporting. 
The least favoured opinions about improving reporting were using a dropbox and making ADR 
reporting compulsory. A suggestion about making ADR reporting compulsory was not an idea 
welcomed by most HCPs. They believed that it was important to first establish the knowledge 
base through education and training before approaching the issue of compulsory reporting. As 
mentioned earlier, developed countries such as Sweden, France and Italy have made reporting 
compulsory, which has accounted for the high number of ADR reports generated by HCPs. 
Interventions for improving reporting in such countries, therefore, often show no difference in 
reporting rates (Hazell and Shakir, 2006). Even though using a dropbox has been shown to 
increase reporting among doctors in other low- and middle-income countries, such as India, 
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where ADR reports increased from 14 to 32 in three months (Amit and Rataboli, 2008), it was 
a less popular option for HCPs in this study.    
 
6.4 Triangulation Protocol  
 
As mentioned earlier in the methods and methodology chapter, triangulation is an important 
component of mixed methods research which ensures that both qualitative and quantitative 
methods are integrated. The triangulation protocol proposed by Farmer (2006) has been used 
widely and is explored to identify where the convergence, complementarity and discrepancies 
in the data are inherent. These are based on the research questions and findings from both the 
qualitative and quantitative phases of this research (Table 25). 
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Table 25: Triangulation protocol (Farmer et al., 2006) 





do HCPs have of 
ADR reporting? 
 
HCPs showed a low level of 
awareness by their response to five 
general knowledge-based questions 
on ADR reporting. Even though 
more than a quarter (31.7%) were 
aware of the existence of a national 
pharmacovigilance centre, the 
majority (94.9%) were unaware of 
the SMS short code for reporting an 
ADR, basic information required on 
an ADR form (65.2%), required 
number of days to submit any type of 
ADR (99.5%) or serious reaction 
(80.0%). 
  
Further exploration of HCP knowledge was 
based on a personal account of the reporting 
process and awareness of pharmacovigilance. 
It emerged that pharmacy and medical staff 
were more aware of the term 
‘pharmacovigilance’ than nursing staff. 
Nursing staff reflections were characterised 
by long pauses, and they often guessed the 
meaning of the word ‘pharmacovigilance’.  
There was uncertainty about the reporting 
process and what to report, especially by 
nursing staff. 
Both phases of the study mutually enforced each other, 
showing a general lack of awareness about ADRs and 
how to report them. Pharmacy staff were, however, 
much more knowledgeable and aware of the reporting 
process compared to other HCPs. 
  
What are the 




Among the 14 attitudinal parameters 
explored on a five-point Likert-type 
scale, 92.3% either strongly agreed or 
agreed that patient safety could be 
improved by reporting. On the other 
hand, 81.2% strongly disagreed or 
disagreed that HCPs were lethargic. 
They felt their busy work schedules 
were not a hindrance to reporting. 
Among the 7 Inman attitudes tested, 
ignorance of the reporting process 
was considered a cardinal factor; 
78.8% either agreed or strongly 
agreed about it. 
  
A key theme from the findings was centred 
on human and system factors. The majority 
of HCPs’ accounts were human attitudes 
which were influenced by system factors. 
HCP attitudes identified were linked to their 
perceived patient attitudes including 
reluctance to report, the severity of incidence, 
confusion between ADR and medication 
error (ME), fear of consequence and product 
misconception. 
  
Both phases of the research revealed different 
perspectives of HCP attitudes. Even though there were 
similarities in attitudinal parameters measured, the 
qualitative aspect provided an in-depth view. For 
example, the theme reluctance to report was similar to 
lethargy in the quantitative aspect, where 81.4% either 
disagreed or strongly disagreed that there were so many 
patients and ADR became unimportant. The qualitative 
aspect, however, showed that HCPs considered it is 
important, citing forgetfulness, workload and 
uncertainty about what to report as an explanation for 
their reluctance to report ADR. Additionally, perceived 
patient attitudes were identified, which HCPs felt were 









HCPs reported about practical 
organisational and personal factors 
affecting reporting. Organisationally, 
only 11.8% and 23% received 
feedback and training from the FDA, 
respectively. 28% reported that 
forms were available in their 
facilities. A combination of personal 
factors resulted in an annual 
reporting rate of 25% with 18.4% 
reporting at least 5 ADRs. 14% 
reported to have completed a form 
for it. 75% of HCPs had never 
reported an ADR in practice. The 
majority (39%) of HCPs preferred to 
report ADR to the medical staff. Half 
(50%) of HCPs felt ADR reporting 
was the ultimate responsibility of all, 
while a quarter felt it was nurses’ 
responsibility. In terms of relations 
with patients, 50% of HCPs 
confirmed that patients reported 
ADRs and 62% indicated that they 
were able to educate their clients 
during working hours. 
  
HCPs confirmed they observed more ADR 
than they reported. Emerging themes 
included sub-district experience, taking 
responsibility, perceived workload/burnout, 
lack of technical expertise and interpersonal 
relations among HCPs. 
HCPs also identified perceived practices of 
patients which affected reporting, including 
ignorance, apprehensive clients, hospital 
hopping/self-medication and surrogate 
reporting. 
Other broader system practices which 
influenced reporting were verbal reporting 
predominance, form availability, policy 
issues, funding, management and leadership, 
sociotechnical issues and stakeholder 
influence (i.e. FDA, MOH and 
pharmaceutical companies). 
  
The quantitative phase highlighted why 75% of HCPs 
had never reported an ADR. The more extensive 
system practice of verbal reporting affected reporting. 
Most (39%) HCPs preferred to report to the doctor. 
This type of reporting was, however, seen as verbal as 
most HCPs said: 
“[…] having to write a report like a written report and 
presenting it, I think I would not be very convenient. 
People will end up not reporting […]” (Doctor 19). 
There was an agreement between data that the form 
was complex. 
Discord about the responsibility of reporting. While the 
majority wanted to report to medical staff and half 
agreed reporting was the responsibility of all, the 
qualitative phase showed that pharmacists were 
identified as the principal staff members who should be 
reporting ADRs. 
Stakeholder influence, management and leadership, 
and funding were not considered in the quantitative 
phase. 
  





The importance of reporting was 
captured in some attitudinal 
questions on patient safety and 
lethargy. In these, HCPs strongly 
agreed patient safety could be 
improved, and disagreed strongly 
that patients were many and they did 
The majority understood pharmacovigilance 
and the importance of reporting. A few 
nursing staff, however, were not aware of the 
term ‘PV’. Concluding remarks from 
interviews showed that HCPs considered 
reporting important, for example both 
medical and pharmacy staff considered 
reporting as an essential aspect of practice. 
Of those who knew what pharmacovigilance was, 
they equally knew the significance of reporting. The 
importance of ADR reporting was highlighted in both 
phases of the study, but it was more explicit in the 
quantitative phase than the qualitative phase. 
Attitudinal questions and questions on the 
responsibility of reporting showed how HCPs 
perceived the importance of reporting. Concluding 
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not have time, so ADRs became 
unimportant. 
  
  remarks of the qualitative interviews also highlighted 
the importance and how HCPs wished they could 
report if only they had an enabling environment. 
How is ADR 
reporting 
undertaken? 
Open-ended questions – to whom 
did you report to and where did you 
report? – were a precursor to the 
process of reporting among HCPs. 
Most reports were verbal, and junior 
HCPs preferred to report to a doctor, 
pharmacist or in-charge. 
The reporting process was characterised by 
5 stages, namely identification, judging 
severity of reaction, assessment by a clinical 
pharmacist, documentation of details and 
collection by the FDA. 
Challenges of prevalent verbal reporting, knowledge 
about the reporting process, complicated forms and 
unavailable forms affected the reporting process. 








There was significant difference 
between some background 
characteristics and knowledge, 
attitude, practice and suggested ways 
of reporting ADRs. 
Statistically significant variables 
were age, sex, number of patients 
seen per day, educational 
qualification and years of practice. 
NA Awareness of PV was significantly affected by age, 
sex and number of patients seen per day. Most HCPs 
who were aware of PV were in the 31–40 age bracket 
which was similar to a study in Nigeria (Okezie and 
Olufunmilayo, 2008).  
What are the 
suggested ways of 
improving ADR 
reporting in the 
hospital setting? 
  
HCPs concurred to all 13 suggested 
methods for improving ADRs. There 
were, however, variations in the 
levels of agreement. The majority 
were in favour of continuous medical 
education (97%), while compulsory 
reporting (83%) was the least 
favourite. Additionally, there was a 
higher level of neutral responses for 
mobile apps (8%) and compulsory 
reporting (10%) compared to the 
other methods. 
Key suggestions among HCPs were on 
governance and policy changes, monitoring 
and motivation. Among the governance and 
policy issues HCPs wanted changes to 
nursing care plans, supply of forms, an 
improved patient folder system and CPD 
points for HCPs who report. HCPs 
suggested getting a responsible person 
monitoring units and departments. 
Motivation included sustaining self-
motivation, financial motivation, reminders 
and education. 
There was agreement about continuous medical 
education, feedback, reminders, HOD support, focal 
person/contact person for ADR, access to forms and 
multi-media use. This allowed in-depth 
understanding. There was, however, silence in the 
qualitative phase on communication, drug awareness, 
ADR network, compulsory reporting and a dropbox. 
Issues of governance and policy on CPD points, 
nursing care plan and improving the patient folder 









This study is the first to explore ADR reporting among HCPs in the northern region of Ghana 
using a mixed methods approach. Using mixed methods research helped to triangulate the 
findings, draw on the strengths and minimise the weaknesses of undertaking this research as 
individual methodologies. The study used multiple approaches, including a random sample of 
386 with a high response rate (86%), and a variable group of HCPs and hospital facilities, 
which enhanced the generalisability of the study. Previous studies on this subject have mainly 
focused on nurses (Bäckström et al., 2007; De Angelis et al., 2015; Paul et al., 2014), 
pharmacists only (Wilbur, 2013; Jarernsiripornkul et al., 2009; Terblanche et al., 2018; Granas 
et al., 2007) or doctors only (Sabblah et al., 2014; Khan et al., 2013; Adedeji et al., 2013; 
Okezie and Olufunmilayo, 2008; Oshikoya and Awobusuyi, 2009). A varied combination of 
HCPs therefore enhanced the validity, reliability and trustworthiness of the findings. 
Additionally, the qualitative phase, which also used both focus groups and in-depth interviews, 
further generated rich data, which added depth to the study and which has not been undertaken 
in the study area before. The different healthcare facilities sampled gave multiple perspectives 
of primary, secondary, tertiary and private healthcare. 
  
The study used a combination of deductive and inductive theoretical approaches to answer the 
research questions, including the exploration of Inman’s theoretical ‘seven deadly sins’, and 
Herdeiro and Obonyo’s works (Herdeiro et al., 2006; Inman, 1996; Obonyo, 2014).  
Being a Ghanaian from the study location also became a strength because it helped to build 
rapport quickly with participants and gatekeepers. This resulted in a high response rate and the 
large number of interviews undertaken. Additionally, the report reflects the in-depth feedback 
from the supervision team and also experience of the study setting, which gives authority to 
the interpretation of the findings while reflecting on my own bias as researcher. Additionally, 
feedback from HCPs indicated they learnt a lot from participating in this study, which in itself 





The reporting of findings was guided by recommended, recognised guidelines and frameworks 
such as the Good Reporting of a Mixed Methods Study (GRAMMS) (O’Cathain et al., 2008) 
and the Triangulation Protocol (Farmer et al., 2006). This enhanced the validity and reliability 
of the research findings. The literature review was also based on systematic approaches, 
ensuring current relevant literature was retrieved. 
  
Limitations 
   
Nurses formed the majority of the study participants in both phases of the study. Randomisation 
did not account for an equal number of participants in the different professional categories of 
the study. Despite the significance of focus group discussions (FGD) where recall bias is 
reduced, enhancing inter/intra HCP comparison (Vaivio, 2012), doctors and pharmacists were 
unable to participate in the FGD for practical reasons; only nurses participated in the 
FGD.  Medical and pharmacy staff, however, participated in an in-depth face-to-face interview 
to share their perspectives on ADR reporting. 
Even though sampled hospitals gave multi-perspectives of different levels of health service 
delivery, i.e. primary, secondary and tertiary, the study focused on only metropolitan hospitals, 
excluding patients, rural and community clinics, and pharmacies. Perspectives of community 
pharmacists, patients and rural clinics about ADR reporting were given in the viewpoint of the 
HCP. Even though accounts from these other stakeholders may be useful for the 
implementation of HCP intervention approaches, they were not directly from patients, 
community pharmacists and rural healthcare providers, and thus further work may be required 
on their perspective about ADR reporting. 
The limited number of earlier studies was a major challenge; only three studies were found in 
Ghana. This therefore affected the scope and depth of discussion of the findings in the local 
context. For example, only one study was found in Tamale and it focused only on nurses.  
Even though it was reflected upon and the response rate was high, the survey of 67 items on 
the questionnaire could have introduced respondent fatigue (Lavrakas, 2013), where the latter 
end of the survey, which were Likert items, could have been given less thoughtful responses. 
Also, the design of the survey items resulted in many categorical variables which resulted in 
limited in-depth inferential statistics. 
This study is not claiming generalisability of findings but shows important insights into 






This section presents recommendations for public health policy, practice and future research. 
They may require further feasibility and acceptability testing with stakeholders responsible for 




• As a major stakeholder, the MOH should be more active and visible in relation to ADR 
monitoring. The FDA and MOH should jointly develop policies and protocols for routine 
hospital monitoring and reporting. The MOH should be visible in taking the lead in 
implementation of some of the strategies because HCPs were not taking reporting seriously 
because they came from the FDA rather than the MOH. There is a need for efficient internal 
systems of healthcare governance on PV and ADR reporting.   
 
• HCPs valued recognition and feedback as motivations for reporting ADR. The FDA, MOH 
and pharmaceutical companies should develop innovative feedback and souvenirs for 
reporters to encourage reporting. 
 
• Also, the general lack of knowledge of PV and ADR reporting among HCPs suggests the 
need for continuous education and training of HCPs. Where funds are limited, priority 
should be given to nurses and lower ranking frontline HCPs, because they have the greatest 
lack of awareness. The need for tailored education focusing on a non-blame culture, patient 
safety culture, and differentiation between error and malpractice is important.  Education 
should also be patient-centred and focused on encouraging and engaging in patient 
discussions, since patients were seen as apprehensive and ignorant about medication safety.  
 
• The FDA has CPD points and eLearning programmes on PV for pharmacy staff. This is, 
however, lacking for doctors and nurses. As part of collaborative efforts with stakeholders, 
the FDA should liaise with the Nurses and Midwives Council, and also the Medical and 
Dental Council to accept PV eLearning courses as CPD points for their members. This was 




• Furthermore, it was apparent in this study that combined strategies may be useful for 
improving reporting. For example, TTH is a University Teaching Hospital and can 
therefore be an effective strategic and collaborative partner in the provision of PV-driven 
academic research and training support for HCPs. 
 
• HCPs in this study were concerned about the lack of direct involvement of pharmaceutical 
companies in PV activities. Pharmaceutical companies relied on HCPs for ADR reports 
(O’Callaghan et al., 2018), but the lack of involvement was worrying. The FDA already 
requires that all companies must have a qualified person for pharmacovigilance (QPPV) 
but these were lacking in study hospitals. It is therefore recommended that the FDA should 
nudge MAH to get involved in general PV, general awareness and training, and not only 
marketing of their products but safety as well. PV should be part of their corporate social 




• There were also power, bureaucratic and hierarchical issues identified in this study. This 
may cause delays to access to essential reporting tools or create communication barriers. 
The use of reporting tools should therefore be accessible to appropriate staff and reporting 
should be without blame and bureaucracy. 
 
• There were organisational challenges and lack of critical frontline staffing. Pharmacy staff 
experienced high shortages in study locations. Reporting of ADRs may not require expert 
guidance or causality assessment before reporting. Where there are shortages of clinical 
pharmacists, it would be beneficial to have departmental contact persons and unit 
representatives to facilitate reporting. These individuals can work in close partnership with 
pharmacy staff to collate reports and educate other HCPs on PV. The role of the pharmacist 
was considered important. Reporting was often perceived as the duty of the pharmacist, but 
they rarely went on ward rounds. An academic detailing strategy could be beneficial by 
mentoring other HCPs on PV and ADR reporting.  
 
• This study also showed low levels of knowledge, shortage of clinical pharmacists and how 
clear roles and responsibilities about reporting were lacking. Soumerai and Avorn (1990) 
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have shown academic detailing to be beneficial in educating and changing attitudes and 
behaviours of HCPs. Hospital management can therefore form incidence committees for 
individual hospitals to have oversight responsibility for academic detailing on ADR 
reporting and other patient safety issues since this is a characteristic of an effective and 
functional PV system. 
 
• The reporting process was challenged by administrative and infrastructural issues. For 
example, Wi-Fi was limited, there are no institutional websites with content about the 
health centres and no institutional email addresses for HCPs. Adopting an efficient IT 
communication system within hospitals could facilitate the efficient circulation of 




6.7 Further Research 
 
•     Based on the factors identified in this study, further research could explore patient-related 
factors affecting ADR reporting. In this research patients’ attitudes were reported as a key 
factor that was influencing non-reporting of ADR in Ghana. From the literature review, very 
few studies have focused on exploring patient-related factors. This is an area that needs to be 
considered for future research.  
 
• Further research using a universally acceptable approach to assessing knowledge, attitude and 
practice of PV and ADR is also needed. Even though this study used validated questions from 
previous studies, the adopted studies had varied questions and assessment criteria. Further 
research to design a standardised scale or algorithm for the assessment of knowledge and 
attitude would therefore provide an acceptable approach measuring these important aspects of 
PV. Additionally, practical aspects, such as assessing specific type of drugs and reactions based 
on system classifications, can help identify and focus on specific ADR issues. 
 
• The study showed that 86% of HCPs used smartphones and the majority of HCPs were in 
favour of the introduction of mobile applications. With the introduction of reporting apps (Med 
Safety) by the Ghanaian FDA, further studies on the potential of mobile apps, electronic 
reporting, use of electronic patient records and other interventional approaches in Ghana would 
be beneficial to measure impact and sustainability of these interventions. 
 
• Further research on the role of other stakeholder pharmaceutical companies, the MOH and 
academia would be useful.   
 
• Understanding ADR reporting in population-specific studies, such as paediatric, geriatric 
population and public health programmes, would be important in understanding reporting in 









6.8 Reflective Insights 
 
This section follows on from a consideration of the study strengths and limitations and 
represents a summary of reflections and insights gained on both specific aspects unique to this 
study as well as wider learning from the research process. It is written based on the premise 
that reflective practice fosters experiential learning, thus the need to record and present our 
experiences transparently. Reflective writing within research is a key component of reflective 
practice, which is an important aspect of self-directed, experiential learning and can ultimately 
change one’s attitude and practice (Jasper, 2005). Bulman (2013) describes it as: 
 
“when an individual thinks critically about an event in order to understand how it made them 
feel, why they behaved the way they did, what other factors influenced the event, and what they 
might have done differently” (p.33).  
 
My experiences over the past four years of undertaking this research have had a significant 
(and positive) impact on me, both personally and professionally, and in this section I want to 
explore in particular the cultural changes that shaped both myself and the research, as well as 
logistical aspects and latter recognition of specific learning needs. In doing so, it is hoped that 
this will provide insights that may be of relevance to future researchers working in such 
settings. 
Moving from Ghana to study in the UK as an international student, being in a different culture 
and educational environment had its own challenges. The University, however, created a 
supportive environment where I was able to adapt and quickly settle down for studies. I started 
the programme not having any foundation in qualitative research, even though it was an integral 
part of my proposed research. My previous experience in quantitative methods and information 
retrieval were barely utilised in my previous job, thus the need for a refresher course as well. 
Being out of education for a while, I undertook courses provided by the University in 
qualitative research methods, systematic reviews and introductory statistics. It was an exciting 
time to learn new skills and develop existing ones. These gave me the required foundation in 





As part of my training, my goal was to develop as many transferable skills as possible through 
internal and external activities. I therefore participated in competitions, consultancies, 
conferences, seminars, online courses, workshops, departmental and PGR-led activities to 
improve my knowledge, communication, networking, teamwork, organisation and presentation 
skills. In addition, I also supported teaching and learning activities and gained recognition as 
an Associate Fellow of the Higher Education Academy, UK, which has enhanced my CV.  
 
Going into the field as a novice researcher and collecting primary data for the first time, made 
me nervous. Moreover, collecting data and being supervised remotely was also problematic. 
Frequent power outages, internet glitches and administrative bureaucracies further delayed the 
process, but the advice, support and guidance of my supervisory team helped me to overcome 
them. During interviews, I was also sometimes faced with participants’ misconceptions about 
ADRs. I had to take the information as it was and discuss it further after the interviews. For 
example, a pharmacist suggested drugs manufactured by renowned pharmaceutical companies 
were less likely to have adverse effects. Through these further discussions about ADRs, HCPs 
suggested they learnt a lot from participating in the study. Researchers collecting data from 
similar settings must take into account the possibility of some of these challenges and make 
adequate preparation and backup plans.  
 
Reflecting in particular on the intense data collection period, I believe I experienced a reverse 
cultural shock when I returned to collect data in Ghana. This is a recognised phenomenon 
(Gaw, 2000) which occurs when individuals, such as overseas students for example, return to 
their home countries following often extended periods away in another location where the 
culture and other practices may be different. Of note were the inefficient manual processes and 
bureaucracies I had to go through to get permits for my study. This sharply contrasted the 
structured and almost seamless processes I became accustomed to in the UK. As it is with many 
lower- and middle-income countries, the ethics application process involved submission of a 
lot of hard copy forms which resulted in printing more than 300 pages of hard copies. In 
addition, I had to travel more than 10 hours from the primary study site in Tamale to the capital 
city Accra in order to facilitate the application process. This was both physically and mentally 
exhausting. Even though the application was initially submitted in May for a June start, the 
project officially began in September. Administrative bureaucracies and delays affected the 
main study design which was eventually modified from a sequential to a concurrent mixed 
method because of limited time and resources. Lack of electronic infrastructure (e.g. 
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institutional email) and inefficient physical infrastructure (home postal address system) at the 
study site (Tamale) made it difficult to utilise a postal or online survey. Questionnaires were 
either self-administered or face-to-face with several call backs to retrieve completed 
questionnaires. Being familiar with the study setting and organisational culture, however, 
helped me to recruit a high number of study participants in the short time I had. 
  
These logistical issues impacted on planned aspects of the research design and delivery, and in 
particular on the proposed use of an explanatory sequential approach. As noted previously in 
the methods chapter, the aim had been to deploy the surveys first, and collect data and analyse 
them fully before undertaking the qualitative stage.  Using a concurrent mixed method 
eventually answered the research questions but an explanatory sequential approach could have 
helped in the design of specific qualitative questions after analysing the quantitative data. For 
example, I asked participants about ways to improve ADR reporting, both in the qualitative 
and quantitative phases, and the suggested responses were similar. If I had analysed the 
quantitative first, the most prominent suggestion, which was ‘education and training’, could 
have been explored specifically in depth in the qualitative phase for a deeper understanding of 
that theme. I learnt that advanced preparation and familiarisation with local guidelines could 
have minimised some of the challenges encountered.  
 
After I returned from data collection, transcribing the data was time-consuming, but it gave me 
first-hand experience of the data and allowed me to familiarise myself with the data as 
suggested by Braun and Clark. While the standard for transcribing an hour of audio is estimated 
at about four hours, I was taking between five to six hours depending on audio quality, which 
was time-consuming, but a great way to learn. Analysis of the data and report writing was also 
challenging because of my underlying specific learning difficulties. Additional reiterations and 
support from Mathematics and Statistics Help (MASH), Disability and Dyslexia Support 
Service (DDSS), colleagues and the supervisory team helped me to overcome and improve my 
writing skills. However, in hindsight, I recognise that if these challenges had been identified 







In conclusion, this research found that Ghanaian HCPs do recognise the importance of 
reporting ADRs in their work. Even though HCPs recognised ADR reporting as important for 
patient safety in routine clinical practice, there were several challenges, particularly poor self-
reported practices and knowledge related to ADR reporting which were of more concern. 
Greater opportunities for the role of pharmacists were identified, but also many other factors 
both within and beyond the hospital setting and involving human factors, relating to patients 
and also HCPs, affected reporting. Patient-related barriers identified further challenged HCP 
practice resulting in low/poor ADR reporting. To adequately estimate and reduce ADR-related 
morbidity and mortality, policymakers may need to focus on re-evaluation of current strategies 
and introduction of innovative interventions, such as academic detailing by designated staff, 
especially pharmacists, to improve ADR reporting. Key opportunities exist to enhance 
education and training for HCPs and the public, and enhance the role of pharmacists, 
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Age  Sex  Years of practice  Patients per day  
20-30 31-
40 























































































































































































































































































































































































































































































Appendix T: Search Strategy 
REVIEW TOPIC: KNOWLEDGE, ATTITUDE, PERCEPTION AND PRACTICE OF 
ADVERSE DRUG REACTION REPORTING  
 
DataBases Google Scholar, Embase, PsychInfo and Medline (via Ovid or Pubmed) 
Date of 
Search 
November, 2019 (Updated January 2020) 
Outcome “Knowledge and Attitude and Practice” OR KAP OR knowledge OR attitude OR 
perception* OR practice OR approach OR perspective OR understanding OR 
familiarity OR awareness OR recognition OR principle* 
Setting Hospital or healthcare or ‘clinical facility’ or clinic or ‘health centre’ 
Intervention 
 
“Adverse drug reaction*” OR PV OR ADR* OR pharmacovigilance OR Adverse 
reaction reporting” OR “Medicine safety” OR “drug” OR  “safety reporting” OR 
“Drug surveillance” OR “Safety reporting” OR “Adverse drug event reporting” OR 
“Spontaneous event reporting” OR “Spontaneous adverse drug  reporting” OR 




Population 1 “Healthcare professionals” OR doctor OR nurse OR pharmacist OR “general 
practitioner” OR “medical officer” OR “medical doctor*” OR “nurse practitioner*” 






(‘‘Africa’’[MeSH] OR Africa*[tw] OR Algeria[tw] OR Angola[tw] OR 
Benin[tw] OR Botswana[tw] OR ‘‘Burkina Faso’’[tw] OR Burundi[tw] OR 
Cameroon[tw] OR ‘‘Canary Islands’’[tw] OR ‘‘Cape Verde’’[tw] OR ‘‘Central 
African Republic’’[tw] OR Chad[tw] OR ComORos[tw] OR Congo[tw] OR 
‘‘Democratic Republic of Congo’’[tw] OR Djibouti[tw] OR Egypt[tw] OR 
‘‘EquatORial Guinea’’[tw] OR Eritrea[tw] OR Ethiopia[tw] OR Gabon[tw] OR 
Gambia[tw] OR Ghana[tw] OR Guinea[tw] OR ‘‘Guinea Bissau’’[tw] OR ‘‘IvORy 
Coast’’[tw] OR ‘‘Cote d’Ivoire’’[tw] OR Jamahiriya[tw] OR Jamahiryia[tw] OR 
Kenya[tw] OR Lesotho[tw] OR Liberia[tw] OR Libya[tw] OR Libia[tw] OR 
Madagascar[tw] OR Malawi[tw] OR Mali[tw] OR Mauritania[tw] OR 
Mauritius[tw] OR Mayote[tw] OR MORocco[tw] OR Mozambique[tw] OR 
Mocambique[tw] OR Namibia[tw] OR Niger[tw] OR Nigeria[tw] OR Principe[tw] 
OR Reunion[tw] OR Rwanda[tw] OR ‘‘Sao Tome’’[tw] OR Senegal[tw] OR 
Seychelles[tw] OR ‘‘Sierra Leone’’[tw] OR Somalia[tw] OR ‘‘South Africa’’[tw] 
OR ‘‘St Helena’’[tw] OR Sudan[tw] OR Swaziland[tw] OR Tanzania[tw] OR 
Togo[tw] OR Tunisia[tw] OR Uganda[tw] OR ‘‘Western Sahara’’[tw] OR Zaire[tw] 
OR Zambia[tw] OR Zimbabwe[tw] OR ‘‘Central Africa’’[tw] OR ‘‘Central 
African’’[tw] OR ‘‘West Africa’’[tw] OR ‘‘West African’’[tw] OR ‘‘Western 
Africa’’[tw] OR ‘‘Western African’’[tw] OR ‘‘East Africa’’[tw] OR ‘‘East 
African’’[tw] OR ‘‘Eastern Africa’’[tw] OR ‘‘Eastern African’’[tw] OR ‘‘NORth 
Africa’’[tw] OR ‘‘NORth African’’[tw] OR ‘‘NORthern Africa’’[tw] OR 
‘‘NORthern African’’[tw] OR ‘‘South African’’[tw] OR ‘‘Southern Africa’’[tw] 
OR ‘‘Southern African’’[tw] OR ‘‘sub Saharan Africa’’[tw] OR ‘‘sub Saharan 
African’’[tw] OR ‘‘subSaharan Africa’’[tw] OR ‘‘subSaharan African’’[tw]) NOT 
(‘‘guinea pig’’[tw] OR ‘‘guinea pigs’’[tw] OR ‘‘aspergillus niger’’[tw]) 
 
Exclude NOT “disease condition” OR cancer OR malaria OR vaccination OR hepatitis OR 
diabetes OR immunization OR osteopORosis OR HIV OR AIDS OR TB OR 
Asthma OR “clinical trials” 
NOT Drug OR “Clavulanic acid” OR Paracetamol OR Warfarin OR Analgesic* 
OR Antibiotic*OR anti-infective* OR antidepressant OR antipsychotic* OR 
anaphylaxis OR  psychotropic* 
 
 NOT Student* OR “pharmacy student*” 
OR “nurse* student*” OR dentist OR “medical student*” OR “Medical college” 
OR teacher* OR Patient* OR consumer 












Appendix U: Summary of Review Findings of African Studies 
 
PUBLICATION YEAR SUMMARY OF FINDINGS 
1. (Ezeuko et al., 2015)  2015 Knowledge was generally low, and pharmacist had better knowledge comparatively. Common reasons for non-reporting 
were unavailability of electronic reporting (83.6%), unavailability of reporting forms (66.4%) and ignorance (58.2%). 
Others of lesser importance were the bureaucratic reporting process (39.9%), no incentives (32.5%) legal implication of 
reporting (26.6%).  Workshops and mass media were highly (62.5%) suggested to increase awareness.  
2. (Nde et al., 2015)  2015 62.2% ever reported ADR and averaged of 82.5% heard about the PV System but only 40.1% could define PV. No 
functional PV system was available. Majority of HCPs (90%) reported ADRs to Pharmaceutical companies. Most 
common reason for non-reporting “was not knowing” whom to report to. 
3. (Katusiime et al., 2015)  2015 HCPs had a fair level of knowledge (40%). 69.1% understood the concept of ADR reporting, who to report to (75.3%), 
knew the national PV centre (41.7%), availability of forms on wards (25.3%). Only 16.6% ever reported an ADR. Most 
encouraging factor was unusual reaction (91.1%) and lack of time (56.5%) was the most discouraging factor.  
4. (Ameade et al, 2014)  2014 Knowledge was low (36.45%) and attitude above average (59.4%). Most HCPs knew the difference between ADR and 
side effects (67.2%), but not the definition of ADR (21.9%). 94.4% indicated reporting was important but only 8.8% of 
nurses completed a form after observation. Common reasons for non-reporting were client failure to report (18.4%) and 
lack of knowledge (42.2%). The most commonly suggested way to prevent ADRs and increase reports was workshops 
(51.2%). 
5. (Bello and Umar, 2011) 2011 Majority (70.5%) encountered ADR but only 4.9% reported resulting in a low reporting rate of (7%) among doctors. Lack 
of physician awareness about the reporting channels appear to be a major cause of under-reporting. 
6. (Kiguba et al., 2014)  2014 52% ever heard of PV and 31.2% were aware of the national centre. 21% suspected an ADR in the last one month, 15% 
reported in last 12months but only 3% submitted a report to the national centre. Most common facilitator was the ADR 
being serious (18%) and for patient safety (18%) and barrier being “not knowing” how to report (45%). Attitudinally 76% 
saw reporting as a professional obligation, majority (73.3%) disagreed it took time, or should be financially motivated to 
report (58.0%) or put their careers at risk (76%). 
7. (Sabblah et al., 2014)  2014  Doctors had excellent knowledge (51%) and 27.4% ever had training. 59.5% had seen a suspected ADR but only 20% 
completed an ADR form. Common reasons for non-reporting was unavailability of forms (43.1%) and lack of knowledge 
about the reporting process (28.5%). 
 
8. ( Angamo et al., 2012)  2012  76.8% had inadequate knowledge but positive attitude (75%) with majority (57.3%) agreeing reporting was part of their 
duty, improves healthcare (73.17%) and quality of patient care (73.17%). 51.2% agreed reporting creates workload. 




9. (Awodele et al., 2011)  2011 82.9% had heard about PV and 79.3% gave correct definition. 97.6% agreed ADR reporting was essential. Only 5.6% 
reported ADR in the last month with 2.4% to regulatory authority and majority did not know how to report (56.2%) or 
where to obtain a form (71.7%). 
10. (Ohaju-Obodo and Iribhogbe, 2010)   78% of doctors had inadequate knowledge about PV with 71.2% unaware about yellow forms. 92.4% observed ADRs at 
work but only 25.5% of cases were reported with only 7.5% of reports to the national centre. Further assessment showed 
47.4% were not aware of the reporting process. Common reasons for non-reporting was lack of awareness (47.7%), 
commitment from regulators (12.5%) and unavailability of forms (11.9%). 
11. (Elnour et al. 2009)  2009 81.7% had an idea about ADRs and 96.2% saw ADR monitoring to be important. Only 26.1% ever reported an ADR. 
Common reasons for non-reporting of ADRs was not knowing how to report (27%) and unaware of the existence of a 
reporting system (27.1%).  
12. (Oshikoya and Awobusuyi, 2009)  2009 89.9% knew they could report ADRs but only 51.5 % knew about the national PV centre and 32.3% aware of the yellow 
card system. Attitude was positive, as 64.6% felt reporting was a professional obligation. Factors encouraging reporting 
was seriousness of ADR (77.8%) it being unusual (70.7%). The most discouraging factor was the concern that report may 
be wrong (47.5%). Majority disagreed (66.7) lack of time discouraged reporting. 
 
13. (Okezie and Olufunmilayo, 2008) 2008 General knowledge was good with 63.5% above the knowledge mean score of 27.5 with no statistical difference in age, 
sex and years of practice in relation to knowledge. 58.3% had general knowledge and were aware of reporting guidelines. 
Most (89.5%) had observed ADRs and only 32% have ever reported. There is lack of knowledge about reporting forms. 
Uncertainty about causality of ADR is a limiting factor to reporting. Demographic characteristics like sex, age, faculty, 
cadre or years of practice were associated with reporting awareness. Efforts must be made to educate about the reporting 
process by using posters in wards and clinics and giving active feedback to doctors 
14. (Adedeji et al., 2013)  2013 There was poor knowledge of reporting procedures (48.6%), national PV centre (71.4%), ADR forms (57.1%).  85.7% 
observed ADRs but 2.9% reported with yellow forms. Reasons for non-reporting included ADR information not being 
useful (85.7%), time consuming (8.6%), litigation issues (14.3%), extra workload (17.1% and negative consequences to 
manufacturers (11.4%).  
 
15. (Seid et al., 2018)  2018 52.9% had adequate knowledge with 66% aware of the difference between ADR and side effect, 12.1% knew the term 
PV, 49% knew they national reporting system. 86.3% had positive attitude and 56% encountered ADRs but only 49.1% 
reported with 21.4 directly to regulatory authority. Having previous training, being a nurse or health officer were 
associated with reporting knowledge. 
16. (Muringazuva et al., 2017) 2017 There was 100% awareness the reporting system but 79% did not see the reporting system as necessary especially if the 
reactions were known or minor. Only 38% were aware of reporting time frames and only 21% were aware reporting could 




17. (Mulatu and Worku, 2014)  2014 34.2% had sufficient knowledge. 52.3% knew the definition of PV, aware of ADR reporting (42.9%), the yellow form 
(21.4%) and how to report (27.8%). Attitudinally, 95.4 agreed reporting was their duty, patient safety could be 
improved (93.8%) and 68.1% feared litigation issues. Non reporting was due to uncertainty about what to report 
(43.4%) and where to report (37.8%).  16.2% ever reported an ADR and 38.1% recorded the reports, mainly to 
regulatory agency (27.7%). 
 
18. (Shanko and Abdela, 2018)  2018 In terms of knowledge, 29.5% familiar with the term PV,33.6% knew the difference between ADR and side effects, 59.3% 
knew about the national reporting system and availability of forms (61.4%). Pharmacist were more aware than other HCPs 
and y10 to 14 ears of experience was associated with knowledge. Attitude was positive, 60.8% saw reporting as part of 
their duty, important for public health (83.4%) and important in healthcare system (73.2%). 62.4% felt reporting did not 
create additional workload and common reasons for non-reporting were unavailability of forms (53.9%), uncertainty 
about how to report (51.9%) and lack of feedback (41%). 49.2% encountered ADRs especially doctors (72.7%), 37.3% 
recorded in patient folder, 34.2% advice patients especially pharmacists (66.6%) 
19. (Kefale et al., 2017)  2017 Overall knowledge was 33%. 31% knew the term PV, the national monitoring system (36.6%), the ADR form (27.7%) 
and 53.5 knew the difference between ADR and side effects. Attitudinally majority agreed reporting was part of their 
duty (84%), needed to establish causality before report (77%), reported only serious ADRs (35.2%) and making reporting 
compulsory (21.4%). 36.6% saw ADRs in the last 12months and 90.2% reported. Reporting were mostly to either the 
head of pharmacy (37.8%) or the regulatory agency (49.8%). Also, 38.5% advice patients about ADRs. 
20. (Khoza et al., 2004)  2004 Lack of knowledge on how to report (47.2%). 75.5% indicated reporting was important professional obligation. 
Participants agreed that non-reporting was due poor feedback (59%), inaccessibility (45.8%), one report makes no 
difference (46.5%). Only 16% of HCPs agreed reporting took their time and disagreed (83.3%) reporting may risk their 
carrier. Only 20.1% ever reported an ADR. 
21. (Gurmesa and Dedefo, 2016)  2016 KAP was generally low but doctors and pharmacist had better awareness than nurses. 62.4% heard about ADR reporting, 
the yellow form (37.4%), knew where to report (30.8%) and 24% reported to regulatory agency. In terms of attitude, 
77.4% indicated reporting is essential, 57% wanted reporting made compulsory, fewer (43.6%) HCPs were for reporting 
only serious ADRs. Reason for non-reporting were uncertainty about what to report (45.5%), the reporting system (9%) 
and unavailable forms (40.9%). 27% observed ADRs, 38.8% reported, 78.5% reporting at most three with 50% reported 
to the hospitals and 14.3% to regulatory authority. 
22. (Fadare et al., 2011a) 2011 60.5% lacked knowledge about Yellow form, reporting guidelines (57%) and hospital PV committee (44.6). Ignorance 
about how to report (66.1%) and verbal reporting (75%) was common. Average of 69.8% observed ADRs but only 42.7% 
ever reported. More doctors (85.7%) observed ADRs but more nurses reported (75%) than doctors (30.8%). 
23. (Terblanche et al. 2017)  2017 Knowledge was generally low (17.5%). Only 18.9% were aware of the local PV reporting system, 15.2% were aware of 




was positive, 82.6 preferred reporting to be compulsory, 92.6 did not want remuneration for reporting and 89.4 saw 
reporting as their professional obligation. Only 12% reported an ADR and the two most common reason for non-reporting 
was uncertainty about how, where and when to report (54.5%) and lack of time (37.1%). 
24. (Kamal et al. 2014) 2014 Doctors’ awareness of PV and reporting was low/poor. Only18.9% were aware of the NPVC and only 6.9% reported and 
ADR. Reasons for non-report were uncertainty (50.0%), lack of time (46.0%) and not knowing how (60.0%). Attitude 
was positive, 81.5% said reporting was necessary and 74% wanted it made mandatory. 60.0% were concerned with patient 
confidentiality and were less concerned about getting involved in litigation (47.4%). Years of practice influenced 
knowledge and attitude. 
25. (Charles,et al 2017)  2017 Knowledge was low (23.9%) among HCPs with an average mean score of 8.1%/20. Pharmacist were more aware (56%) 
of PV than physicians (32.0%) and nursing staff (30%). Main reason for non-reporting; availability of forms (70.4%) and 
ignorance (24.8%). Only 1.7% reported ADR and reporting rate to the NPVC was 0.65%. Attitude was positive, 94.7% 
said reporting was necessary. 
26. (Alemu and Biru, 2019) 2019 Knowledge was generally inadequate (75.4%) with nurses more likely to be poor knowledge. 50% of HCPs did not report 
ADRs but attitude was positive (74%). Training awareness and feedback is encouraged. 
27. (Amedome and Dadson 2017) 2017 On average 83.3% of HCPs aware of ADR reporting system especially pharmacists (92.2%). Attitudes were generally 
positive (74%) with HCPs responding that reporting was the responsibility of all HCPs and reporting would increase 
patient safety. 
28. (Udoye et al., 2018) 2018 All pharmacists were aware of PV but only 24.3% officially reported and 73.4% had seen a patient with ADR. Poor 
attitude and practice with reasons such as lack of time, one report makes no difference and lack of incentives. Ensure 
form availability and continuous education and reminders. 
29. (Joubert and Naidoo, 2016) 2016 Majority of pharmacists (62.8%) were familiar with PV and deemed it as valuable (79.4%) but 44.1% reported ADRs. 









Appendix V: Participant Information Sheet (Survey) 
 
 
Research Information Sheet 
(SURVEY) 
Factors Affecting Spontaneous Adverse Drug Reaction Reporting Among Healthcare 
Professionals in Northern Ghana 
Invitation You are invited to take part in the above research project which is being undertaken by the University of 
Sheffield in the United Kingdom. Before you decide whether or not to participate in the research, it is important for you 
to understand why the research is being carried out and what it will involve and why you have been invited to take part 
Purpose of the Research and why you have been selected. Adverse drug reactions (ADRs) are recognised events in 
all health systems and there is considerable research in many countries about their incidence and in particular what 
influences reporting of ADRs. Little is known about this however, in Ghana and specifically from the perspective of 
health professionals. This study aims to understand the experiences and views of nurses, pharmacists and doctors in 
different hospitals in northern Ghana in relation to ADRs and their associated reporting. 
What will happen to you if you take part There are two main stages in this research and this sheet relates to the first 
which involves participating in a questionnaire which will take between 20 to 30 minutes to complete. You will be 
invited to participate in an interview if you choose to. You do not have to participate in in both stages. There are no 
recognised personal advantages or disadvantages associated with taking part in this research,  
Do I have to take part? No. Your participation in the first questionnaire stage is entirely voluntary, as is participation 
in the subsequent stages which would involve further interviews. It is up to you to decide whether or not you wish to 
participate in this and later stages. 
Will my taking part in this research be kept confidential? Yes, the questionnaire is completely anonymous, and no 
information will be collected that could identify you. All data will be anonymised, and you will not be identifiable in 
any report or publication. Personal data will be kept for  2 years once the study has ended and then destroyed. 
Anonymised data will be kept indefinitely and may be used in future research. 
What will happen to the results of the research project? The data generated from this research will be submitted as 
a PhD thesis, in academic journals and abstracts will be submitted at key conferences.  
Who has ethically reviewed the project? This research has been ethically approved by the Ghana Health Service 
Ethics Review Committee.  Relevant hospital permission has also been granted ranted to carry out this research. 
Who is organising and funding this research? This research is organised by the University of Sheffield and is not 
funded. 
What if I want more information or have a complaint regarding this research? If you would like more information 
about his research, please contact Walter-Rodney Nagumo, the researcher, on +233208390330 / 07826136439. If you 
wish to raise a complaint or a concern about any aspect of this research, please contact Dr Richard Cooper  (email 
Richard.cooper@sheffield.ac.uk, telephone +0044 1142220683). If for any reason you are not satisfied you should 






Appendix W: Mixed Theoretical Model by Herdeiro (Herdeiro et al., 2004) 
 
 
 
 
 
 
 
 
